Page last updated: 2024-12-05

edetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

solasodine: RN given refers to (3beta,22alpha,25R)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

solasodine : An oxaspiro compound and steroid alkaloid sapogenin with formula C27H43NO2 found in the Solanum (nightshade) family. It is used as a precursor in the synthesis of complex steroidal compounds such as contraceptive pills. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129316900
MeSH IDM0007067
PubMed CID6049
CHEMBL ID858
CHEBI ID4735
CHEBI ID42191
MeSH IDM0007067

Synonyms (287)

Synonym
solasodine
purapuridine;solancarpidine;solasodin
ethylenediaminetetraacetic acid, 2na (edta)
BIDD:ER0565
ethylenediamine-n,n,n',n'-tetraacetic acid
n,n'-1,2-ethanediylbis[n-(carboxymethyl)glycine]
ethylene-n,n'-biscarboxymethyl-n,n'-diglycine
(ethylenedinitrilo)tetraacetic acid
acide edetique
edathamil
n,n'-1,2-ethane diylbis-(n-(carboxymethyl)glycine)
CHEBI:4735
ethylenedinitrilotetraacetic acid
h4edta
edta (chelating agent)
2,2',2'',2'''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid
(ethane-1,2-diyldinitrilo)tetraacetic acid
2-([2-[bis(carboxymethyl)amino]ethyl](carboxymethyl)amino)acetic acid
acido edetico
acidum edeticum
KBIO1_000777
DIVK1C_000777
glycine, n,n'-1,2-ethanediylbis[n-(carboxymethyl)-
brn 1716295
nullapon b acid
nervanaid b acid
einecs 200-449-4
ethylenediamine tetraacetic acid
n,n'-1,2-ethanediylbis(n-(carboxymethyl)glycine)
nullapon bf acid
glycine, n,n'-1,2-ethanediylbis(n-(carboxymethyl))-
D00052
edetic acid (nf/inn)
versene acid (tn)
c10h16n2o8
SPECTRUM_001018
SPECTRUM5_000955
BSPBIO_001964
versene
edetate calcium disodium (usp)
disodium ethylenediamine-n,n,n',n'-tetraacetate
disodium (ethylenedinitrilo)tetraacetic acid
triplex iii
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid
endrate disodium
nsc2760
versenate
cbc 50152966
versene na2
acetic acid, (ethylenedinitrilo)tetra-, disodium salt
disodium diacid ethylenediaminetetraacetate
sequestrene sodium 2
edetic acid disodium salt
(ethylenedinitrilo)tetraacetic acid, disodium salt
metaquest b
perma kleer di crystals
disodium versenate
glycine, n,n'-1, {2-ethanediylbis[n-(carboxymethyl)-,} disodium salt
disodium dihydrogen(ethylenedinitrilo)tetraacetate
cheladrate
disodium versene
chelaton iii
kiresuto b
disodium tetracemate
ethylenediaminetetraacetic acid, disodium salt
perma kleer 50 crystals disodium salt
sequestrene na2
trilon b
inchi=1/c10h16n2o8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6h2,(h,13,14)(h,15,16)(h,17,18)(h,19,20
disodium salt of edta
d'e.d.t.a. disodique
2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid
dr-16133
ethylenediaminetetraacetate, disodium salt
versene na
chelaton 3
chelaplex iii
diso-tate
selekton b2
edathamil disodium
trilon bd
disodium sequestrene
dissolvine e
seq 100
edta acid
cheelox bf acid
ai3-17181
perma kleer 50 acid
warkeelate acid
metaquest a
hamp-ene acid
kyselina ethylendiamintetraoctova [czech]
sequestric acid
vinkeil 100
chelest 3a
acide edetique [inn-french]
trilon bw
edetic acid [ban:inn]
trilon bs
acroma dh 700
questex 4h
tetrine acid
acetic acid, 2,2',2'',2'''-(1,2-ethanediyldinitrilo)tetrakis-
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
caswell no. 438
epa pesticide chemical code 039101
gluma cleanser
sequestrene aa
acetic acid, (ethylenedinitrilo)tetra-
EDT ,
zonon ao
acidum edeticum [inn-latin]
titriplex
cheelox
celon a
universne acid
titriplex ii
versene acid
4-04-00-02449 (beilstein handbook reference)
komplexon ii
ethylenebisiminodiacetic acid
yd 30
sequestrol
celon ath
acide ethylenediaminetetracetique [french]
havidote
clewat taa
hsdb 809
glycine, n,n'-1,2-ethanediylbis(n-(carboxymethyl)-
icrf 185
acido edetico [inn-spanish]
quastal special
ccris 946
techrun do
3,6-diazaoctanedioic acid, 3,6-bis(carboxymethyl)-
chemcolox 340
60-00-4
ethylenediaminetetraacetic acid
C00284
edetic acid
EDTA ,
ethylenediaminetetraacetic acid, 99.995% trace metals basis
ethylenediaminetetraacetic acid, bioultra, anhydrous, >=99% (titration)
ethylenediaminetetraacetic acid, anhydrous, crystalline, bioreagent, suitable for cell culture
ethylenediaminetetraacetic acid, purified grade, >=98.5%, powder
ethylenediaminetetraacetic acid, acs reagent, 99.4-100.6%, powder
(ethane-1,2-diyldinitrilo)tetraacetate
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
(ethylenedinitrilo)tetraacetic acid, ion(4-)
acide ethylenediaminetetracetique
CHEBI:42191 ,
edta, ion(4-)
DB00974
NCGC00159485-02
calcium disodium versenate (tn)
NCGC00159485-03
KBIO3_001184
KBIOSS_001498
KBIO2_004066
KBIO2_001498
KBIOGR_001161
KBIO2_006634
SPECTRUM2_000003
NINDS_000777
SPBIO_000005
SPECTRUM4_000531
SPECTRUM3_000412
IDI1_000777
NCGC00159485-04
acid, ethylenedinitrilotetraacetic
caedta
acid, ethylenediaminetetraacetic
acid, edetic
STK386291
37C3C5E7-D921-445F-82D6-FEBF1AE5AEF5
AC-10615
MLS001249457
smr000058776
CHEMBL858 ,
ethylenebis(iminodiacetic acid)
edetate
AKOS001574475
tricon bw
FT-0668254
E0084
2-[2-[bis(2-hydroxy-2-oxoethyl)amino]ethyl-(2-hydroxy-2-oxoethyl)amino]ethanoic acid
A832566
9g34hu7rv0 ,
unii-9g34hu7rv0
edetic acid [inn:ban:nf]
ec 200-449-4
kyselina ethylendiamintetraoctova
688-55-1
glycine, (n,n'-1,2-ethanediylbis(n-(carboxymethyl)-, labeled with carbon-14
{[2-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid(edta)
{[2-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
[{2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino]acetic acid
bdbm50330325
2,2'',2'''',2''''''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid
2-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid
dtxsid6022977 ,
tox21_202736
NCGC00260284-01
dtxcid902977
cas-60-00-4
calcium disodium edetate (jan)
FT-0626319
anticoagulant ethylenediamine tetraacetic acid (edta)
anticoagulant ethylenediamine tetraacetic acid
edetic acid [usp-rs]
edetic acid [hsdb]
edta [mi]
edetic acid [who-dd]
edetic acid [inn]
edetic acid [ii]
edetic acid [mart.]
edta [inci]
edta [vandf]
edetic acid [ep monograph]
S6350
versene-13c4
470462-56-7
edta, anhydrous
ethylenediamine-tetraacetic acid (edta)
disodium-edta
ethylenediamine tetracetic acid
ethylenediamine-tetraacetic acid
ethylenediamine tetra-acetic acid
ethylene-diamine tetraacetic acid
ethylenediaminetetracetic acid
J-610078
([2-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino)-acetic acid
edta, free base
edta, free acid
(ethylenedintrilo)tetraacetic acid
diaminoethanetetra-acetic acid
n,n'-1,2-ethanediylbis[n-(carboxymethyl)]glycine
ethylene diamine tetraacetic acid
AB00053468_03
mfcd00003541
ethylenediaminetetraacetic acid, electrophoresis grade
ethylenediaminetetraacetic acid, cell culture reagent
ethylenediaminetetraacetic acid, anhydrous, free-flowing, redi-dri(tm), >=98%
sr-01000883946
SR-01000883946-1
edetic acid, united states pharmacopeia (usp) reference standard
ethylenediaminetetraacetic acid, saj special grade, >=99.0%
ethylenediaminetetraacetic acid, bioultra, >=99.0% (kt)
ethylenediaminetetraacetic acid, >=98.0% (kt)
edta, anhydrous acs grade
ethylenediaminetetraacetic acid, lr, >=98%
ethylenediaminetetraacetic acid, p.a., 98.0%
ethylenediaminetetraacetic acid, anhydrous, free-flowing, powder, redi-dri(tm), acs reagent, 99.4-100.6%
ethylenediaminetetraacetic acid, vetec(tm) reagent grade, 98%
SBI-0051360.P003
Q408032
Z2588038976
ethylenediamine-n,n,n inverted exclamation mark ,n inverted exclamation mark -tetraacetic acid-13c4 (|a-labels)
FT-0668253
STR08855
ethylenediaminetetraacetic-acid
ethylen-ediamine tetra-acetic acid
ethylenediaminetetraacetic acid sodium salt solution
CS-B1827
n,n-1,2-ethanediylbis[n-(carboxymethyl)]glycine
HB5135
HY-Y0682
EN300-71613
n, n-1,2-ethanediylbis(n-(carboxymethyl)glycine)
edetic
edetic acid (mart.)
edetic acid (usp-rs)
caswell no 438
acide edetique (inn-french)
edetic acid (ep monograph)
ethylene diamine tetra acetic acid
(ethylenedinitrilo) tetraacetic acid
usepa/opp pesticide code: 039101
glycine, n, n'-1,2-ethanediylbis-n-(carboxymethyl)
ethylene bis (iminodiacetic acid)
acidum edeticum (inn-latin)
acido edetico (inn-spanish)
versenic acid
edetic acid (ii)
3,6-diazooctanedioic acid, 3,6-bis(carboxymethyl)-
n,n'-1,2-ethanediylbis(n-carboxymethyl)-glycine
((-(bis-carboxymethyl-amino)-ethyl)-carboxymethyl-amino)-acetic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A product of global importance, the potato tuber contains toxic glycoalkaloids (GAs) that cause sporadic outbreaks of poisoning in humans, as well as many livestock deaths."( Potato glycoalkaloids: true safety or false sense of security?
El'skaya, AV; Jaffrezic-Renault, N; Korpan, YI; Martelet, C; Nazarenko, EA; Skryshevskaya, IV, 2004
)
0.32
" Toxicity of proteases expressed as LD50 units equals 78 - 10(3) TU per larva of Galleria mellonella."( Exocellular proteases of Serratia marcescens and their toxicity to larvae of Galleria mellonella.
Chaloupka, J; Kaska, M; Lysenko, O, 1976
)
0.26
"Calcium chelating agents, such as ethylenediaminetetraacetate are toxic to urothelium."( Rationale for local toxicity of calcium chelators.
Cuvelier, C; Oosterlinck, W; Verbeeck, R; Vergauwe, D, 1992
)
0.28
" We propose that oxidative events contribute to the toxic mechanism of action of methyl mercury in isolated cerebellar granule neurons."( Oxidative mechanisms underlying methyl mercury neurotoxicity.
Sarafian, T; Verity, MA, 1991
)
0.28
"The effect of toxic substances on the functional state of liver mitochondria has been studied."( [Activation of lipid peroxidation in the liver mitochondria and acute toxicity of chemical compounds].
Chamorovskaia, LT; MItrokhin, NM; Zhigacheva, IV, 1991
)
0.28
" This hypothesis is supported by acute toxicity experiments, which demonstrate that despite a 50-fold range of LD50 values for four Gd complexes, all become lethally toxic when they release precisely the same quantity of Gd3+, and by subchronic rodent toxicity experiments, which demonstrate a set of gross and microscopic findings similar to those known to be caused by Zn2+ deficiency."( The relationship between thermodynamics and the toxicity of gadolinium complexes.
Cacheris, WP; Quay, SC; Rocklage, SM, 1990
)
0.28
" Chromium proved to be much more toxic than tin, as it inhibited growth yield (49%), carbon fixation (53%), and nitrate reductase (79%), glutamine synthetase (30%), and nitrogenase activities (77%) at its sublethal concentration, whereas tin induced less inhibition of growth yield (42%), carbon fixation (50%), and nitrate reductase (66%), glutamine synthetase (32."( Protective effects of certain natural and synthetic complexans on the toxicity of chromium and tin to a N2-fixing cyanobacterium, Anabaena doliolum.
Dubey, SK; Rai, LC, 1989
)
0.28
"The LD50 of the following metal-binding chelating drugs, EDTA, diethylenetriaminepentaacetic acid (DTPA), hydroxyethylenediaminetriacetic acid (HEDTA), cyclohexanediaminotetraacetic acid (CDTA) and triethylenetetraminehexaacetic acid (TTHA) was evaluated in terms of mortality in rats after intraperitoneal administration and was found to be in the order: CDTA greater than EDTA greater than DTPA greater than TTHA greater than HEDTA."( Evaluation of LD50 of some polyaminocarboxylic acids used as chelating drugs in metal intoxication.
Athar, M; Behari, JR; Dwivedi, PP; Srivastava, RC,
)
0.13
" We conclude that in vitro oxygen metabolites, extracellularly generated, have a direct toxic effect on gastric mucosal cells; hydrogen peroxide is a major mediator of oxygen metabolite-induced gastric cell injury; the oxygen-derived superoxide and hydroxyl radicals are less toxic to gastric mucosal cells than hydrogen peroxide; and intracellular glutathione, which detoxifies hydrogen peroxide, may be involved in antioxidant defense mechanisms."( Oxygen metabolite-induced cytotoxicity to cultured rat gastric mucosal cells.
Hiraishi, H; Ivey, KJ; Ota, S; Sugimoto, T; Terano, A, 1987
)
0.27
" The results suggest that many adverse effects of lead in pregnant rats can be favourably reduced by CaNa2EDTA."( Influence oe calcium disodium edetate on the toxic effects of lead administration in pregnant rats.
Flora, SJ; Tandon, SK,
)
0.13
"A drug registry was established at Southern California College of Optometry (SCCO) to study use rates and incidence of adverse side effects of the nine pharmaceutical agents in the California optometry law."( Use of diagnostic pharmaceutical agents and incidence of adverse effects.
Applebaum, M; Jaanus, SD, 1983
)
0.27
" This toxic side effect was significantly reduced by oral treatment with CaNa2EDTA."( Mitigation of intestinal cytotoxicity of cisplatin by EDTA in rats.
Choie, DD; Copley, MP; Gindhart, TD, 1983
)
0.27
" None of the tested agents was able to reduce the toxic effects of triethyl lead."( On the toxic effects of tetraethyl lead and its derivatives on the chrysophyte Poterioochromonas malhamensis. IV. Influence of lead antidotes and related agents.
Röderer, G, 1983
)
0.27
" Irreversible cardiomyopathy is a serious and dose-limiting side effect after chronic administration."( Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Bast, A; van Acker, SA; van Asbeck, BS; van der Vijgh, WJ; Voest, EE, 1994
)
0.29
"We evaluated the toxic effects of four currently used chemolytic solvents--dimethyl sulfoxide (DMSO, 99%), ethyl propionate (EP, 99%), tetrasodium ethyl-dimethyl tetraacetate (4Na-EDTA, 2%, pH 11), and methyl tert-butyl ether (MTBE, purity = 99."( Toxic effects of cholelitholytic solvents on gallbladder and liver. A piglet model study.
Chang, KK; Chen, CY; Chou, TC; Chow, NH; Leow, TC; Lin, XZ, 1995
)
0.29
" The no observable adverse effect level (NOAEL) for maternal and developmental toxicity of CDTA in mice was 540 mg/kg/day."( Developmental toxicity of cyclohexanediaminetetraacetic acid (CDTA) in mice.
Colomina, MT; Corbella, J; Domingo, JL; Llobet, JM; Sánchez, DJ, 1994
)
0.29
" The authors conclude that slow administration of 5 mumol/kg Mn-DPDP at a concentration of 10 mumol/mL is safe and efficient enough to proceed to further clinical trials."( Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients.
Aicher, KP; Claussen, CD; Duda, SH; Grönewäller, E; Kopp, AF; Laniado, M,
)
0.13
" No toxicity was observed when cells were exposed to 100 microM Zn- or Fe-EDTA, but the same concentration of Cu-EDTA was as toxic as Na-EDTA."( On the toxicity of low doses of tetrasodium-ethylenediamine-tetraacetate (Na-EDTA) in normal rat kidney (NRK) cells in culture.
Hugenschmidt, S; Planas-Bohne, F; Taylor, DM, 1993
)
0.29
" Elevation of temperature increased intracellular Cd uptake and this resulted in enhanced toxic effects."( Role of certain environmental factors on cadmium uptake and toxicity in Spirodela polyrhiza (L.) Schleid. and Azolla pinnata R. Br.
Gaur, JP; Noraho, N, 1995
)
0.29
" The most toxic pore water samples were from stations near a rayon factory, known as a source of copper and ammonium discharges."( Toxicity identification evaluation of Lake Orta (Northern Italy) sediments using the Microtox system.
Bartone, C; Guzzella, L; Muntau, H; Ross, P; Tartari, G, 1996
)
0.29
" These results suggest that H2O2 is more toxic to colonic epithelial cells than 02."( Hydrogen peroxide-mediated cytotoxicity to cultured colonic epithelial cells.
Hata, Y; Hiraishi, H; Ivey, KJ; Kawabe, T; Ota, S; Terano, A, 1997
)
0.3
" Hg was more toxic in ASTM than in M7 and in EEC media."( Suitability of test media containing EDTA for the evaluation of acute metal toxicity to Daphnia magna straus.
Diamantino, TC; Gonçalves, F; Guilhermino, L; Ribeiro, R; Soares, AM, 1997
)
0.3
"We studied the enhancing and toxic effects of five different absorption enhancers on the transport of FITC-dextran with an average molecular weight of 4000 (FD-4) across Caco-2 cell monolayers, and their enhancing effects were also compared with those in rat intestine."( Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers.
Fujita, T; Hattori, K; Lundborg, E; Murakami, M; Muranishi, S; Quan, YS; Yamamoto, A, 1998
)
0.3
" Comparison of toxic effects based on cell viability and adenine nucleotide levels showed that beta-thujaplicin was more toxic than tropolone or tropone in Krebs-Henseleit buffer containing EDTA (4 mM)."( Mechanism of mitochondrial dysfunction and cytotoxicity induced by tropolones in isolated rat hepatocytes.
Nakagawa, Y; Tayama, K, 1998
)
0.3
" Monovalent nitrate mercury Hg(NO3)2 was more toxic than bivalent Hg(NO3)2."( Toxicity of organic and inorganic mercury to Saccharomyces cerevisiae.
Aoyama, I; Kungolos, A; Muramoto, S, 1999
)
0.3
" The toxic effects of EDTA included breast-milk cell loss, disruption of milk fat globule membrane and subsequent release of membrane-bound protein, free fatty acids and reduction in pH."( Cytotoxicity of EDTA used in biological samples: effect on some human breast-milk studies.
Ogundele, MO,
)
0.13
"Hemoglobin (Hb) is a toxic molecule responsible for the extreme lethality associated with experimental Escherichia coli peritonitis, but the mechanism has yet to be elucidated."( Hemoglobin toxicity in experimental bacterial peritonitis is due to production of reactive oxygen species.
Han, JA; Kim, KM; Kim, SS; Kim, YM; Lea, HZ; Yoo, YM, 1999
)
0.3
" For this latter cell type, the presence of WC almost doubled (at 25 microg Co/well) the toxic effects compared to pure Co, but this synergy between Co and WC only occurred if the particles were in close contact with the cells."( In vitro cytotoxicity of various forms of cobalt for rat alveolar macrophages and type II pneumocytes.
Demedts, M; Dinsdale, D; Hoet, PH; Nemery, B; Roesems, G, 2000
)
0.31
"The hypothesis, that metal toxicity is dominated by free ion activity, was tested by comparing calculated metal activities with measured toxic responses to a genetically modified, luminescent bacterium, Escherichia coli."( The effect of EDTA and fulvic acid on Cd, Zn, and Cu toxicity to a bioluminescent construct (pUCD607) of Escherichia coli.
Campbell, CD; Hird, M; Lumsdon, DG; Meeussen, JC, 2000
)
0.31
" In chronic toxicity studies, diets containing as much as 5% EDTA were without adverse effects."( Safety assessment of iron EDTA [sodium iron (Fe(3+)) ethylenediaminetetraacetic acid]: summary of toxicological, fortification and exposure data.
Borzelleca, J; Dickmann, R; Heimbach, J; Mohamedshah, F; Rieth, S; Samuel-Fernando, P; Sheehan, T; Slesinski, R, 2000
)
0.31
" Ibuprofen may be a suitable candidate for sustained release formulations since its effect may be prolonged without the danger of a shift of side effect from the upper to the lower GI tract."( Evaluation of gastrointestinal toxicity of ibuprofen using surrogate markers in rats: effect of formulation and route of administration.
Jamali, F; Khazaeinia, T,
)
0.13
" Adverse events were reported for 23% of the patients; most were mild to moderate in intensity, did not require treatment, and were not drug related."( Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety).
Anderson, MW; Borello, JA; Bova, JG; Brown, JJ; Chezmar, JL; Dachman, AH; Federle, MP; Fenstermacher, M; Foster, GS; Francis, IR; Freeny, PC; Halford, HH; Harmon, B; Harms, SE; Johnson, CD; Kenney, PJ; Klippenstein, DL; Lee, JK; Mattrey, R; Mitchell, DG; Pelsang, RE; Rubin, DL; Saini, S; Semelka, RC; Turner, DA; Weinreb, JC, 2000
)
0.31
" Minor adverse reactions, including nausea (1%-2% for all agents) and hives (<1% for all agents), occur in a very low percent of cases."( Safety of approved MR contrast media for intravenous injection.
Runge, VM, 2000
)
0.31
"This study was designed to determine whether a mixture of iodinated contrast material and gadopentetate dimeglumine used during MR arthrography yields free gadolinium ion, a systemically toxic metal."( Is a mixture of gadolinium and iodinated contrast material safe during MR arthrography?
Brown, RR; Clarke, DW; Daffner, RH, 2000
)
0.31
"Gadopentetate dimeglumine and iodinated contrast material can be mixed before MR imaging without any release of free gadolinium and are therefore safe for confirming the intraarticular placement of contrast material before MR arthrography."( Is a mixture of gadolinium and iodinated contrast material safe during MR arthrography?
Brown, RR; Clarke, DW; Daffner, RH, 2000
)
0.31
" Ammonium tetrathiomolybdate was itself toxic after injection into the hippocampus, but this toxicity was reduced by formation of a metal ion/tetrathiomolybdate complex with Cu+2."( Comparative effects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus.
Armstrong, C; Lees, GJ; Leong, W, 2001
)
0.31
" The most common adverse events were hypotension, atrial fibrillation, and hypocalcaemia."( Safety and efficacy of propofol with EDTA when used for sedation of surgical intensive care unit patients.
Cason, B; Fulda, GJ; Hall, JB; Herr, DL; Hickey, R; Kelly, K; Nejman, AM; Teres, D; Ulatowski, J; Zaloga, GP, 2000
)
0.31
" The lowest dose reported to cause a toxic effect in animals was 750 mg/kg/day."( Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA.
Lanigan, RS; Yamarik, TA, 2002
)
0.31
" Exposures, including adverse events, to iron supplements and iron-containing vitamins for the years 1999 and 2000 were 23,215 and 24,249, respectively."( Acute toxicity of carbonyl iron and sodium iron EDTA compared with ferrous sulfate in young rats.
Ali, SF; Dunkel, VC; Imam, SZ; Whittaker, P, 2002
)
0.31
"Sediment toxicity in silty marine harbor sediments is frequently dominated by ammonia or sulfide, leaving the adverse effects of persistent toxic substances unnoticed."( A toxicity identification evaluation of silty marine harbor sediments to characterize persistent and non-persistent constituents.
Dubbeldam, MC; Ho, KT; Schot, ME; Stronkhorst, J, 2003
)
0.32
" EDDS was also less toxic to soil fungi, as determined by phospholipid fatty acid (PLFA) analysis, and caused less stress to soil microorganisms, as indicated by the trans to cis PLFA ratio."( Ethylenediaminedissuccinate as a new chelate for environmentally safe enhanced lead phytoextraction.
Grcman, H; Lestan, D; Velikonja-Bolta, S; Vodnik, D,
)
0.13
" Adverse events and discomfort were recorded and graded in all patients."( Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis.
de Beeck, BO; Fagertun, H; Fog, AF; Kane, P; Martí-Bonmatí, L, 2003
)
0.32
" Further, in vitro hatching of the separated embryos was successful indicating that the present technique is safe and effective in achieving individual separation of prawn embryos."( Enzymatic digestion--a safe and rapid technique for individual separation of Macrobrachium rosenbergii embryos for cryopreservation studies.
Mohanty, J; Pillai, BR, 2003
)
0.32
"Since the San Francisco Regional Monitoring Program (RMP) sampling began, elutriate samples prepared with sediment from the Grizzly Bay monitoring station have been consistently toxic to bivalve larvae (Mytilus galloprovincialis)."( Causes of sediment toxicity to Mytilus galloprovincialis in San Francisco Bay, California.
Anderson, BS; Hoenicke, R; Hunt, JW; Lowe, S; Phillips, BM; Thompson, B; Tjeerdema, R, 2003
)
0.32
" Among the 13 priority pollutant metals, beryllium (Be) was found to be the most toxic in the test (LOEC=0."( Toxicity of the 13 priority pollutant metals to Vibrio fisheri in the Microtox chronic toxicity test.
Hsieh, CY; Pancorbo, OC; Ryan, DK; Tsai, MH, 2004
)
0.32
" However, metals in sewage sludge might accumulate in soil after repeated sludge applications, and metal concentrations might reach concentrations that are toxic to microorganisms, soil organisms and/or plants."( Identification of metal toxicity in sewage sludge leachate.
Ahlberg, G; Dave, G; Fjällborg, B; Nilsson, E, 2005
)
0.33
"Both EDTA and citric acid had effects on macrophages cells ex vivo, but citric acid was less toxic in periods from 1 to 7 days of use."( Cytotoxicity analysis of EDTA and citric acid applied on murine resident macrophages culture.
Amaral, KF; Borelli, P; Fock, RA; Gavini, G; Rogero, MM, 2007
)
0.34
" Vaporized KMT reagent could be used for the safe and easy sterilization of cabinets contaminated with Bacillus spores."( Sterilization of a biological safety cabinet by vaporized KMT reagent.
Kida, N; Mochizuki, Y; Taguchi, F, 2007
)
0.34
" In order to understand the toxic effects of these additives, membrane status by AFM vis-à-vis K(+) ion efflux were followed in the absence and in the presence of Cu(II) ions or its complexes."( Toxicity of free and various aminocarboxylic ligands sequestered copper(II) ions to Escherichia coli.
Bhattacharyya, SN; Chakraborty, A; Saha, A; Saha, KC; Selvaraj, S, 2009
)
0.35
"This study for the first time, clearly demonstrated the significantly less toxic effect of MA at a comparable dose of EDTA, suggesting its potential for use as root canal irrigant."( A comparative in vitro evaluation of cytotoxic effects of EDTA and maleic acid: root canal irrigants.
Ballal, NV; Bhat, S; Kundabala, M; Rao, BS; Rao, N, 2009
)
0.35
"A previous study found that coke leachates (CL) collected from oil sands field sites were acutely toxic to Ceriodaphnia dubia; however, the cause of toxicity was not known."( Identifying the causes of oil sands coke leachate toxicity to aquatic invertebrates.
Liber, K; Puttaswamy, N, 2011
)
0.37
" No adverse effects, abnormal blood biochemical markers, or organ damage were observed in rats 1 mo following intraperitoneal injection with EDTA at doses up to 60 mmol/L."( Safety and efficacy of ethylenediaminetetraacetic acid for removing microcapsules.
Feng, J; Gao, Q; Liu, R; Lv, B; Ren, M; Wu, Y; Zhao, Z; Zhou, Y, 2013
)
0.39
" An innovative sample preparation procedure based on the quick, easy, cheap, effective, rugged and safe (QuEChERS) method was developed."( Determination of 136 pharmaceuticals and hormones in sewage sludge using quick, easy, cheap, effective, rugged and safe extraction followed by analysis with liquid chromatography-time-of-flight-mass spectrometry.
Peysson, W; Vulliet, E, 2013
)
0.39
" Manufacturers have responded by offering packs with a donor line break cannula (DLBC) to prevent these adverse effects."( The donor line break cannula: effect on the donation process, blood component quality and transfusion microbiology testing of an important new blood bag safety feature.
Beard, MJ; Bennett, J; Hambleton, R; Nightingale, MJ; Ramskill, S; Thomas, S, 2013
)
0.39
"Results indicated no clinically significant adverse effect from the DLBC on the activation state of platelets, the coagulation cascade or increased haemolysis."( The donor line break cannula: effect on the donation process, blood component quality and transfusion microbiology testing of an important new blood bag safety feature.
Beard, MJ; Bennett, J; Hambleton, R; Nightingale, MJ; Ramskill, S; Thomas, S, 2013
)
0.39
" Toxic impacts are discussed and appear to be proportional to body burden of cadmium."( Cadmium toxicity and treatment.
Bernhoft, RA, 2013
)
0.39
" Fractionation and leachability of toxic metals were analyzed by sequential extraction and TCLP and metal bioaccessibility by UBM tests."( Effect of EDTA washing of metal polluted garden soils. Part I: Toxicity hazards and impact on soil properties.
Jelusic, M; Lestan, D, 2014
)
0.4
" Furthermore, SEM analysis indicated test treatments were not toxic or damaging to mucosal cilia."( Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis.
Boase, S; Cleland, E; Drilling, A; James, C; Jardeleza, C; Jervis-Bardy, J; Morales, S; Speck, P; Tan, NC; Vreugde, S; Wormald, PJ, 2014
)
0.4
" Although a widely used and extremely safe insect repellent, DEET can be highly toxic in large but easily obtainable doses."( A lethal case of DEET toxicity due to intentional ingestion.
Casavant, M; Castillo, U; Russell, J; Spiller, H; Wiles, D; Yee, J,
)
0.13
" All patients tolerated the therapy without any acute adverse effects."( 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum, RP; Klette, I; Kulkarni, HR; Mueller, D; Schottelius, M; Schuchardt, C; Singh, A; Wester, HJ; Wiessalla, S; Wirtz, M, 2016
)
0.43
" Inorganic cobalt salts are quite toxic (cyanide and cobalt antagonise one another's toxicity) and complexes such as dicobalt edetate were studied with the aim of identifying compounds that were less acutely toxic, but which retained the antidotal properties of cobalt salts."( The efficacy and adverse effects of dicobalt edetate in cyanide poisoning.
Marrs, TC; Thompson, JP, 2016
)
0.43
"The aim of this study was to evaluate the published evidence for the efficacy and adverse effects of dicobalt edetate."( The efficacy and adverse effects of dicobalt edetate in cyanide poisoning.
Marrs, TC; Thompson, JP, 2016
)
0.43
" Adverse effects of dicobalt edetate: Adverse effects reported have included hypertension, tachycardia, nausea, retrosternal pain, sweating, palpebral, facial and laryngeal oedema, vomiting, urticaria and/or a feeling of impending doom."( The efficacy and adverse effects of dicobalt edetate in cyanide poisoning.
Marrs, TC; Thompson, JP, 2016
)
0.43
"Dicobalt edetate is an effective cyanide antidote when given to patients with systemic cyanide poisoning, but it has the potential to give rise to adverse reactions, particularly when administered in the absence of intoxication."( The efficacy and adverse effects of dicobalt edetate in cyanide poisoning.
Marrs, TC; Thompson, JP, 2016
)
0.43
" The primary end-point was the occurrence of hydraulic resistance and secondary safety end-point was adverse drug reactions related to the lock solutions."( The CLOCK trial, a double-blinded randomized controlled trial: Trisodium citrate 30% and minocycline 3 mg/mL plus EDTA 30 mg/mL are effective and safe for catheter patency maintenance among CKD 5D patients on hemodialysis.
Luiz, MV; Scavone, C; Tzanno, C, 2017
)
0.46
" The objective of this study was to investigate the efficacy of this drug in patients with Extended Spectrum Beta Lactamases/Metallo Beta lactamases infections and identify the incidence of adverse events in real clinical settings."( Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Ayub, SG; Chaudhary, M; Mir, MA,
)
0.13
" Information regarding demographic, clinical and microbiological parameters, dosage and treatment duration, efficacy and adverse events (AEs) associated with the treatment were recorded."( Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Ayub, SG; Chaudhary, M; Mir, MA,
)
0.13
"In this post-marketing surveillance study, CSE-1034 was found to be an effective and safe option against Pip tazo and meropenem in management of patients with multi-drug resistant (MDR) bacterial infections under routine ward settings."( Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Ayub, SG; Chaudhary, M; Mir, MA,
)
0.13
" The reporting of clinical adverse events (AEs) and the measurement of blood pressure (BP) and heart rate (HR) were performed prior to injection (baseline); immediately after injection of Ga-PSMA-11 (postinjection); at 1, 10, and 60 minutes after injection; and after acquisition of the PET/CT scan (postscan)."( A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials.
Dettmann, K; Haberkorn, U; Langkilde, NC; Nielsen, JB; Nielsen, KM; Petersen, LJ; Zacho, HD, 2017
)
0.46
" We consider Ga-PSMA-11 to be safe for human application."( A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials.
Dettmann, K; Haberkorn, U; Langkilde, NC; Nielsen, JB; Nielsen, KM; Petersen, LJ; Zacho, HD, 2017
)
0.46
"A MNP containing a low dose of highly bioavailable iron reduces anaemia, and the addition of GOS mitigates most of the adverse effects of iron on the gut microbiome and morbidity in African infants."( Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomised controlled study in Kenyan infants.
Barth-Jaeggi, T; Boekhorst, J; Cercamondi, CI; Karanja, S; Kortman, GAM; Lacroix, C; Moretti, D; Paganini, D; Schwab, C; Timmerman, HM; Uyoga, MA; Zimmermann, MB, 2017
)
0.46
" DMSA has considerably lower toxicity than the classic heavy metal antagonist BAL (2,3-dimercaptopropanol) and is also less toxic than DMPS."( Metal chelators and neurotoxicity: lead, mercury, and arsenic.
Aaseth, J; Bjørklund, G; Mutter, J, 2017
)
0.46
" Although these results were obtained from experimental animals, ophthalmologists should keep in mind the potential ophthalmic adverse effects of this medicine and/or its excipients and exercise caution with drugs containing xylometazoline, ethylene diamine tetra acetic acid, benzalkonium chloride and sorbitol for patients with underlying ocular problems."( Ophthalmic adverse effects of nasal decongestants on an experimental rat model.
Basal, Y; Birincioglu, S; Cakiroz, G; Cakmak, H; Demirci, B; Eliyatkın, N; Kocaturk, T; Unsal, A; Unsal, AIA; Yukselen, O,
)
0.13
" Both products were safe and well tolerated with no secondary cases of VVC; vulvovaginal burning was the most common adverse event (9."( Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial.
Dithmer, D; Dombrowski, JC; Marrazzo, JM; Perlowski, C; Pontius, A; Schwebke, J; Wierzbicki, MR, 2019
)
0.51
"TOL-463, especially in vaginal insert form, is effective and safe in treating BV and VVC."( Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial.
Dithmer, D; Dombrowski, JC; Marrazzo, JM; Perlowski, C; Pontius, A; Schwebke, J; Wierzbicki, MR, 2019
)
0.51
" This regimen was introduced in the 1970s and has remained largely unchanged even though the initial NAC infusion is frequently associated with adverse reactions, in particular nausea, vomiting, and anaphylactoid reactions."( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi
Dear, J, 2019
)
0.51
" This study will provide valuable data regarding the incidence of adverse events caused by the 12-h NAC plus PP100-01 regimen and may provide evidence of PP100-01 efficacy in the treatment of paracetamol-induced liver injury."( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi
Dear, J, 2019
)
0.51
"Neurotoxicity can be caused by numerous direct agents, of which toxic metals, organophosphorus pesticides, air pollution, radiation and electromagnetic fields, neurotoxins, chemotherapeutic and anesthetic drugs, and pathogens are the most important."( EDTA Chelation Therapy for the Treatment of Neurotoxicity.
Ferrero, ME; Fulgenzi, A, 2019
)
0.51
" The "hybrid" Phase I-Phase II TIE sequence proved to be a reliable and effective tool for the identification of main toxicant of concern in a highly toxic and contaminated interstitial water sample, also in presence of high concentration of potential confounding factors (ammonia)."( A Hybrid Phase I-Phase II Toxicity Identification Evaluation (TIE) for the Simultaneous Characterization and Identification of Toxicants of Concern in Coastal and Estuarine Environments.
Corami, F; Picone, M; Vendramin, S; Volpi Ghirardini, A, 2019
)
0.51
" Primary endpoints: all participants experienced ≥1 adverse event (AE), most commonly gastrointestinal."( Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial).
Black, P; Dear, JW; Gallagher, B; Grahamslaw, J; Henriksen, D; Lee, RJ; Morrison, EE; O'Brien, R; Oatey, K; Oosthuyzen, W; Weir, CJ, 2019
)
0.51
" Toxicities related to radioligand therapy were low and transient with no serious adverse effects."( Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bal, C; Ballal, S; Damle, NA; Sahoo, RK; Seth, A; Tripathi, M; Yadav, MP, 2020
)
0.56
"Lu-PSMA-617 radionuclide therapy is a safe and effective approach to the treatment of mCRPC patients."( Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bal, C; Ballal, S; Damle, NA; Sahoo, RK; Seth, A; Tripathi, M; Yadav, MP, 2020
)
0.56
"Cetrimide alone as well as in combination with EDTA and MA at dilutions of 1/10 and 1/100 was significantly more toxic as compared to untreated controls (P < 0."( Antimicrobial activity, toxicity and accumulated hard-tissue debris (AHTD) removal efficacy of several chelating agents.
Ballal, NV; Bidossi, A; Das, S; Del Fabbro, M; Ferrari, L; Giardino, L; Maddalone, M; Rao, BSS; Savadori, P, 2020
)
0.56
"Both intravenous and oral treatments evaluated in this study, were effective and safe about the cardiovascular risk in "frailty" elderly patients, as resulted from non-linear HRV analysis."( A pilot study on secondary anemia in "frailty" patients treated with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine: safety of treatment explored by HRV non-linear analysis as predictive
Curcio, A; Iannarelli, N; Marchitto, N; Paparello, PT; Petrucci, A; Pironti, M; Raimondi, G; Romano, A, 2020
)
0.56
"Non-linear HRV evaluation confirmed that oral administration of Ferric Sodium EDTA, in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine (Ferachel forte®) did not impact the cardiovascular risk, without causing adverse events typically reported with other iron supplementation therapies, both oral and intravenous."( A pilot study on secondary anemia in "frailty" patients treated with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine: safety of treatment explored by HRV non-linear analysis as predictive
Curcio, A; Iannarelli, N; Marchitto, N; Paparello, PT; Petrucci, A; Pironti, M; Raimondi, G; Romano, A, 2020
)
0.56
"Fomepizole (4-methylpyrazole) is safe and has shown efficacy in preclinical models, human hepatocytes and in volunteers against APAP overdose."( Novel strategies for the treatment of acetaminophen hepatotoxicity.
Akakpo, JY; Jaeschke, H; Ramachandran, A, 2020
)
0.56
" The bioconcentration of toxic metals in edible plant parts was generally lower in the remediated soils."( Demonstration gardens with EDTA-washed soil. Part III: Plant growth, soil physical properties and production of safe vegetables.
Gluhar, S; Kastelec, D; Kaurin, A; Lestan, D; Vodnik, D; Zupanc, V, 2021
)
0.62
" Short-term HBED administration appeared to be safely tolerated by horses, therefore it was anticipated it would also be safe to administer to black rhinos for the management of iron overload."( Safety and efficacy of a novel iron chelator (HBED; (N,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid)) in equine (Equus caballus) as a model for black rhinoceros (Diceros bicornis).
Knutson, M; Lavin, SR; Livingston, S; Sullivan, KE; Valdes, EV; Warren, LK, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The method was successfully applied to a pharmacokinetic study of solasodine after oral administration of 20mg/kg in rats."( Development and validation a liquid chromatography mass spectrometry for determination of solasodine in rat plasma and its application to a pharmacokinetic study.
An, X; Ding, X; Lin, C; Lin, G; Ma, J; Sun, C; Wang, X; Yang, X, 2014
)
0.4
" This method was applied to a pharmacokinetic and bioavailability study of solasodine."( Pharmacokinetics, oral bioavailability and metabolic analysis of solasodine in mice by dried blood spot LC-MS/MS and UHPLC-Q-Exactive MS.
Cheng, Z; Hu, B; Liu, K; Lu, T; Pang, J; Qu, M; Wang, Q; Xiao, Q; Xu, T; Xue, P; Zhang, Q, 2022
)
0.72
" Estimations of levels were made from the pharmacokinetic data (half life, distribution volume) which serve as a basis for the recommendation of isoconcentration dosages."( [Pharmacokinetics of intravenous Cefradin in normal and restricted renal function (author's transl)].
Höffler, D; Koeppe, P, 1975
)
0.25
"The pharmacokinetic properties of the x-ray contrast medium, iodixanol, a new nonionic dimer, were investigated in a phase I study including 40 healthy male volunteers."( Human pharmacokinetics of iodixanol.
Andrew, E; Haider, T; Hals, PA; Langseth-Manrique, K; Svaland, MG, 1992
)
0.28
" Average half-life of the markers was 8 h in the rumens of the less susceptible animals."( Rumen clearance rates in relation to the occurrence of alfalfa bloat in cattle. 1. Passage of water-soluble markers.
Hall, JW; Kalnin, CM; Majak, W; Rode, LM, 1986
)
0.27
"We investigated the influence of size and lipid composition on the pharmacokinetic behavior of liposomes and their contents in the rabbit eye."( Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes.
Barza, M; Stuart, M; Szoka, F, 1987
)
0.27
" The pharmacokinetic properties of iohexol, in combination with its low toxicity, make it a suitable agent for determination of glomerular filtration rate in clinical practice."( Contrast media and glomerular filtration: dose dependence of clearance for three agents.
Bäck, SE; Krutzén, E; Nilsson-Ehle, P, 1988
)
0.27
" Whole blood distribution and pharmacokinetic parameters were studied in nine cancer patients, and the results compared with previously reported studies using 57Co-bleomycin."( Pharmacokinetics of indium-111 BLEDTA in man.
DeRiemer, LH; Fajardo, LF; Goodwin, DA; Meares, CF; Sartoris, DJ,
)
0.13
" The biologic half-life was 121 minutes, comparable with that of other intravascular contrast media."( Human pharmacokinetics of iohexol. A new nonionic contrast medium.
Andrew, E; Aulie, A; Olsson, B; Sveen, K,
)
0.13
" Pharmacokinetic analysis showed that the elimination rate of warfarin was significantly decreased in the uraemic group after 2 weeks duration of uraemia and was even further decreased at the second examination 6 months later."( Pharmacokinetics of warfarin in rabbits during short-term and long-term uraemia.
Ladefoged, J; Ladefoged, O; Tvedegaard, E, 1981
)
0.26
" Two further equations were developed that use the 51Cr-EDTA half-life (t1/2) to calculate the GFR and these may reduce errors resulting from inaccurate measurement of the volume of distribution for 51Cr-EDTA."( Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
Balmanno, K; Calvert, AH; Keir, M; Lewis, IJ; Newell, DR; Pearson, AD; Pinkerton, CR; Price, L; Stevens, MC; Wyllie, RA, 1993
)
0.29
" Pharmacokinetic results were complementary with those of the biodistribution studies and provide a basis for the study of in vivo metabolic mechanisms of linker-immunoconjugates."( Introduction of five potentially metabolizable linking groups between 111In-cyclohexyl EDTA derivatives and F(ab')2 fragments of anti-carcinoembryonic antigen antibody--II. Comparative pharmacokinetics and biodistribution in human colorectal carcinoma-bea
Chatal, JF; Faivre-Chauvet, A; Gestin, JF; Mease, RC; Meinken, GE; Sai-Maurel, C; Slinkin, M; Srivastava, SC; Thédrez, P, 1993
)
0.29
" Plasma clearance was calculated by dividing the dose of marker with the area under the plasma concentration curve (AUC) from the time of injection to infinity using one-compartment (ClAUC-slope) and three-compartment (ClAUC-3comp) models."( Clearance of iohexol, chromium-51-ethylenediaminetetraacetic acid, and creatinine for determining the glomerular filtration rate in pigs with normal renal function: comparison of different clearance techniques.
Almén, T; Chai, CM; Frennby, B; Jönsson, BA; Månsson, S; Sterner, G, 1996
)
0.29
"The manganese (Mn) moiety is rapidly removed from plasma with an elimination half-life of less than 25 min in both species, reflecting a rapid distribution to the tissues and an early excretion."( Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration.
Grant, D; Hustvedt, SO; Southon, TE; Zech, K, 1997
)
0.3
" Thus, quantitative estimations of radiolabeling reagents were performed only by animal biodistribution studies, and the present pharmacokinetic analyses would be useful for screening of newly designed reagents for protein radiopharmaceuticals."( Pharmacokinetic models to evaluate radiolabeling reagents for protein radiopharmaceuticals.
Arano, Y; Mukai, T; Nakamura, J; Nishida, K; Saji, H; Sasaki, H; Yokoyama, A, 1998
)
0.3
" The outflow patterns of [111In]Gal-BSAs at various inflow concentrations were simultaneously fitted to a one-organ pharmacokinetic model, by which we can characterize their binding to the cell surface and internalization processes separately."( Pharmacokinetic analysis of hepatic uptake of galactosylated bovine serum albumin in a perfused rat liver.
Hashida, M; Nishikawa, M; Ogawara, K; Takakura, Y, 1998
)
0.3
" Originally, the ratio between the intravenously injected amount of tracer and the total area under the plasma concentration curve was used for the calculation of total 51Cr-EDTA plasma clearance (C(T))."( Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA.
Hansen, HP; Hommel, E; Mathiesen, ER; Parving, HH; Rossing, P; Smidt, UM, 1998
)
0.3
" Several alternative pharmacokinetic models are used for the calculation of clearance using various filtration markers with slightly different pharmacokinetic properties."( Pharmacokinetic aspects of measurement of glomerular filtration rate in the dog: a review.
Heiene, R; Moe, L,
)
0.13
"5 mg/kg), and racemic KT (5 mg/kg) were administered orally to male Sprague-Dawley rats and plasma samples were collected for 6 h post-dose for pharmacokinetic assessments."( Stereospecific pharmacokinetics and toxicodynamics of ketorolac after oral administration of the racemate and optically pure enantiomers to the rat.
Aberg, G; Corrigan, BW; Davies, NM; Jamali, F; Lovlin, R, 1999
)
0.3
" Pharmacokinetic studies demonstrated that concentrations of 90Y-labeled B72."( Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Cheung, L; Gano, J; Kavanagh, JJ; Kudelka, AP; Murray, JL; Rosenblum, MG; Verschraegen, CF, 1999
)
0.3
" Pharmacokinetic analysis showed rapid absorption and metabolism."( A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Bissett, D; Breimer, L; Campbell, S; Cassidy, J; DeMario, M; Ritland, S; Salazar, R; Twelves, C; Zhi, J, 2004
)
0.32
" This regimen is convenient, well tolerated, and has a favorable pharmacokinetic profile."( A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Bissett, D; Breimer, L; Campbell, S; Cassidy, J; DeMario, M; Ritland, S; Salazar, R; Twelves, C; Zhi, J, 2004
)
0.32
" To evaluate possible pharmacokinetic determinants of this response variability, we developed a sensitive and specific liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for quantification of unmodified inactive clopidogrel, its inactive carboxyl metabolite, and its active thiol metabolite in plasma."( Pharmacokinetics of clopidogrel after administration of a high loading dose.
Gorchakova, O; Harlfinger, S; Kastrati, A; Lazar, A; Schömig, A; Schömig, E; Taubert, D; von Beckerath, N, 2004
)
0.32
"The objective of this study was to determine pharmacokinetic parameters of sulfated tibolone metabolites after single dose and their accumulation after multiple doses of tibolone."( Pharmacokinetic parameters of sulfated tibolone metabolites in postmenopausal women after single and multiple doses of tibolone.
Kloosterboer, HJ; Timmer, CJ; Verheul, HA, 2007
)
0.34
"Tigecycline and ciprofloxacin were employed as the model compounds to study the effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA), which is used during plasma sample preparations, on the determination of pharmacokinetic parameters."( Effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA) on the estimation of pharmacokinetic parameters: A case study with tigecycline and ciprofloxacin.
Chen, Q; Ciccotto, SL; Ortiga, R; Ramsay, KA; Strauss, JR; Tang, W; Tung, EC, 2008
)
0.35
" Commonly, only the final part of the plasma concentration curve is measured, and a one-pool clearance (slope-intercept clearance), Cl(1), is computed."( Reassessment of a classical single injection 51Cr-EDTA clearance method for determination of renal function in children and adults. Part I: Analytically correct relationship between total and one-pool clearance.
Brøchner-Mortensen, J; Jødal, L, 2009
)
0.35
"Cl was determined in 149 subjects (M/F/children: 71/46/32) from a complete plasma concentration curve followed for 4-5 h after injection of (51)Cr-EDTA (range of clearance: 8-183 mL/min/1."( Reassessment of a classical single injection 51Cr-EDTA clearance method for determination of renal function in children and adults. Part I: Analytically correct relationship between total and one-pool clearance.
Brøchner-Mortensen, J; Jødal, L, 2009
)
0.35
"The influence of chitosan glutamate and carbomer 974P (alone and in combination with EDTA-Na2) on the in vitro Caco-2 permeability and oral pharmacokinetic profile in the rat of acyclovir was investigated."( Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.
Christoffersen, C; El-Kattan, A; Merzlikine, A; Poe, J; Rago, B; Rotter, C; Thomas, VH; Troutman, M, 2009
)
0.35
"To determine the pharmacokinetic (PK) profile of manganese (Mn) after a 2-hour intravenous infusion of mangafodipir at 5 micromol/kg body weight and to correlate Mn concentrations with oxidative stress, early decrease in serum total bilirubin concentration, and prothrombin time (PT) in chronic alcoholic patients with acute alcoholic hepatitis."( Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.
Batteux, F; Debray, M; Hirt, D; Laurent, A; Pavlovic, S; Poupon, J; Richardet, JP; Sogni, P; Treluyer, JM; Urien, S; Weill, B, 2009
)
0.35
" The primary pharmacokinetic parameters were T(max) (h) = (1."( A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study.
Bapuji, AT; Himabindu, V; Rao, VS; Ravinder, S; Reddy, DC, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" One hundred milimoles solution of TCA had 2-fold activity of a 25mM solution in the dissolution of both the slices and the whole concrement when it was used in combination with EDTA 4Na."( [Effect of proteolytic enzymes and bile salts combined with EDTA 4Na on the dissolution of calcium bilirubinate gallstones].
Cho, H; Shinya, F; Suzuki, N; Takahashi, W, 1987
)
0.27
" A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC) for ultrafilterable carboplatin using the Calvert formula."( A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.
Brunner, V; Bugat, R; Canal, P; Chatelut, E; Chevreau, C; Houin, G; Martinez, M, 1995
)
0.29
"The effects of sucrose esters of fatty acids, alone and in combination with ethylenediaminetetraacetic acid (EDTA), acetic acid, lactic acid and citric acid, on survival, growth and thermal inactivation of Listeria monocytogenes and Staphylococcus aureus were determined."( Inhibitory effects of sucrose monolaurate, alone and in combination with organic acids, on Listeria monocytogenes and Staphylococcus aureus.
Beuchat, LR; Hathcox, AK; Monk, JD, 1996
)
0.29
"Nisin or nisin combined with EDTA was used to treat fresh beef."( Reduction of Listeria monocytogenes and Escherichia coli O157:H7 numbers on vacuum-packaged fresh beef treated with nisin or nisin combined with EDTA.
Mustapha, A; Zhang, S, 1999
)
0.3
" Protamine was tested alone at concentrations from 0 to 10,000 microg/ml, and in combination with EDTA (0."( Antibacterial effect of protamine in combination with EDTA and refrigeration.
Austin, JW; Gill, TA; Hansen, LT, 2001
)
0.31
"The purpose of the present study was to compare ethylenediaminetetraacetic acid conditioning and phosphoric acid conditioning of dentin in combination with two principally different commercial dentin bonding systems."( Acid conditioning combined with single-component and two-component dentin bonding agents.
Blomlöf, J; Cederlund, A; Jonsson, B; Ohlson, NG, 2001
)
0.31
"Use of ethylenediaminetetraacetic acid in combination with All-Bond 2 resulted in a significantly greater bond strength to dentin than did conventional acid etching."( Acid conditioning combined with single-component and two-component dentin bonding agents.
Blomlöf, J; Cederlund, A; Jonsson, B; Ohlson, NG, 2001
)
0.31
" After the required regulatory approval, treatment of whole cantaloupe with nisin in combination with EDTA, NaL, KS, or NaL and KS and of fresh-cut pieces with nisin-NaL or NaL-KS could help ensure the microbiological safety of fresh-cut cantaloupe."( Effect of nisin in combination with EDTA, sodium lactate, and potassium sorbate for reducing Salmonella on whole and fresh-cut cantaloupet.
Fett, WF; Ukuku, DO, 2004
)
0.32
" cerevisiae was significantly enhanced in combination with polygodial."( Effect of EDTA alone and in combination with polygodial on the growth of Saccharomyces cerevisiae.
Ha, TJ; Kubo, I; Lee, SH, 2005
)
0.33
" Its use in combination with flow cytometry brought up new questions about how to interpret LIVE/DEAD staining results."( Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight Kit in combination with flow cytometry.
Berney, M; Bosshard, F; Egli, T; Hammes, F; Weilenmann, HU, 2007
)
0.34
"To identify synergistic combinations of different food additives, the antimicrobial effects of thymol and carvacrol against Salmonella Typhimurium were assessed alone and in combination with various other preservatives including EDTA, acetic acid, lactic acid, and citric acid."( Synergistic effect of thymol and carvacrol combined with chelators and organic acids against Salmonella Typhimurium.
Ji, B; Jiang, H; Li, J; Ren, Y; Yan, W; Yang, Z; Zhang, H; Zhou, F, 2007
)
0.34
" Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBC) of imipenem and meropenem alone and combined with EDTA, time-kill curves, PAE and PLIE were performed as described previously."( Postantibiotic and post-beta-lactamase inhibitor effect of carbapenems combined with EDTA against Pseudomonas aeruginosa strains producing VIM-metallo beta-lactamases.
Beader, N; Bedenić, B; Kalenić, S; Sviben, M; Vranes, J, 2008
)
0.35
"The duration of PAE with meropenem combined with EDTA at 8 x MIC was longer against both VIM-1 and VIM-2 producer than that of imipenem with EDTA on VIM-1- and VIM-2-positive strains."( Postantibiotic and post-beta-lactamase inhibitor effect of carbapenems combined with EDTA against Pseudomonas aeruginosa strains producing VIM-metallo beta-lactamases.
Beader, N; Bedenić, B; Kalenić, S; Sviben, M; Vranes, J, 2008
)
0.35
"The purpose of this study was to evaluate the amounts of debris and smear layer remaining on canal walls after preparation with ProTaper and Hero Shaper instruments in combination with NaOCl and EDTA irrigation in curved root canals."( Scanning electron microscopic evaluation of debris and smear layer remaining following use of ProTaper and Hero Shaper instruments in combination with NaOCl and EDTA irrigation.
Li, H; Wu, H; Yang, G; Zhang, H; Zheng, Y; Zhou, X, 2008
)
0.35
"Within the limitations of this study, both instruments in combination with NaOCl and EDTA irrigation produced a clean and debris-free canal surface in the coronal and middle thirds, but were unable to produce a canal surface free from debris and smear layer in the apical third."( Scanning electron microscopic evaluation of debris and smear layer remaining following use of ProTaper and Hero Shaper instruments in combination with NaOCl and EDTA irrigation.
Li, H; Wu, H; Yang, G; Zhang, H; Zheng, Y; Zhou, X, 2008
)
0.35
"To compare the short- and long-term sealing ability of root canal fillings consisting of AH-26 and laterally compacted gutta-percha in combination with a self-etching dentin bonding system and the Epiphany-Resilon system."( Long-term evaluation of the sealing ability of two root canal sealers in combination with self-etching bonding agents.
Economides, N; Gogos, C; Helvatjoglu-Antoniades, M; Kokorikos, I; Kolokouris, I, 2009
)
0.35
"The Epiphany-Resilon system and the group obturated with AH-26 sealer and gutta-percha, in combination with the self-etching bonding system after removal of the smear layer with EDTA, demonstrated similar sealing ability."( Long-term evaluation of the sealing ability of two root canal sealers in combination with self-etching bonding agents.
Economides, N; Gogos, C; Helvatjoglu-Antoniades, M; Kokorikos, I; Kolokouris, I, 2009
)
0.35
"Degradation of ethylenediaminetetraacetic acid (EDTA) in aqueous solution by means of ozonolysis or ozonolysis combined with sonolysis was investigated for a variety of operating conditions."( Degradation of EDTA in aqueous solution by using ozonolysis and ozonolysis combined with sonolysis.
Guo, P; Li, G; Luo, Z; Wang, J; Wang, X, 2010
)
0.36
"The main objective of this study was to evaluate the clinical effectiveness of platelet-rich fibrin membrane used in combination with a coronally advanced flap (CAF) and to compare it with the use of an enamel matrix derivative (EMD) in combination with a coronally advanced flap in gingival recession treatment."( The coronally advanced flap in combination with platelet-rich fibrin (PRF) and enamel matrix derivative in the treatment of gingival recession: a comparative study.
Aleksic, Z; Dimitrijevic, B; Jankovic, S; Milinkovic, I, 2010
)
0.36
"20 split-mouth cases of maxillary anterior teeth or bicuspids presenting with Miller Class I or II gingival recession were treated with a CAF combined with a platelet-rich fibrin membrane (PRF group) or with EMD (EMD group) placed under a CAF."( The coronally advanced flap in combination with platelet-rich fibrin (PRF) and enamel matrix derivative in the treatment of gingival recession: a comparative study.
Aleksic, Z; Dimitrijevic, B; Jankovic, S; Milinkovic, I, 2010
)
0.36
"This in vitro study evaluated (1) the dissolution of bovine pulp tissue in solutions consisting of varying NaOCl concentrations and combined with EDTA; and (2) the pH of these solutions before and after the experiment."( Dissolution of bovine pulp tissue in solutions consisting of varying NaOCl concentrations and combined with EDTA.
Grazziotin-Soares, R; Irala, LE; Munari, AZ; Pereira, JS; Salles, AA,
)
0.13
"The purpose of the present study is to evaluate the 10-year results following treatment of intrabony defects treated with an enamel matrix protein derivative (EMD) combined with either a natural bone mineral (NBM) or β-tricalcium phosphate (β-TCP)."( Ten-year results following treatment of intrabony defects with an enamel matrix protein derivative combined with either a natural bone mineral or a β-tricalcium phosphate.
Agics, A; Arweiler, NB; Döri, F; Gera, I; Sculean, A; Szántó, E, 2013
)
0.39
" Therefore, we tested metal chelation by means of ethylenediaminetetraacetic acid (EDTA) combined with the permeability enhancer methylsulfonylmethane (MSM) applied topically on the eye to determine if this noninvasive treatment is neuroprotective in rat optic nerve and retinal ganglion cells exposed to oxidative stress induced by elevated IOP."( Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure.
Ansari, NH; Campbell, GA; Hogan, D; Liu, P; Shoeb, M; Syed, MF; Tang, L; Wang, CZ; Zhang, M, 2014
)
0.4
" The aim of this study was to compare the efficacy in smear layer removal of four different irrigation techniques combined with 60 °C 3% NaOCl and 17% EDTA."( Efficacy of four different irrigation techniques combined with 60 °C 3% sodium hypochlorite and 17% EDTA in smear layer removal.
Guo, X; Li, L; Lu, Y; Miao, H; Wu, L; Zhang, S; Zhou, D, 2014
)
0.4
" Gentamicin, amikacin or vancomycin was combined with disodium EDTA or l-arginine for 24 h to reproduce the antibiotic lock therapy (ALT) approach."( In vitro activity of gentamicin, vancomycin or amikacin combined with EDTA or l-arginine as lock therapy against a wide spectrum of biofilm-forming clinical strains isolated from catheter-related infections.
Beloin, C; Ghigo, JM; Lebeaux, D; Leflon-Guibout, V, 2015
)
0.42
" epidermidis biofilms was observed, especially when the peptide was combined with cysteine or EDTA, respectively."( Anti-biofilm properties of the antimicrobial peptide temporin 1Tb and its ability, in combination with EDTA, to eradicate Staphylococcus epidermidis biofilms on silicone catheters.
Batoni, G; Bombardelli, S; Brancatisano, FL; Di Luca, M; Esin, S; Grassi, L; Maisetta, G; Medici, C, 2016
)
0.43
"The aim of this study was to evaluate the effect of DJK-5, a newly developed cationic antimicrobial peptide, on oral multispecies and Enterococcus faecalis biofilms alone or combined with the endodontic chelating agent EDTA in vitro."( Antibiofilm Effect of D-enantiomeric Peptide Alone and Combined with EDTA In Vitro.
Haapasalo, M; Hancock, REW; Ma, J; Shen, Y; Wang, D, 2017
)
0.46
" This research investigated the synergistic effects of PACT mediated by the photosensitizer indocyanine green (ICG) and ethylenediamine tetraacetate (EDTA) combined with antibiotics against common pathogens of diabetic foot ulcer infection, including Staphylococcus aureus and Pseudomonas aeruginosa, in vitro."( Synergistic in vitro effects of indocyanine green and ethylenediamine tetraacetate-mediated antimicrobial photodynamic therapy combined with antibiotics for resistant bacterial biofilms in diabetic foot infection.
Chang, S; Cheng, Q; Huang, W; Li, X; Liu, C; Zheng, X; Zhu, S, 2019
)
0.51
" Furthermore, PACT combined with antibiotic treatment significantly contributed to killing bacteria in the biofilm and disrupting biofilm structure."( Synergistic in vitro effects of indocyanine green and ethylenediamine tetraacetate-mediated antimicrobial photodynamic therapy combined with antibiotics for resistant bacterial biofilms in diabetic foot infection.
Chang, S; Cheng, Q; Huang, W; Li, X; Liu, C; Zheng, X; Zhu, S, 2019
)
0.51
"ICG and EDTA-mediated PACT combined with antibiotics synergistically enhanced the effects of sterilization and biofilm destruction."( Synergistic in vitro effects of indocyanine green and ethylenediamine tetraacetate-mediated antimicrobial photodynamic therapy combined with antibiotics for resistant bacterial biofilms in diabetic foot infection.
Chang, S; Cheng, Q; Huang, W; Li, X; Liu, C; Zheng, X; Zhu, S, 2019
)
0.51
"The antimicrobial activity of cinnamon essential oil and cinnamaldehyde against bacterial and fungal pathogens associated with canine otitis externa, as well as the effect of their combination with EDTA were investigated."( Antimicrobial effects of cinnamon essential oil and cinnamaldehyde combined with EDTA against canine otitis externa pathogens.
Deo, P; Khazandi, M; Pi, H; Sim, JXF; Trott, DJ; Venter, H, 2019
)
0.51
"Cinnamon essential oil and cinnamaldehyde, either used alone or in combination with EDTA, were effective against the causative micro-organisms of canine otitis externa."( Antimicrobial effects of cinnamon essential oil and cinnamaldehyde combined with EDTA against canine otitis externa pathogens.
Deo, P; Khazandi, M; Pi, H; Sim, JXF; Trott, DJ; Venter, H, 2019
)
0.51
"This study shows that cinnamon essential oil and cinnamaldehyde, especially the latter, could be used in combination with EDTA as novel treatment for sensitive and resistant bacterial and fungal pathogens involved in canine otitis externa."( Antimicrobial effects of cinnamon essential oil and cinnamaldehyde combined with EDTA against canine otitis externa pathogens.
Deo, P; Khazandi, M; Pi, H; Sim, JXF; Trott, DJ; Venter, H, 2019
)
0.51
"To examine the antibacterial effects of manuka oil combined with ethylenediaminetetraacetic acid-tromethamine (Tris-EDTA) against Gram-negative bacteria isolates from dogs with otitis externa."( In vitro antibacterial activity of the manuka essential oil from Leptospermum scoparium combined with Tris-EDTA against Gram-negative bacterial isolates from dogs with otitis externa.
Hwang, CY; Hyun, JE; Kang, JH; Song, SY, 2020
)
0.56
"The study findings suggest that manuka oil, especially when combined with Tris-EDTA, may be a promising alternative therapeutic option for Gram-negative otic pathogens."( In vitro antibacterial activity of the manuka essential oil from Leptospermum scoparium combined with Tris-EDTA against Gram-negative bacterial isolates from dogs with otitis externa.
Hwang, CY; Hyun, JE; Kang, JH; Song, SY, 2020
)
0.56
" In a recent study we explored the effect and the tolerability of the administration of Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine (Ferachel Forte®) in "frailty" patients with secondary anemia and low kidney failure, by analysing the HRV frequency domain."( A pilot study on secondary anemia in "frailty" patients treated with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine: safety of treatment explored by HRV non-linear analysis as predictive
Curcio, A; Iannarelli, N; Marchitto, N; Paparello, PT; Petrucci, A; Pironti, M; Raimondi, G; Romano, A, 2020
)
0.56
" The patients were divided in 2 groups: Group A (N=23 patients) received oral administration of Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine (Ferachel Forte®) 2 tabs/day, containing 60 mg of Fe3+, for 24 days; Group B (N=29 patients) received intravenous administration of ferrous gluconate 63 mg/day added to saline solution, while they were hospitalized (15±5 days)."( A pilot study on secondary anemia in "frailty" patients treated with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine: safety of treatment explored by HRV non-linear analysis as predictive
Curcio, A; Iannarelli, N; Marchitto, N; Paparello, PT; Petrucci, A; Pironti, M; Raimondi, G; Romano, A, 2020
)
0.56
"Non-linear HRV evaluation confirmed that oral administration of Ferric Sodium EDTA, in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine (Ferachel forte®) did not impact the cardiovascular risk, without causing adverse events typically reported with other iron supplementation therapies, both oral and intravenous."( A pilot study on secondary anemia in "frailty" patients treated with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine: safety of treatment explored by HRV non-linear analysis as predictive
Curcio, A; Iannarelli, N; Marchitto, N; Paparello, PT; Petrucci, A; Pironti, M; Raimondi, G; Romano, A, 2020
)
0.56
" Indifference to additive activity was observed for tested combinations and MIC value of cefotaxime or gentamicin in combination with EDTA was less than antibiotic alone in the most tested isolates."( The effect of EDTA in combination with some antibiotics against clinical isolates of gram negative bacteria in Mansoura, Egypt.
Abdelmegeed, ES; Aboelenin, AM; Hassan, R, 2021
)
0.62
" The aim of this study was to evaluate the use of the new oral formulation based on ferric sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate, and selenomethionine (Ferachel Forte®) in patients with moderate CKD and functional IDA, analyzing the inflammatory status in addition to iron blood parameters, in comparison with oral ferrous sulfate and liposomal iron therapies."( Comparison of Ferric Sodium EDTA in Combination with Vitamin C, Folic Acid, Copper Gluconate, Zinc Gluconate, and Selenomethionine as Therapeutic Option for Chronic Kidney Disease Patients with Improvement in Inflammatory Status.
Curcio, A; Di Lullo, L; Giliberti, A; Marchitto, N; Nano, F; Paolozzi, F; Pironti, M; Raimondi, G, 2022
)
0.72
" Combined with chitosan, XFII could spontaneously lyse Gram-negative bacteria without pretreatment."( Characterization of Salmonella endolysin XFII produced by recombinant Escherichia coli and its application combined with chitosan in lysing Gram-negative bacteria.
Chang, Y; Lu, X; Qi, Q; Yuan, Y; Zhang, Q; Zhang, S, 2022
)
0.72
"This paper discussed the dredging effect and safety of ethylenediaminetetraacetic acid (EDTA) combined with C-pilot files and microultrasound (mUS) on root canal calcification."( EDTA Combined with C-Pilot Files and Microultrasound for Root Canal Calcification: Dredging Effect and Safety Analysis.
Chu, T; Ni, X; Zhu, Y, 2022
)
0.72
" Among them, 64 cases who received EDTA combined with C-pilot Files and mUS plus ultrasonic instruments to dredge calcified root canals were regarded as the research group (RG), and another 68 cases given ultrasonic instruments plus C-pilot files were regarded as the control group (CG)."( EDTA Combined with C-Pilot Files and Microultrasound for Root Canal Calcification: Dredging Effect and Safety Analysis.
Chu, T; Ni, X; Zhu, Y, 2022
)
0.72
"EDTA combined with C-pilot files and mUS can effectively improve the dredging success rate of root canals obstructed by calcification, shorten the dredging time, and improve patient comfort, which is an effective method for clinical dredging of calcification obstructed root canals."( EDTA Combined with C-Pilot Files and Microultrasound for Root Canal Calcification: Dredging Effect and Safety Analysis.
Chu, T; Ni, X; Zhu, Y, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" However, little is known about its oral bioavailability and metabolic process."( Pharmacokinetics, oral bioavailability and metabolic analysis of solasodine in mice by dried blood spot LC-MS/MS and UHPLC-Q-Exactive MS.
Cheng, Z; Hu, B; Liu, K; Lu, T; Pang, J; Qu, M; Wang, Q; Xiao, Q; Xu, T; Xue, P; Zhang, Q, 2022
)
0.72
" The rate of absorption decreased from the colon to the duodenum (colon greater than ileum greater than jejunum greater than duodenum)."( Intestinal oxalate absorption. I. Absorption in vitro.
Caspary, WF, 1977
)
0.26
" The rate varied with the bioavailability of the iron in each complex."( Unidirectional uptake of iron across intestinal brush border.
Sheehan, RG, 1976
)
0.26
"Bisphosphonates are poorly absorbed when given orally and their absorption is subject to a large inter- and intraindividual variability."( Sodium EDTA enhances intestinal absorption of two bisphosphonates.
Fleisch, H; Janner, M; Mühlbauer, RC, 1991
)
0.28
" Bioavailability of EDTA-enhanced fortificants, FeSO4 + Na2EDTA and NaFe(III)EDTA, was compared with that of FeSO4 in six groups of ten animals repleted with a ground Egyptian bread meal or a casein-based AIN diet fortified with one of the three compounds."( Effect of EDTA on the bioavailability to rats of fortification iron used in Egyptian balady bread.
Vanderveen, JE; Whittaker, P, 1990
)
0.28
" The beneficial effects of methionine may be attributed to its ability to increase the bioavailability of glutathione (GSH), useful in chelating Pb and counter-acting the toxic effects, as evidenced by restoration of the Pb-induced decrease in hepatic GSH level by treatment with methionine."( Influence of methionine supplementation in chelation of lead in rats.
Kachru, DN; Khandelwal, S; Tandon, SK, 1989
)
0.28
"The stability of the neuroleptic peptide des-enkephalin-gamma-endorphin (DE gamma E; Org 5878) in the rectal lumen and the rectal bioavailability of DE gamma E were investigated in conscious rats."( Rectal absorption enhancement of des-enkephalin-gamma-endorphin (DE gamma E) by medium-chain glycerides and EDTA in conscious rats.
Breimer, DD; de Boer, AG; Heijligers-Feijen, CD; van Hoogdalem, EJ; Verhoef, JC, 1989
)
0.28
" Differences in absorption rate of 99mTc-EDTA, a poorly absorbable marker, were found, as morphine caused nearly all radioactive compound to be retained in the colon, while rhein significantly facilitated the transfer of marker from colon through mucosal barrier to blood."( The antagonistic effect of morphine on rhein-stimulated fluid, electrolyte and glucose movements in guinea-pig perfused colon.
Geeraerts, VC; Lemli, J; Verhaeren, EH, 1987
)
0.27
" The implications of this observation pertain to toxicity effects when EDTA is incorporated into ocular drug products for stability purposes, or novel stratagems for improving ocular bioavailability of topically applied drugs are employed."( Mechanisms of corneal drug penetration. I: In vivo and in vitro kinetics.
Grass, GM; Robinson, JR, 1988
)
0.27
" The implications of this observation pertain to both toxicity effects, when EDTA is incorporated into ocular drug products for stability purposes, and novel strategems for improving ocular bioavailability of topically applied drugs."( Effects of calcium chelating agents on corneal permeability.
Grass, GM; Robinson, JR; Wood, RW, 1985
)
0.27
" When Fe is present in the chelated form it remains in solution and is relatively well absorbed because it is protected from inhibitory ligands."( Factors affecting the absorption of iron from Fe(III)EDTA.
Bezwoda, WR; Bothwell, TH; Charlton, RW; Derman, DP; MacPhail, AP; Mayet, F; Torrance, JD, 1981
)
0.26
" These reactions among fiber, inorganic iron, and other constituents of food may influence the bioavailability of dietary iron and the simple systems described here offer a means of dissecting interactions that are complex in vivo."( Components of fiber bind iron in vitro.
Fernandez, R; Phillips, SF, 1982
)
0.26
" Subdural deposition of the contrast medium and 51Cr-ethylenediaminetetraacetic acid resulted in a faster absorption rate and higher achieved blood levels than a subarachnoid injection of the two substances, where a slow absorption to lower blood concentrations was observed."( Absorption after subarachnoid and subdural administration of iohexol, 51Cr-EDTA, and 125I-albumin to rabbits.
Holtz, E; Jacobsen, T; Michelet, AA,
)
0.13
" Therefore, the use of chelated iron as the iron source in the nutrient medium should not affect assessments of bioavailability of iron from plants."( Radiolabeled iron in soybeans: intrinsic labeling and bioavailability of iron to rats from defatted flour.
Elliott, JG; Mason, AC; Meyer, NR; Schmitt, HA; Stuart, MA; Weaver, CM, 1984
)
0.27
"4 mg of nickel sulfate hexahydrate containing 5 mg of elemental nickel, the bioavailability of nickel was estimated in human subjects."( Bioavailability of nickel in man: effects of foods and chemically-defined dietary constituents on the absorption of inorganic nickel.
Nielsen, FH; Shuler, TR; Solomons, NW; Viteri, F, 1982
)
0.26
" The net calcium absorption rate from a Thirty-Vella loop of jejunum increased with increasing intraluminal Ca concentration and was increased by the addition of 1 alpha-hydroxy-cholecalciferol (3 micrograms/l) to the loop fluid."( Effects of dietary phosphorus and calcium on the intestinal absorption of Ca in sheep.
Abdel-Hafeez, HM; Care, AD; Mañas-Almendros, M; Marshall, DH; Ross, R, 1982
)
0.26
" Because the bioavailability of IGF-I is modulated by IGF-binding proteins (IGFBPs), we examined the regulation of IGFBPs by IGFs in primary cultures of rat aortic smooth muscle cells (SMCs)."( Expression and insulin-like growth factor-dependent proteolysis of insulin-like growth factor-binding protein-4 are regulated by cell confluence in vascular smooth muscle cells.
Fagin, JA; Forrester, JS; Kamyar, A; Mohan, S; Pirola, CJ; Sharifi, B; Wang, HM, 1994
)
0.29
" Thus, the increased subcutaneous bioavailability of hEGF in the presence of absorption promoters (except EDTA) was mainly attributed to the inhibitory effect of absorption promoters against the enzymic degradation of hEGF at the subcutaneous tissues."( Effect of absorption promoters on subcutaneous absorption of human epidermal growth factor in rats.
Amagase, H; Fuwa, T; Higashi, Y; Kojima, Y; Misaki, M; Murakami, T; Yamada, M; Yata, N; Yuki, M, 1993
)
0.29
" Efforts to increase its oral bioavailability are now in progress."( Results from a phase I clinical trial of HBED.
Giardina, PJ; Grady, RW; Hilgartner, MW; Salbe, AD, 1994
)
0.29
" Na2EDTA, added to food to prevent oxidation, enhances iron bioavailability by chelating added iron."( EDTA and the absorption of iron from food.
Bothwell, TH; Lamparelli, RD; MacPhail, AP; Patel, RC, 1994
)
0.29
" Bioavailability of their iron was tested through several parameters."( Iron from complex salts and its bioavailability to rats.
Dutra-de-Oliveira, JE; Ferreira, JF; Freitas, ML; Gonçalves, AL; Marchini, JS, 1995
)
0.29
"This study was designed to examine the effect of benzalkonium chloride/ethylenediaminetetraacetic acid (BAK/EDTA) on the ocular bioavailability (Focular) of ketorolac tromethamine after ocular instillation to normal and de-epithelialized corneas of rabbits both in vitro and in vivo."( Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits.
Madhu, C; Nguyen, TG; Rix, PJ; Shackleton, MJ; Tang-Liu, DD, 1996
)
0.29
"NaFe(III)EDTA is a promising iron (Fe) compound for food fortification programs because of its high Fe bioavailability from meals containing dietary inhibitors of Fe absorption such as phytic acid."( Sodium iron EDTA [NaFe(III)EDTA] as a food fortificant does not influence absorption and urinary excretion of manganese in healthy adults.
Almgren, A; Davidsson, L; Hurrell, RF, 1998
)
0.3
" Presumably, this leads to destabilization of the ternary IGF-IGFBP-3-acid-labile subunit complex in the circulation and an increased bioavailability of IGFs."( Insulin-like growth factor-binding protein-3 protease activity in Snell normal and Pit-1 deficient dwarf mice.
Hoogerbrugge, CM; Koedam, JA; van Buul-Offers, SC, 1998
)
0.3
"Iron EDTA [sodium iron (Fe(3+)) ethylenediaminetetraacetic acid (EDTA)], shown to have a significant beneficial effect on iron status by increasing iron bioavailability in human diets, has been proposed for use as a fortificant in certain grain-based products including breakfast cereals and cereal bars."( Safety assessment of iron EDTA [sodium iron (Fe(3+)) ethylenediaminetetraacetic acid]: summary of toxicological, fortification and exposure data.
Borzelleca, J; Dickmann, R; Heimbach, J; Mohamedshah, F; Rieth, S; Samuel-Fernando, P; Sheehan, T; Slesinski, R, 2000
)
0.31
" When M2M medium was amended with EDTA, sMMO activity was similar to that in NMS medium, indicating that EDTA-bound copper had lower bioavailability than pyrophosphate-bound copper."( Effect of copper speciation on whole-cell soluble methane monooxygenase activity in Methylosinus trichosporium OB3b.
Hayes, KF; Morton, JD; Semrau, JD, 2000
)
0.31
" The high absorbability predicted by physicochemical and computer simulation methods was corroborated by in vivo experiments in marmoset monkeys where the monoethyl ester derivative of HBED was well-absorbed orally while the parent compound was nearly ineffective in the same model."( Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network.
Faller, B; Sergejew, T; Spanka, C; Tschinke, V, 2000
)
0.31
"This study was conducted to determine the bioavailability of iron amino acid chelate (ferrochel) added to fortify breads prepared from either precooked corn flour or white wheat flour + cheese and margarine compared with the same basal breakfast enriched with either ferrous sulfate or iron-EDTA."( Iron bioavailability in humans from breakfasts enriched with iron bis-glycine chelate, phytates and polyphenols.
Arguello, F; Barón, MA; García-Casal, MN; Layrisse, M; Leets, I; Llovera, D; Ramírez, J; Solano, L; Tropper, E, 2000
)
0.31
" The search, therefore, continues for compounds of high bioavailability which do not cause organoleptic changes in the vehicles to which they are added."( Iron fortification with special reference to the role of iron EDTA.
Bothwell, TH, 1999
)
0.3
" NT also facilitated transcellular uptake of (3)H-glucose and (3)H-leucine and increased paracellular uptake to (51)Cr-EDTA and (3)H-mannitol, but did not alter the absorption rate for (14)C-antipyrine."( Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats.
Carraway, RE; Gui, X, 2001
)
0.31
" Furthermore, the secretion seems predominantly to inhibit the passive absorption at the basal parts of the villus while the absorption rate at the villus tips is better preserved."( Effect of cholera toxin on passive transepithelial transport of 51Cr-ethylenediaminetetraacetic acid and 14C-mannitol in rat jejunum.
Fihn, BM; Jodal, M; Sjöqvist, A, 2001
)
0.31
" Two experiments were conducted to estimate the relative bioavailability of Cu from the organic Cu supplements for chicks when added at high dietary concentrations to practical corn-soybean meal diets."( Chemical characteristics and relative bioavailability of supplemental organic copper sources for poultry.
Ammerman, CB; Cao, J; Guo, R; Henry, PR; Holwerda, RA; Littell, RC; Miles, RD, 2001
)
0.31
" Its applicability to the study of estrogen bioavailability and bioequivalence is suggested."( Reversed-phase liquid chromatographic method for estrogen determination in equine biological samples.
Lima, SB; Ribeiro Neto, LM; Verreschi, IT, 2001
)
0.31
"The bioavailability of iron from a new commercial source containing ferric gluconate stabilized with glycine sold under the trade name Bioferrico was studied in this work by means of the prophylactic-preventive test in rats."( Bioavailability studies of a new iron source by means of the prophylactic-preventive method in rats.
Boccio, J; Caro, R; Ettlin, E; Lysionek, A; Salgueiro, J; Zubillaga, M, 2001
)
0.31
"The goal was to evaluate the bioavailability of iron from meals based on corn tortillas and black bean paste that were fortified with ferrous fumarate, ferrous sulfate, or NaFeEDTA and to investigate the potential of Na(2)EDTA to increase the bioavailability of iron from ferrous fumarate."( Iron bioavailability from iron-fortified Guatemalan meals based on corn tortillas and black bean paste.
Boy, E; Davidsson, L; Dimitriou, T; Hurrell, RF; Walczyk, T, 2002
)
0.31
"With use of a crossover study design, iron bioavailability was measured in Guatemalan girls aged 12-13 y by a stable-isotope technique based on erythrocyte incorporation 14 d after intake."( Iron bioavailability from iron-fortified Guatemalan meals based on corn tortillas and black bean paste.
Boy, E; Davidsson, L; Dimitriou, T; Hurrell, RF; Walczyk, T, 2002
)
0.31
"The bioavailability of iron from ferrous fumarate was not improved by the addition of Na(2)EDTA, contrary to what was previously shown for ferrous sulfate in other cereal-based meals."( Iron bioavailability from iron-fortified Guatemalan meals based on corn tortillas and black bean paste.
Boy, E; Davidsson, L; Dimitriou, T; Hurrell, RF; Walczyk, T, 2002
)
0.31
" The transport of water was monitored, and the absorption rate of the probes was calculated by their disappearance from the perfusate."( Water absorption enhances the uptake of mannitol and decreases Cr-EDTA/mannitol permeability ratios in cat small intestine in situ.
Bijlsma, PB; Fihn, BM; Groot, JA; Jodal, M; Sjöqvist, A; Taminiau, JA, 2002
)
0.31
" Presumed functions at the maternal-fetal interface are to proteolyze IGFBP-4 and thus increase IGF bioavailability locally in the placenta, to promote IGF-II-mediated trophoblast invasion into the maternal decidua, and to modulate IGF regulation of steroidogenesis and glucose and amino acid transport in the villous."( Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane.
Giudice, LC; Overgaard, MT; Oxvig, C; Sun, IY, 2002
)
0.31
" In general, however, food contaminations with metals are too low to have an impact on the bioavailability of essential metals."( The impact of food contaminants on the bioavailability of trace metals.
Elsenhans, B; Schümann, K, 2002
)
0.31
" It is highly bioavailable when used to correct iron deficiency anemia."( Acute toxicity of carbonyl iron and sodium iron EDTA compared with ferrous sulfate in young rats.
Ali, SF; Dunkel, VC; Imam, SZ; Whittaker, P, 2002
)
0.31
" The results are discussed in relation to the possible mechanisms by which EDTA may change the solubility and bioavailability of Cd in the soil and the potential for plant uptake and environmental risk due to leaching losses to groundwater."( Soil Cd availability to Indian mustard and environmental risk following EDTA addition to Cd-contaminated soil.
Baker, AJ; Christie, P; Jiang, XJ; Luo, YM; Wong, MH; Zhao, QG, 2003
)
0.32
" The results are discussed in relation to the mobility and bioavailability of the metals in polluted soils."( Chemical speciation and extractability of Zn, Cu and Cd in two contrasting biosolids-amended clay soils.
Christie, P; Luo, YM; Qiao, XL; Wong, MH, 2003
)
0.32
"05 M EDTA) were used to assess the bioavailability of Zn."( Changes in soil microbial biomass and Zn extractability over time following zn addition to a paddy soil.
Christie, P; Ding, KQ; Jiang, XJ; Liu, SL; Luo, YM; Wu, SC; Zhao, QG, 2003
)
0.32
"The EDTA and sodium caprate (Na caprate) effects on the oral bioavailability of norfloxacin were tested."( Improvement of norfloxacin oral bioavailability by EDTA and sodium caprate.
Bonini, F; Dos Santos, I; Fawaz, F; Lagueny, AM, 2003
)
0.32
" Fortifying fish sauce with iron by using a water-soluble, highly bioavailable compound (NaFeEDTA) is a promising strategy for combating iron deficiency anemia in Vietnam."( Regular consumption of NaFeEDTA-fortified fish sauce improves iron status and reduces the prevalence of anemia in anemic Vietnamese women.
Berger, J; Cook, JD; Davidsson, L; Hurrell, RF; Khan, NC; Khoi, HH; Lam, NT; Thuy, PV, 2003
)
0.32
" Due to high concentrations of inhibitors of iron absorption, the bioavailability from this matrix is unknown."( Iron bioavailability in corn-masa tortillas is improved by the addition of disodium EDTA.
Olivares, M; Pizarro, F; Walter, T, 2003
)
0.32
" However, their bioavailability is unknown."( The poor bioavailability of elemental iron in corn masa flour is not affected by disodium EDTA.
Abrams, SA; Boy, E; Pizarro, F; Walter, T, 2004
)
0.32
" It is proposed that AA enhances Fe bioavailability in hypersaline solutions by formation of lipophylic Fe-AA complexes which are taken-up and utilized by the algae."( The respiratory inhibitor antimycin A specifically binds Fe(III) ions and mediates utilization of iron by the halotolerant alga Dunaliella salina (Chlorophyta).
Pick, U, 2004
)
0.32
"Phytoremediation is emerging as a potential cost-effective solution for remediation of contaminated soils, and bioavailability of metal in the soil for plant uptake is an important factor for successful phytoremediation."( Chelators effect on soil Cu extractability and uptake by Elsholtzia splendens.
Jiang, LY; Yang, XE, 2004
)
0.32
" NaFe-EDTA has been extensively studied and validated as an excellent choice for iron fortification programs and extensive research has demonstrated its high bioavailability specially for cereal based foods."( Ethylenediaminetetraacetic acid (EDTA) does not increase iron uptake or ferritin synthesis by Caco-2 cells.
García-Casal, MN; Layrisse, M; Leets, I, 2004
)
0.32
"The purpose of this study was to investigate the transport mechanisms and causes of low bioavailability of leuprolide."( Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer.
Dong, J; Feng, L; Guo, J; Jiang, G; Li, C; Li, Z; Ping, Q; Qi, S, 2004
)
0.32
" Comparing with the test groups exposed to Cu2+, the Cu-EDTA complex had changed the bioavailability and decreased the toxicity of the heavy metal."( [Effects of copper (Cu2+) and Cu-EDTA complex on the induction of HSP70 in the fish brain].
Liu, H; Shen, H; Wang, XR; Zhang, JF; Zhao, YJ, 2004
)
0.32
" Determination of the bioavailability of these nutrients is a critical step before commencing a fortification program."( Na2EDTA enhances the absorption of iron and zinc from fortified rice flour in Sri Lankan children.
Abrams, SA; Hettiarachchi, M; Hilmers, DC; Liyanage, C, 2004
)
0.32
" No information is available on iron bioavailability from NaFeEDTA or the influence of NaFeEDTA on minerals and trace elements in infants."( Sodium iron EDTA [NaFe(III)EDTA] as a food fortificant: erythrocyte incorporation of iron and apparent absorption of zinc, copper, calcium, and magnesium from a complementary food based on wheat and soy in healthy infants.
Davidsson, L; Hurrell, R; Walczyk, T; Zeder, C; Ziegler, E, 2005
)
0.33
"We aimed to compare iron bioavailability from a complementary food based on wheat and soy fortified with either NaFeEDTA or ferrous sulfate plus ascorbic acid."( Sodium iron EDTA [NaFe(III)EDTA] as a food fortificant: erythrocyte incorporation of iron and apparent absorption of zinc, copper, calcium, and magnesium from a complementary food based on wheat and soy in healthy infants.
Davidsson, L; Hurrell, R; Walczyk, T; Zeder, C; Ziegler, E, 2005
)
0.33
"Iron bioavailability from a high-phytate, cereal-based complementary food fortified with either NaFeEDTA or ferrous sulfate plus ascorbic acid was not significantly different."( Sodium iron EDTA [NaFe(III)EDTA] as a food fortificant: erythrocyte incorporation of iron and apparent absorption of zinc, copper, calcium, and magnesium from a complementary food based on wheat and soy in healthy infants.
Davidsson, L; Hurrell, R; Walczyk, T; Zeder, C; Ziegler, E, 2005
)
0.33
"The use of two EDTA concentrations for enhancing the bioavailability of cadmium, chromium, and nickel in three natural soils (Ohio, New Mexico and Colombia) was investigated."( The effect of EDTA on Helianthus annuus uptake, selectivity, and translocation of heavy metals when grown in Ohio, New Mexico and Colombia soils.
Cutright, TJ; Pepe, MK; Turgut, C, 2005
)
0.33
" As compared with subcutaneous injection, the relative pharmacological bioavailability was 17."( [Studies on the insulin-liposomes double-coated by chitosan and chitosan-EDTA conjugates].
Cai, P; Lei, XM; Li, JY; Ping, QN; Song, YM; Wu, ZH, 2004
)
0.32
" The distribution of Pb in the sequential extraction procedure showed that the Pb level in the exchangeable+carbonate-bound fraction with CCA was significantly lower than that with solid EDTA or EDTA solution, further indicating that slow release of CCA improves the bioavailability of metals in the soil to match plant uptake of those metals."( Slow release chelate enhancement of lead phytoextraction by corn (Zea mays L.) from contaminated soil--a preliminary study.
Christie, P; Cui, Y; Dong, Y; Li, H; Wang, Q, 2005
)
0.33
" Since an important factor in its causation is the poor bioavailability of iron in the cereal-based diets of many developing countries, SUSTAIN set up a Task Force, consisting of nutritional, medical, industry, and government experts to consider strategies for enhancing the absorption of fortification iron."( Enhancing the absorption of fortification iron. A SUSTAIN Task Force report.
Bothwell, T; Cori, H; Glahn, R; Hertrampf, E; Hurrell, RF; Kratky, Z; Lynch, S; Miller, D; Rodenstein, M; Streekstra, H; Teucher, B; Turner, E; Yeung, CK; Zimmermann, MB, 2004
)
0.32
" However, little is known about the relative bioavailability of different zinc compounds that may be used in food fortification."( Zinc absorption from zinc oxide, zinc sulfate, zinc oxide + EDTA, or sodium-zinc EDTA does not differ when added as fortificants to maize tortillas.
DeHaene, J; Hotz, C; King, JC; Rivera, JA; Villalpando, S; Woodhouse, LR, 2005
)
0.33
"A rhizosphere-based method was compared with DTPA, EDTA, CaCl2, and NaNO3 extraction methods for the evaluation of bioavailability of heavy metals in soil to barley."( A comparison of the rhizosphere-based method with DTPA, EDTA, CaCl2, and NaNO3 extraction methods for prediction of bioavailability of metals in soil to barley.
Feng, MH; Shan, XQ; Wen, B; Zhang, S, 2005
)
0.33
"Phytoextraction of copper (Cu) from contaminated soils greatly depends on the metal bioavailability in the soils and metal uptake ability of the plant."( Phytoextraction of copper from contaminated soil by Elsholtzia splendens as affected by EDTA, citric acid, and compost.
He, ZL; Jiang, LY; Peng, HY; Yang, XE, 2005
)
0.33
"Although substances, which can increase the paracellular permeability of intestinal mucosa, could be very helpful for increasing the bioavailability of hydrophilic drugs, they are not used therapeutically due to the possibilities of acute or long-term toxicity (intestinal inflammations due to penetration of bacterial fragments into subepithelial spaces)."( The effect of clodronate on the integrity and viability of rat small intestine in vitro-a comparison with EDTA.
Kristl, A; Vadnjal, L; Zakelj, S, 2005
)
0.33
" Collectively, these results might be considered that EDTA elevates the bioavailability of Pb in soil and this native species is particularly suited to use in Pb phytoextraction."( EDTA-assisted phytoextraction of lead from lead-contaminated soils by Echinochloa crusgalli var. frumentacea.
Bae, B; Baek, KH; Chang, YY; Kim, HH; Lee, IS, 2005
)
0.33
" Soil amendments such as ethylene diaminetetraacetate (EDTA) have been suggested to increase heavy metal bioavailability and uptake in aboveground plant parts."( Enhanced phytoextraction: I. Effect of EDTA and citric acid on heavy metal mobility in a calcareous soil.
Hopgood, M; Lamsal, S; Lesage, E; Meers, E; Tack, FM; Verloo, MG; Vervaeke, P, 2005
)
0.33
"High biomass producing plant species, such as Helianthus annuus, have potential for removing large amounts of trace metals by harvesting the aboveground biomass if sufficient metal concentrations in their biomass can be achieved However, the low bioavailability of heavy metals in soils and the limited translocation of heavy metals to the shoots by most high biomass producing plant species limit the efficiency of the phytoextraction process."( Enhanced phytoextraction: II. Effect of EDTA and citric acid on heavy metal uptake by Helianthus annuus from a calcareous soil.
Hopgood, M; Lamsal, S; Lesage, E; Meers, E; Tack, FM; Verloo, MG; Vervaeke, P, 2005
)
0.33
"Copper bioavailability in the tissues of goldfish and antioxidant defenses in the liver of fish were investigated in vivo following 40 days of exposure to different species of copper solutions at different concentrations."( Effects of copper and its ethylenediaminetetraacetate complex on the antioxidant defenses of the goldfish, Carassius auratus.
Liu, H; Wang, W; Wang, X; Zhang, J, 2006
)
0.33
"The effect of soil ozonation on Pb and Zn extraction with EDTA, bioavailability (Ruby's Physiologically Based Extraction Test, PBET) and mobility (Toxicity Characteristic Leaching Procedure, TCLP) of Pb was studied on contaminated soils taken from 7 different locations in the Mezica Valley, Slovenia."( Influence of ozonation on extractability of Pb and Zn from contaminated soils.
Finzgar, N; Hanc, A; Lestan, D, 2005
)
0.33
"Laboratory-based algal assays were developed to explore the bioavailability of copper to the marine alga Thalassiosira weissflogii."( An algal probe for copper speciation in marine waters: laboratory method development.
Hemming, JD; Karner, DA; Overdier, JT; Shafer, MM; Sonzogni, WC, 2006
)
0.33
"The purpose of this study was to investigate the transport characteristics and mechanisms for discovering the possible causes of the low bioavailability of astragaloside IV and to develop an absorption enhancement strategy."( Absorption enhancement study of astragaloside IV based on its transport mechanism in caco-2 cells.
Huang, CR; Li, H; Lv, H; Sun, JG; Wang, GJ; Wu, XL; Xie, HT,
)
0.13
"Chemical speciation modeling is a vital tool for assessing the bioavailability of inorganic species, yet significant uncertainties in thermodynamic parameters and model form limit its potential for decision-making."( A stochastic regression approach to analyzing thermodynamic uncertainty in chemical speciation modeling.
Small, MS; Vanbriesen, JM; Weber, CL, 2006
)
0.33
"4%/h, respectively), but propionate had a higher absorption rate (19."( Comparison of techniques to determine the clearance of ruminal volatile fatty acids.
Bôer, H; Pereira, MN; Resende Júnior, JC; Tamminga, S, 2006
)
0.33
"Despite major interest in sodium iron (III) ethylenediaminetetraacetic acid's (EDTA) potential use in food fortification programs in potentially curbing the global problem of iron deficiency and its anemia, synthesis methods of stable isotope-labeled sodium iron (III) EDTA for use in human bioavailability studies are incomplete, incorrect or totally lacking."( Sodium iron (III) ethylenediaminetetraacetic acid synthesis to reduce iron deficiency globally.
Lachmann, G; Lieshout, MV; Loots, du T; van Lieshout, M, 2007
)
0.34
" Tungsten appears to be relatively immobile when subjected to sequential extraction but increased bioavailability is indicated when single stage extraction using EDTA is employed."( Bio-availability of tungsten in the vicinity of an abandoned mine in the English Lake District and some potential health implications.
Pyatt, FB; Wilson, B, 2006
)
0.33
"Sodium iron(III) ethylenediaminetetraacetate (NaFeEDTA) has considerable promise as an iron fortificant because of its high bioavailability in foods containing iron absorption inhibitors."( Iron uptake by Caco-2 cells from NaFeEDTA and FeSO4: Effects of ascorbic acid, pH, and a Fe(II) chelating agent.
Glahn, RP; Miller, DD; Yeung, CK; Zhu, L, 2006
)
0.33
"Sodium iron ethylenediaminetetraacetate (NaFeEDTA) has superior iron bioavailability especially in foods containing iron absorption inhibitors."( Iron dissociates from the NaFeEDTA complex prior to or during intestinal absorption in rats.
Glahn, RP; Miller, DD; Yeung, CK; Zhu, L, 2006
)
0.33
" Pharmacokinetic testing in rats confirmed the improved drug bioavailability and demonstrated an in vitro-in vivo correlation."( In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.
Brandt, GC; Costantino, HR; Foerder, CA; Leonard, AK; Quay, SC; Sileno, AP, 2007
)
0.34
"The higher absorption rate of NaFeEDTA suggested that NaFeEDTA would be a better iron fortificant used in soy sauce for the controlling of iron deficiency anemia in China."( NaFeEDTA fortified soy sauce showed higher iron absorption rate in Chinese females.
Chen, JS; Gao, JQ; Huo, JS; Lu, CQ; Miao, H; Piao, JH; Yang, XG; Yu, B, 2007
)
0.34
"The effect of two ecologically contrasting earthworm species Eisenia fetida (epigeic) and Octolasion tyrtaeum (endogeic) on the fractionation (accessed using sequential extractions), mobility (toxicity characteristic leaching procedure, TCLP) and oral bioavailability (Ruby's physiologically based extraction test, PBET) of Pb, Zn and Cd was studied before and after soil remediation with soil leaching."( The effect of earthworms on the fractionation, mobility and bioavailability of Pb, Zn and Cd before and after soil leaching with EDTA.
Lestan, D; Plavc, Z; Udovic, M, 2007
)
0.34
" The addition of citric acid (80 mg/100 g) along with ferrous sulfate increased bioavailability by about 104% over that in controls."( In vitro bioavailability of iron and sensory qualities of iron-fortified wheat biscuits.
Govindaraj, T; KrishnaRau, L; Prakash, J, 2007
)
0.34
"From both the subjective and the objective evaluation of biscuits, it can be concluded that the addition of NaFeEDTA along with either citric acid (80 mg/100 g) or tartaric acid (100 mg/100 g) results in improved iron bioavailability with an organoleptically acceptable product."( In vitro bioavailability of iron and sensory qualities of iron-fortified wheat biscuits.
Govindaraj, T; KrishnaRau, L; Prakash, J, 2007
)
0.34
"The beta-lactam antibiotic ampicillin has a relatively poor oral bioavailability in animals and man (30-40%), and its widespread agricultural use in livestock may be contributing to the emergence of antibiotic resistance in the environment."( Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter.
Arellano, C; Bousquet-Mélou, A; Dupouy, V; Gandia, P; Houin, G; Lafforgue, G; Philibert, C; Vachoux, C; Woodley, J, 2008
)
0.35
"The choice of iron fortificant usually represents a balance between bioavailability of the compound and its tendency to cause organoleptic problems."( Fortifying brown bread with sodium iron EDTA, ferrous fumarate, or electrolytic iron does not affect iron status in South African schoolchildren.
Dhansay, MA; Lombard, CJ; Smuts, CM; van Stuijvenberg, ME, 2008
)
0.35
" However, contradictory results regarding iron bioavailability to humans from ferritin are not yet fully clarified."( Ferritin-iron is released during boiling and in vitro gastric digestion.
Hoppler, M; Hurrell, RF; Meile, L; Schönbächler, A; Walczyk, T, 2008
)
0.35
"The present study investigates how dissolved organic matter (DOM) alters copper bioavailability at environmentally relevant concentrations (1-5 microg/L of dissolved copper, 1-4 mg/L of dissolved organic copper)."( More than inorganic copper is bioavailable to aquatic mosses at environmentally relevant concentrations.
Ferreira, D; Ridame, C; Tousset, N; Tusseau-Vuillemin, MH, 2008
)
0.35
" Because total metal concentrations correlate poorly with bioavailability and toxicity, a need exists for more information linking Cu speciation, bioavailability, and toxicity."( Differential bioavailability of copper complexes to bioluminescent Pseudomonas fluorescens reporter strains.
Brandt, KK; Holm, PE; Ibrahim, YM; Nybroe, O; Tom-Petersen, A, 2008
)
0.35
" Metal bioavailability in soil at the end of the experiment was higher in the trials treated with EDTA than in those treated with tartrate and glutamate, the latter not being significantly different from the control."( Heavy metal distribution between contaminated soil and Paulownia tomentosa, in a pilot-scale assisted phytoremediation study: influence of different complexing agents.
Azzarello, E; Checchini, L; Del Bubba, M; Doumett, S; Lamperi, L; Mancuso, S; Mugnai, S; Petruzzelli, G, 2008
)
0.35
"Liposomal entrapment of L-cysteine (L-CySH) could be a solution to enhance its oxidative stability and its intracellular bioavailability for glutathione (GSH) synthesis."( L-cysteine encapsulation in liposomes: effect of phospholipids nature on entrapment efficiency and stability.
Chaumeil, JC; Cynober, L; Dumortier, G; El Kateb, N, 2008
)
0.35
" EDTA was applied to study its effect in increasing the bioavailability of Cd and Pb and their uptake by these Indian mustards."( Pot experiment to study the uptake of Cd and Pb by three Indian mustards (Brassica juncea) grown in artificially contaminated soils.
Chen, SW; Chen, ZS; Lai, HY,
)
0.13
" This approach may allow for effective, untargeted in-home fortification of complementary foods with low amounts of highly bioavailable iron."( Optimization of a phytase-containing micronutrient powder with low amounts of highly bioavailable iron for in-home fortification of complementary foods.
de Pee, S; Egli, I; Hurrell, RF; Troesch, B; Zeder, C; Zimmermann, MB, 2009
)
0.35
" Fractionation using sequential extractions, mobility, and phytoavailability of Pb, Zn and Cd and Pb oral bioavailability were determined for aged and non-aged soil."( Pb, Zn and Cd mobility, availability and fractionation in aged soil remediated by EDTA leaching.
Lestan, D; Udovic, M, 2009
)
0.35
" Soil-metal interactions by sorption, precipitation and complexation processes, and differences between plant species in metal uptake efficiency, transport, and susceptibility make a general prediction of soil metal bioavailability and risks of plant metal toxicity difficult."( Assessment of the efficacy of chelate-assisted phytoextraction of lead by coffeeweed (Sesbania exaltata Raf.).
Begonia, G; Begonia, M; Hundley, O; Miller, G; Ntoni, J, 2008
)
0.35
" We hypothesized that the bioavailability of Pb for plant uptake can be increased through chelate amendments."( Bioavailability and uptake of lead by coffeeweed (Sesbania exaltata Raf.).
Begonia, G; Begonia, M; Miller, G; Ntoni, J, 2008
)
0.35
"The bioavailability and therefore toxicity of a metal depends on the chemical species present in a particular environment."( Effect of pH, EDTA, and anions on heavy metal toxicity toward a bioluminescent cyanobacterial bioreporter.
Fernández-Piñas, F; González-García, C; Leganés, F; Rodea-Palomares, I, 2009
)
0.35
" The results highlight the importance of distinguishing between the thermodynamically predominant species versus the kinetically relevant ones in considerations of dynamic speciation analysis and bioavailability in natural and engineered systems."( Outer-sphere and inner-sphere ligand protonation in metal complexation kinetics: the lability of EDTA complexes.
Town, RM; van Leeuwen, HP, 2009
)
0.35
" In rat, chitosan glutamate doubled oral bioavailability of acyclovir and tripled the amount of acyclovir excreted unchanged into urine."( Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.
Christoffersen, C; El-Kattan, A; Merzlikine, A; Poe, J; Rago, B; Rotter, C; Thomas, VH; Troutman, M, 2009
)
0.35
"Metal bioavailability depends on the presence of organic ligands in the water and on the concentrations of competitive cations."( A model predicting waterborne cadmium bioaccumulation in Gammarus pulex: the effects of dissolved organic ligands, calcium, and temperature.
Geffard, O; Gourlay-francé, C; Kermoal, T; Lacour, C; Pellet, B; Tusseau-vuillemin, MH, 2009
)
0.35
" The post-transcriptional control of TGF-beta bioavailability points out the need to determine TGF-beta at the protein level."( Bioactive TGF-beta levels can be preserved in plasma samples collected into heparin but not EDTA.
Jallow, IK; Jeffries, D; Walther, B; Walther, M, 2009
)
0.35
"Soil remediation with ethylenediamine tetraacetic acid (EDTA) leaching is capable of removing only part of the total metal concentration in the soil, mostly the labile, bioavailable metal species (metal bioavailability stripping)."( Fractionation and bioavailability of Cu in soil remediated by EDTA leaching and processed by earthworms (Lumbricus terrestris L.).
Lestan, D; Udovic, M, 2010
)
0.36
"The acidification caused by the dissolution of anthropogenic carbon dioxide (CO2) in the ocean changes the chemistry and hence the bioavailability of iron (Fe), a limiting nutrient in large oceanic regions."( Effect of ocean acidification on iron availability to marine phytoplankton.
Hopkinson, BM; Morel, FM; Shi, D; Xu, Y, 2010
)
0.36
" Moreover, this feature is intended to be used to analyze formulation approaches aiming for an improved oral drug bioavailability by application of excipients that increase the paracellular permeability of the intestinal epithelial barrier."( Online monitoring of transepithelial electrical resistance (TEER) in an apparatus for combined dissolution and permeation testing.
Balbach, S; Eichinger, T; Koenig, P; Lehr, CM; Loos, P; Muendoerfer, M; Schaefer, UF; Walk, JS, 2010
)
0.36
" The bioavailability of diverse iron compounds added to the mostly vegetable diets of such populations showed the superior absorption of chelated iron (NaFeEDTA) and its strong effectiveness in correcting iron deficiency when added to sugar."( INCAP studies of hematologic and gastrointestinal function in healthy individuals and those with protein-energy malnutrition and infection.
Viteri, FE, 2010
)
0.36
" The effect of earthworms as main soil biotic factors on the residual Pb, Zn, and Cd fraction lability (mobility, bioavailability to plants, and oral-availability) was investigated."( Redistribution of residual Pb, Zn, and Cd in soil remediated with EDTA leaching and exposed to earthworms (Eisenia fetida).
Lestan, D; Udovic, M, 2010
)
0.36
" fetida mirrored the decreasing pattern of metal potential bioavailability gained by leaching the soil with increasing EDTA concentrations."( Eisenia fetida avoidance behavior as a tool for assessing the efficiency of remediation of Pb, Zn and Cd polluted soil.
Lestan, D; Udovic, M, 2010
)
0.36
"Following epidural administration, cerebrospinal fluid bioavailability of local anesthetics is low, one major limiting factor being diffusion across the arachnoid mater barrier."( Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers.
Brandhonneur, N; Chevanne, F; Deniau, AL; Dollo, G; Estèbe, JP; Le Corre, P; Legrand, A; Ratajczak-Enselme, M, 2011
)
0.37
" Even with the use of a very well absorbed ferrous iron compound, iron fortification in this population does not increase NTBI, suggesting a low risk for adverse health consequences."( Fortification iron as ferrous sulfate plus ascorbic acid is more rapidly absorbed than as sodium iron EDTA but neither increases serum nontransferrin-bound iron in women.
Egli, I; Hurrell, RF; Troesch, B; Zeder, C; Zimmermann, MB, 2011
)
0.37
" It produces fewer organoleptic effects than other fortificants do, especially when the matrix of the food vehicle contains fat, and has a bioavailability two to four times higher than that of ferrous sulfate."( Development of fortified biscuit using NaFeEDTA.
Abedi, AS; Ahmadian, FS; Azizi, MH; Mohammadi, M; Pouraram, H, 2011
)
0.37
"Excess P decreased the distribution of Zn in grain, while Zn enhanced the uptake of Zn and P in grain, The combined application of Zn fertilizer with the extensive use of P fertilizer can effectively increase the P and Zn concentration and Zn bioavailability of wheat grain, and hence Zn nutritional quality."( Impacts of phosphorus and zinc levels on phosphorus and zinc nutrition and phytic acid concentration in wheat (Triticum aestivum L.).
Cao, YX; Chen, ZH; Lu, XC; Tian, XH; Yang, XW, 2011
)
0.37
" In addition, the impact of soil properties, soil nutrients, and soil enzyme activities on bioavailability of vanadium is discussed in this study."( Bioavailability of vanadium extracted by EDTA, HCl, HOAC, and NaNO3 in topsoil in the Panzhihua urban park, located in southwest China.
Song, L; Teng, Y; Wang, J; Yang, J, 2011
)
0.37
" The higher efficiency of the extracted chains of magnetosomes compared with that of the other nanoparticles is attributed to three factors: (i) a specific absorption rate higher for the magnetosomes than for the chemically synthesized superparamagnetic iron oxide nanoparticles, (ii) a more uniform heating for the chains of magnetosomes than for the individual magnetosomes and (iii) the ability of the chains of magnetosomes to penetrate within the cancer cells or bind at the cell membrane following the application of the alternative magnetic field, which enables efficient cell destruction."( Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy.
Alphandéry, E; Chebbi, I; Faure, S; Guyot, F; Seksek, O, 2011
)
0.37
"As a highly bioavailable iron compound, sodium iron (iii) ethylenediaminetetraacetate (NaFeEDTA) has been recommended as a food additive for fortification."( Fortifying complementary foods with NaFeEDTA--considerations for developing countries.
Schofield, D; Siekmann, J; Yang, Z, 2011
)
0.37
" The aim was to optimize solubilization so as to enhance bioavailability for the purposes of remediation."( Enhancing uranium solubilization in soils by citrate, EDTA, and EDDS chelating amendments.
Blanco Rodríguez, P; Calvo, CP; Lozano, JC; Tomé, FV, 2011
)
0.37
" Effect of sodium iron ethylenediaminetetraacetate (NaFeEDTA) and ferrous sulfate on iron bioavailability and oxidative stress in anemic pregnant women was evaluated."( Moderate NaFeEDTA and ferrous sulfate supplementation can improve both hematologic status and oxidative stress in anemic pregnant women.
Han, XX; Jiang, DC; Li, Y; Ma, AG; Sun, YY; Yang, F; Zhang, FZ, 2011
)
0.37
" To determine factors necessary for bioactivity, we tested the cytotoxicity of different ligand compounds in conjunction with speciation studies and mass spectrometry bioavailability measurements."( Cytotoxicity of a Ti(IV) compound is independent of serum proteins.
Incarvito, CD; Saghatelian, A; Thomas, HR; Tinoco, AD; Valentine, AM, 2012
)
0.38
"A recent study of the effect of pH on Zn and Cd bioavailability shows that binding to weak organic ligands can increase the pool of metals available to phytoplankton in the presence of strong chelating agents."( Weak organic ligands enhance zinc uptake in marine phytoplankton.
Aristilde, L; Morel, FM; Xu, Y, 2012
)
0.38
" However, studies with plants have shown that labile metal complexes enhance metal bioavailability when the uptake is rate-limited by transport of the free ion in solution to the uptake site."( Labile complexes facilitate cadmium uptake by Caco-2 cells.
Degryse, F; Niewold, T; Smolders, E; Verheyen, L, 2012
)
0.38
" These data indicate that in rats fed a high PA diet, bioavailability of commonly used inorganic or chelated Zn compounds does not differ appreciably, but Zn supplied as an EDTA disodium salt has superior bioavailability."( EDTA disodium zinc has superior bioavailability compared to common inorganic or chelated zinc compounds in rats fed a high phytic acid diet.
Bertinato, J; Plouffe, LJ; Sherrard, L, 2012
)
0.38
"Although soil characteristics modulate metal mobility and bioavailability to organisms, they are often ignored in the risk assessment of metal transfer."( Soil parameters are key factors to predict metal bioavailability to snails based on chemical extractant data.
Coeurdassier, M; de Vaufleury, A; Gimbert, F; Pauget, B; Scheifler, R, 2012
)
0.38
" However, the mobility, activity and bioavailability of Pb rely mainly on its various chemical species in soils."( Labile pools of Pb in vegetable-growing soils investigated by an isotope dilution method and its influence on soil pH.
Cai, C; Cao, YL; Huang, ZY; Li, J; Xie, H; Zeng, XC, 2012
)
0.38
"Few studies have evaluated the impact of fortification with iron-rich foods such as amaranth grain and multi-micronutrient powder (MNP) containing low doses of highly bioavailable iron to control iron deficiency anemia (IDA) in children."( Maize porridge enriched with a micronutrient powder containing low-dose iron as NaFeEDTA but not amaranth grain flour reduces anemia and iron deficiency in Kenyan preschool children.
Brouwer, ID; Kok, FJ; Macharia-Mutie, CW; Moretti, D; Mwangi, AM; Omusundi, AM; Van den Briel, N; Zimmermann, MB, 2012
)
0.38
"Present study investigated the significance of the concentration of chelating ligand on Fe(3+)-solubility in growth medium and its influence on Fe bioavailability and uptake in rice plant."( Significance of the concentration of chelating ligands on Fe3+-solubility, bioavailability, and uptake in rice plant.
Hasegawa, H; Kadohashi, K; Maki, T; Rahman, MA; Rahman, MM; Takasugi, Y; Tate, Y, 2012
)
0.38
" To optimize iron bioavailability from an LNS named complementary food fortificant (CFF), 3 stable isotope studies were conducted in 52 young Beninese children."( Iron bioavailability from a lipid-based complementary food fortificant mixed with millet porridge can be optimized by adding phytase and ascorbic acid but not by using a mixture of ferrous sulfate and sodium iron EDTA.
Cercamondi, CI; Egli, IM; Hessou, J; Hounhouigan, JD; Hurrell, RF; Mitchikpe, E; Tossou, F; Zeder, C, 2013
)
0.39
" The combination of UAE and TXRF allows assessing the potential metal mobility and bioavailability in a simple way."( Ultrasound-assisted single extraction tests for rapid assessment of metal extractability from soils by total reflection X-ray fluorescence.
Bendicho, C; Cabaleiro, N; De La Calle, I; Lavilla, I, 2013
)
0.39
"The BCR sequential extraction procedure was compared with EDTA, HCl, and NaNO3 single extractions for evaluating vanadium bioavailability in alfalfa rhizosphere soil."( Comparison of bioavailable vanadium in alfalfa rhizosphere soil extracted by an improved BCR procedure and EDTA, HCl, and NaNO₃ single extractions in a pot experiment with V-Cd treatments.
Song, L; Teng, Y; Yang, J; Zuo, R, 2015
)
0.42
"In addition to phytate, polyphenols (PP) might contribute to low Fe bioavailability from sorghum-based foods."( Sodium iron EDTA and ascorbic acid, but not polyphenol oxidase treatment, counteract the strong inhibitory effect of polyphenols from brown sorghum on the absorption of fortification iron in young women.
Cercamondi, CI; Egli, IM; Hurrell, RF; Zeder, C, 2014
)
0.4
"The toxicity and bioavailability of chromium species are highly dependable on the form or species, therefore determination of total chromium is insufficient for a complete toxicological evaluation and risk assessment."( Application of high performance liquid chromatography with inductively coupled plasma mass spectrometry (HPLC-ICP-MS) for determination of chromium compounds in the air at the workplace.
Janasik, B; Stanislawska, M; Wasowicz, W, 2013
)
0.39
" Cuttings were grown on agricultural soil highly contaminated with Cu and Zn, in the presence or not (controls) of a chelant mixture (EDTA/EDDS) known to enhance metal bioavailability and, hence, uptake by plant roots, or the not yet investigated synthetic, highly biodegradable polyaspartic acid (PASP)."( Polyaspartate, a biodegradable chelant that improves the phytoremediation potential of poplar in a highly metal-contaminated agricultural soil.
Baldantoni, D; Biondi, S; Castiglione, S; Cicatelli, A; Grimaldi, M; Lingua, G; Proto, A; Todeschini, V; Torrigiani, P, 2014
)
0.4
"4 mg day(-1)  kgbw(-1) would enable iron EDTA, an iron fortificant with proven bioavailability in phytate-rich meals, to be added in adequate amounts to cereal-based meals for children 6-24 months of age, who are at risk of iron deficiency."( Reasons for raising the maximum acceptable daily intake of EDTA and the benefits for iron fortification of foods for children 6-24 months of age.
Wreesmann, CT, 2014
)
0.4
"The low bioavailability of Pb and low number of Pb-tolerant plant species represent an important limitation for Pb phytoextraction."( EDTA-enhanced phytoremediation of lead-contaminated soil by the halophyte Sesuvium portulacastrum.
Abdelly, C; Chmingui, W; Ghabriche, R; Ghnaya, T; Lakhdar, A; Lutts, S; Zaier, H, 2014
)
0.4
" The above results demonstrated that water management of AWD combined with ZnSO4 fertilization was an effective agricultural practice to elevate grain yield and increase Zn accumulation and bioavailability in rice grains."( Improved yield and Zn accumulation for rice grain by Zn fertilization and optimized water management.
Dong, LX; Feng, Y; Lu, LL; Pan, FS; Wang, YY; Wei, YY; Yang, XE; Zhang, J, 2014
)
0.4
" Here we examine Fe bioavailability to phytoplankton by analyzing iron uptake from various Fe substrates by several species of phytoplankton grown under conditions of Fe limitation and comparing the measured uptake rate constants (Fe uptake rate/ substrate concentration)."( Iron bioavailability to phytoplankton: an empirical approach.
Keren, N; Kranzler, C; Lis, H; Morel, FM; Shaked, Y, 2015
)
0.42
" To test the hypothesis that rapid and substantial bioavailability of the antidotes HI-6 oxime and dicobalt edetate can be achieved via the intraosseous (IO) route, plasma concentration-time profiles of these antidotes were compared after administration by the intravenous and IO routes in a minipig animal model."( Rapid and equivalent systemic bioavailability of the antidotes HI-6 and dicobalt edetate via the intraosseous and intravenous routes.
Blain, PG; Dunn, M; Flecknell, PA; Henderson, D; Hill, SL; Morris, CM; Thomas, AA; Thomas, SH, 2015
)
0.42
"This study demonstrates rapid and similar systemic bioavailability of HI-6 and dicobalt edetate when given by the IO and intravenous routes."( Rapid and equivalent systemic bioavailability of the antidotes HI-6 and dicobalt edetate via the intraosseous and intravenous routes.
Blain, PG; Dunn, M; Flecknell, PA; Henderson, D; Hill, SL; Morris, CM; Thomas, AA; Thomas, SH, 2015
)
0.42
" Therefore, NaFeEDTA-fortified soy sauce does not affect Zn bioavailability in children."( Effect of NaFeEDTA-fortified soy sauce on zinc absorption in children.
Li, M; Li, W; Piao, J; Ren, T; Wang, J; Wang, R; Wu, J; Yang, X, 2015
)
0.42
" The relative bioavailability of FAC and of the FeSO4  + NaFeEDTA was obtained by comparing their iron absorption with that of FeSO4 ."( Iron bioavailability in 8-24-month-old Thai children from a micronutrient-fortified quick-cooking rice containing ferric ammonium citrate or a mixture of ferrous sulphate and ferric sodium ethylenediaminetetraacetic acid.
Chavasit, V; Hurrell, R; Porasuphatana, S; Suthutvoravut, U; Zeder, C, 2015
)
0.42
"Laboratory experiments have established the importance of complexation by organic ligands in determining the bioavailability of trace metals to marine phytoplankton, while electrochemical measurements with field samples have demonstrated that a large fraction of bioactive trace metals are complexed to strong organic ligands in seawater."( Bioavailability and Electroreactivity of Zinc Complexed to Strong and Weak Organic Ligands.
Baars, O; Kim, JM; Morel, FM, 2015
)
0.42
" CF fortified with highly bioavailable iron improved iron status but not Hb concentration, despite three-monthly IPT of malaria."( The effect of iron-fortified complementary food and intermittent preventive treatment of malaria on anaemia in 12- to 36-month-old children: a cluster-randomised controlled trial.
Adiossan, LG; Brittenham, GM; Diakité, VG; Glinz, D; Hurrell, RF; N'Goran, EK; Ouattara, M; Righetti, AA; Seifert, B; Utzinger, J; Wegmüller, R; Zimmermann, MB, 2015
)
0.42
" We also show that cysteine can increase the bioavailability of Cu to Cu-limited cells, of both species, through the reductive release of Cu(I) from fairly strong Cu(II) ligands such as EDTA."( Cysteine Enhances Bioavailability of Copper to Marine Phytoplankton.
Ahner, BA; Goodnow, SD; Richter, LV; Vezeau, GE; Walsh, MJ, 2015
)
0.42
"Nanoparticulate drug delivery systems, mucoadhesive polymers and penetration enhancers have been used individually to overcome ocular barriers and increase bioavailability to eye tissues."( Understanding the influence of surface properties of nanoparticles and penetration enhancers for improving bioavailability in eye tissues in vivo.
Katti, DS; Mahaling, B, 2016
)
0.43
"Previous studies have shown that phytoremediation usually requires soil amendments, such as chelates, to mobilize low bioavailability heavy metals for better plant absorption and, consequently, for remediation efficiency."( An evaluation of EDTA additions for improving the phytoremediation efficiency of different plants under various cultivation systems.
Gu, XW; Luo, J; Qi, S; Wang, J; Xie, X, 2016
)
0.43
" The clinical use of the strong chelator N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) and its alkyl ester prodrugs has been hindered by poor oral bioavailability and lack of conversion to the parent chelator, respectively."( Novel double prodrugs of the iron chelator N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED): Synthesis, characterization, and investigation of activation by chemical hydrolysis and oxidation.
Abboud, KA; Sloan, KB; Thiele, NA, 2016
)
0.43
" It was determined that soil washing agents and their washing order were critical to removal efficiencies of metal fractions, metal bioavailability and potential mobility due to different levels of dissolution of residual fractions and inter-transformation of metal fractions."( Removal of arsenic and cadmium with sequential soil washing techniques using Na2EDTA, oxalic and phosphoric acid: Optimization conditions, removal effectiveness and ecological risks.
Chen, J; Wang, X; Wei, M, 2016
)
0.43
" In this study, we employed diffusive gradients in thin-films (DGT) and traditional chemical extraction methods (soil solution, HOAc, EDTA, CaCl₂, and NaOAc) to determine the Cd bioavailability in Cd-contaminated soil with the addition of Pb."( A Diffusive Gradient-in-Thin-Film Technique for Evaluation of the Bioavailability of Cd in Soil Contaminated with Cd and Pb.
Liu, C; Wang, C; Wang, P; Wang, T; Yao, Y; Yuan, Y, 2016
)
0.43
" These results were applied to predict the Cd bioavailability after the addition of colza cake to Cd-contaminated soil."( The Combination of DGT Technique and Traditional Chemical Methods for Evaluation of Cadmium Bioavailability in Contaminated Soils with Organic Amendment.
Ding, SM; Miao, LZ; Sun, Q; Wang, C; Wang, PF; Yao, Y, 2016
)
0.43
"A structurally controllable fluorescence-labeled hollow mesoporous carbon (HMC) was simply prepared to improve the oral bioavailability of insoluble drugs and further trace their delivery process in vivo."( A Eu(3+)/Gd(3+)-EDTA-doped structurally controllable hollow mesoporous carbon for improving the oral bioavailability of insoluble drugs and in vivo tracing.
Cui, Y; Gao, Y; Liu, J; Wang, S; Yue, Y; Zhao, Q; Zhao, Y, 2016
)
0.43
"Enhanced phytoextraction uses soil chelators to increase the bioavailability of heavy metals."( Impact of chelator-induced phytoextraction of cadmium on yield and ionic uptake of maize.
Anwar, S; Ashraf, MY; Fahad, S; Khan, S; Liu, L; Noman, A; Ullah, S; Zafar, S, 2017
)
0.46
" The in situ technique of diffusive gradients in thin film (DGT), the ex situ static equilibrium approach (HAc, EDTA and CaCl2), and the dissolved concentration in soil solution, as well as microwave digestion, were applied to predict the Cd bioavailability of soil, aiming to provide a robust and accurate method for Cd bioavailability evaluation in Yixing."( The Evaluation on the Cadmium Net Concentration for Soil Ecosystems.
Hou, J; Miao, LZ; Wang, C; Wang, PF; Yao, Y, 2017
)
0.46
" Additionally, bioavailability of these metals left in the washed sediment was assessed."( Metal removal and associated binding fraction transformation in contaminated river sediment washed by different types of agents.
Feng, S; Liu, T; Wang, H; Zhang, W, 2017
)
0.46
" The bioavailability of some of the on-column formed CA-Cd complexes explains the previously reported increased accumulation of Cd in periphyton in the ecosystem downstream of wastewater treatment plants."( Environmentally relevant concentrations of aminopolycarboxylate chelating agents mobilize Cd from humic acid.
Bellavie, AR; Gailer, J; North, AE; Sarpong-Kumankomah, S; White, WM, 2017
)
0.46
"A MNP containing a low dose of highly bioavailable iron reduces anaemia, and the addition of GOS mitigates most of the adverse effects of iron on the gut microbiome and morbidity in African infants."( Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomised controlled study in Kenyan infants.
Barth-Jaeggi, T; Boekhorst, J; Cercamondi, CI; Karanja, S; Kortman, GAM; Lacroix, C; Moretti, D; Paganini, D; Schwab, C; Timmerman, HM; Uyoga, MA; Zimmermann, MB, 2017
)
0.46
"Fe fortification of wheat flour was proposed in Haiti to combat Fe deficiency, but Fe bioavailability from fortificants has never been investigated in Haitian women or preschool children, two key target groups."( In Haitian women and preschool children, iron absorption from wheat flour-based meals fortified with sodium iron EDTA is higher than that from meals fortified with ferrous fumarate, and is not affected by Helicobacter pylori infection in children.
Eliancy, K; Herter-Aeberli, I; Loechl, CU; Marhône Pierre, J; Rathon, Y; Zimmermann, MB, 2017
)
0.46
"Due to low Fe bioavailability and low consumption per meal, lentil must be fortified to contribute significant bioavailable Fe in the Bangladeshi diet."( Relative Bioavailability of Iron in Bangladeshi Traditional Meals Prepared with Iron-Fortified Lentil Dal.
M DellaValle, D; P Glahn, R; Podder, R; T Tyler, R; Tako, E; Vandenberg, A, 2018
)
0.48
"Slow plant growth, low biomass, and low bioavailability of heavy metals in soil are important factors that limit remediation efficiencies."( Improvement of the phytoremediation efficiency of Neyraudia reynaudiana for lead-zinc mine-contaminated soil under the interactive effect of earthworms and EDTA.
Cai, L; Li, Y; Luo, J; Ma, X; Xia, L; Yu, J; Zhou, C, 2018
)
0.48
" However, bioavailability of residual heavy metals in soils and soil properties could be changed during washing processes."( Effect of mixed chelators of EDTA, GLDA, and citric acid on bioavailability of residual heavy metals in soils and soil properties.
Guo, X; He, Q; Qian, T; Wei, Z; Wu, Q; Zhang, G; Zhao, G; Zheng, W, 2018
)
0.48
" Chelates added on 25th d and 25/35th d after sowing, enhanced cadmium (Cd) and zinc (Zn) bioavailability in soil due to complexation."( EDTA and organic acids assisted phytoextraction of Cd and Zn from a smelter contaminated soil by potherb mustard (Brassica juncea, Coss) and evaluation of its bioindicators.
Ali, A; Du, J; Guo, D; Lahori, AH; Li, R; Ren, C; Xiao, R; Zhang, Z, 2019
)
0.51
"Heavy metal(loid) extraction from soils in overlapped areas of farmland and coal resources (OAFCR) is crucial in understanding heavy metal bioavailability in soil and the subsequent risks to crops and consumers."( Application of different single extraction procedures for assessing the bioavailability of heavy metal(loid)s in soils from overlapped areas of farmland and coal resources.
Han, X; Jiang, J; Luo, P; Ma, Y; Sun, X; Wang, H; Xiao, X, 2019
)
0.51
" Chemical analyses concerned determination of ammonia and trace elements in the untreated sample and after manipulation intended to remove or modify bioavailability of ammonia and metals."( A Hybrid Phase I-Phase II Toxicity Identification Evaluation (TIE) for the Simultaneous Characterization and Identification of Toxicants of Concern in Coastal and Estuarine Environments.
Corami, F; Picone, M; Vendramin, S; Volpi Ghirardini, A, 2019
)
0.51
" The success of phytoremediation relies on the size of the plant biomass and bioavailability of the metal for plant uptake."( The effect of Cu-resistant plant growth-promoting rhizobacteria and EDTA on phytoremediation efficiency of plants in a Cu-contaminated soil.
Abbaszadeh-Dahaji, P; Baniasad-Asgari, A; Hamidpour, M, 2019
)
0.51
" Results of chemical speciation showed that the co-application of EDTA and fluorescent pseudomonads strains increased the bioavailability of Zn, Pb, and Cd by their redistribution from less soluble fractions to water-soluble forms."( Effects of plant growth-promoting bacteria on EDTA-assisted phytostabilization of heavy metals in a contaminated calcareous soil.
Abbaszadeh Dahaji, P; Hamidpour, M; Nemati, H; Roosta, HR, 2020
)
0.56
" The concentration and spatial arrangement of heavy metals in larvae as determined by Inductively Coupled Plasma Mass Spectrometry (ICPMS) and X-ray Fluorescence Microscopy (XFM) was consistent with reduced bioavailability of several metals, especially copper and zinc."( Examining the role of ethylenediaminetetraacetic acid (EDTA) in larval shellfish production in seawater contaminated with heavy metals.
Chan, A; de Jonge, MD; Jeffs, AG; McDougall, DR; McGillivray, DJ; Miskelly, GM, 2019
)
0.51
" However, the practical use of phytoremediation is constrained by the low biomass of plants and low bioavailability of heavy metals in soil."( Effects of EDTA and plant growth-promoting rhizobacteria on plant growth and heavy metal uptake of hyperaccumulator Sedum alfredii Hance.
Ding, Y; Guo, J; Hua, L; Jia, H; Lv, X; Muhammad, H; Ren, X; Wei, T, 2020
)
0.56
" Nicotianamine (NA) is a natural chelator of Fe, zinc (Zn) and other metals in higher plants and NA-chelated Fe is highly bioavailable in vitro."( Nicotianamine-chelated iron positively affects iron status, intestinal morphology and microbial populations in vivo (Gallus gallus).
Beasley, JT; Bonneau, JP; Glahn, RP; Johnson, AAT; Kolba, N; Koren, O; Ozeri, L; Tako, E, 2020
)
0.56
"Low bioavailability of iron due to poor solubility of iron(hydr)oxides limits the growth of microorganisms and plants in soils and aquatic environments."( Catalytic effects of photogenerated Fe(II) on the ligand-controlled dissolution of Iron(hydr)oxides by EDTA and DFOB.
Biswakarma, J; Hering, JG; Hug, SJ; Kang, K; Kraemer, SM; Schenkeveld, WDC, 2021
)
0.62
"Our objective was to quantify bioavailability of iron from NaFeEDTA when added to a wheat flour-based meal in both nonanemic women and women with iron deficiency anemia (IDA), when consumed with and without traditional Moroccan green tea."( Tea Consumption Reduces Iron Bioavailability from NaFeEDTA in Nonanemic Women and Women with Iron Deficiency Anemia: Stable Iron Isotope Studies in Morocco.
Aguenaou, H; Al-Jawaldeh, A; Barkat, A; El Kari, K; Elammari, L; Lazrak, M; Loechl, CU; Stoffel, NU; Yahyane, A; Zimmermann, MB, 2021
)
0.62
"Drug formulations such as spray drying are often required to improve the physicochemical properties and bioavailability of hydrophobic drugs."( Oxidative degradation in pharmaceuticals: Mechanism and stabilization of a spray-dried amorphous drug - A case study.
Kotha, RR; Kumar, A; Yehl, P; Zhang, K, 2022
)
0.72
" These findings suggest that using select inhibitors and lipid-based nanocarriers can decrease peptide degradation and may improve oral bioavailability of TP5 following oral administration."( Exploring ex vivo peptideolysis of thymopentin and lipid-based nanocarriers towards oral formulations.
Chen, S; Kang, D; Liu, M; Loh, J; Proft, T; Svirskis, D; Wen, J, 2022
)
0.72
"The bioavailability of copper (Cu) in human cells may depend on a complex interplay with zinc (Zn) ions."( Crystal Structure of the Human Copper Chaperone ATOX1 Bound to Zinc Ion.
Arnesano, F; Belviso, BD; Caliandro, R; Mangini, V; Nardella, MI; Natile, G, 2022
)
0.72
" Elevating dietary micronutrient iron (Fe) intake can reduce Pb oral bioavailability while being beneficial for child nutritional health."( Effects of various Fe compounds on the bioavailability of Pb contained in orally ingested soils in mice: Mechanistic insights and health implications.
Juhasz, AL; Li, HB; Li, SW; Lin, XY; Ma, LQ; Wang, HY; Xue, RY; Zhang, S; Zhang, YS; Zhou, DM; Zhou, L, 2022
)
0.72
" It is well known that iron bioavailability largely influences microbial iron reduction, but the long-term effects of different ferric irons on soil Fe-AOM remain unknown."( Long-term effects of soluble and insoluble ferric irons on anaerobic oxidation of methane in paddy soil.
Feng, J; He, Z; Pan, X; Xu, Y; Zhang, D; Zhu, Y, 2023
)
0.91
" This study discusses the application of β-cyclodextrin (βCD) for the delivery of highly bioavailable and hydrophilic iron, ferric sodium EDTA, which exhibits great functionality in the presence of polyphenols and phytates with potential application in food fortification."( Preparation and characterization of an iron-β-cyclodextrin inclusion complex: factors influencing the host-guest interaction.
Diosady, LL; Saffarionpour, S, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" The results of both positive and non-positive selection systems showed that the mutation frequencies in the livers of the dams dosed with alpha-chaconine, alpha-solanine and solanidine were three to four times higher than historically normal in the livers of this transgenic mouse strain."( A preliminary assessment of the toxic and mutagenic potential of steroidal alkaloids in transgenic mice.
Crawford, L; Myhr, B, 1995
)
0.29
" The slopes of the dose-response curves of the narcotic antagonist analgesics were significantly shallower than those of the narcotic analgesics."( A test for antinociceptive activity of narcotic and narcotic antagonist analgesics in the guinea pig.
Teiger, DG, 1976
)
0.26
" Administration of EDTA alone, in a neutral dosage form, did not significantly change absorption of the drug, which contradicted previous findings."( Compensation of dietary induced reduction of tetracycline absorption by simultaneous administration of EDTA.
Poiger, H; Schlatter, C, 1978
)
0.26
" Since EDTA is excreted much like creatinine, the dosage must be reduced proportionately in response to elevated serum creatinine levels in the patient with renal failure."( Chelation therapy in lead nephropathy.
Morgan, JM, 1975
)
0.25
" The cell damaging and amylase releasing properties of A23187 were distinguished by their time course and dose-response relationship."( Intracellular uptake and alpha-amylase and lactate dehydrogenase releasing actions of the divalent cation ionophore A23187 in dissociated pancreatic acinar cells.
Chandler, DE; Williams, JA, 1977
)
0.26
" While pilocarpine retained some residual hypotensive effect 12 hours after application, twice-daily dosage with the solutions tested gave inadequate control for clinical usefulness."( Intraocular pressure control with twice-daily pilocarpine in two vehicle solutions.
Pollack, IP; Quigley, HA, 1977
)
0.26
" of copper at the recommended dosage of 25 ml), administration of Biodalbene failing to produce any improvement in copper status, which hardly could be expected by such low copper content (0."( [Comparative studies on the effect of injections of copper in cattle showing low blood copper concentrations (author's transl)].
Koopman, JJ; Wijbenga, A, 1977
)
0.26
"Lead absorption and prevention of the serious effects of lead re-examined from the viewpoints of the critical organ and clinical effect concepts and the associated dose-effect and dose-response relationships."( Dose-effect and dose-response relationships for lead in children.
Barrett, MB; Chisolm, JJ; Mellits, ED, 1975
)
0.25
" Dose-response assays in mice demonstrate that hemagglutination-inhibiting and neuraminidase antibodies are induced."( Alkaline-extracted influenza subunit vaccine.
Eckert, EA, 1976
)
0.26
" V(V) did not significantly affect SOD activity when assayed with the sulfite method, which is devoid of interferences with V(V); however, there was an apparent inhibitory dose-response pattern for either V(IV) or V(V) using the pyrogallol assay, owing to an interference of pyrogallol with the metal."( Vanadium effect on the activity of horseradish peroxidase, catalase, glutathione peroxidase, and superoxide dismutase in vitro.
Casella, L; Pintar, A; Sabbioni, E; Serra, MA, 1992
)
0.28
" Increased dosage of FUP1 reduces the concentration of iron in the medium required for efficient growth and confers elevated levels of iron uptake activity in iron-limited cells."( Increased dosage of a transcriptional activator gene enhances iron-limited growth of Saccharomyces cerevisiae.
Eide, D; Guarente, L, 1992
)
0.28
"Groups of parasite-free lambs and calves which were either housed and fed hay and concentrates or were grazing on pasture were dosed separately with the oral anthelmintics fenbendazole and ivermectin (lambs only)."( Effects of diet on plasma concentrations of oral anthelmintics for cattle and sheep.
Blanchflower, WJ; Green, WP; Kennedy, DG; Mallon, TR; Taylor, SM, 1992
)
0.28
" Millimolar concentration of ATP, which is present physiologically, will shift the dose-response relation of IP3 toward the higher IP3 concentration and enhance the maximal effect of IP3."( Effects of adenine nucleotides on inositol 1,4,5-trisphosphate-induced calcium release in vascular smooth muscle cells.
Iino, M, 1991
)
0.28
", norepinephrine dose-response curves were shifted to left in presence of adenosine deaminase or IBMX and to right with 2-chloroadenosine)."( Cold acclimation induces desensitization to adenosine in brown fat cells without changing receptor binding.
Mohell, N; Nedergaard, J; Unelius, L, 1990
)
0.28
" This was the first investigation of a once-daily dosing regimen conducted in seriously ill patients with systemic infections."( Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?
Cronberg, S; Nordström, L; Ringberg, H; Tjernström, O; Walder, M, 1990
)
0.28
" The dose-response profile for HDL2 binding was consistent with a single lipoprotein binding site at all concentrations of HDL2, whereas uptake of cholesteryl ester from HDL2 was biphasic, suggesting a high affinity site at low HDL2 concentrations and a low affinity site at high lipoprotein concentrations."( Selective uptake of cholesteryl ester from high density lipoproteins by plasma membranes of adipose tissue.
Angel, A; Parkes, JG, 1990
)
0.28
" Inhibition by Pi showed no dose-response relationship over the range tested (1-350 microM)."( Analysis of the inhibitory effect of inorganic phosphate on development of four-cell hamster embryos in vitro.
Bavister, BD; Monis, H, 1990
)
0.28
"In experiment 1 chicks and growing mice given diets containing 400 mg Fe kg-1, added as chloride, ethylene diamine tetra-acetate or nitrilotriacetate (NTA), were dosed orally with 59Fe in the form present in the diet and the quantities of 59Fe in liver, spleen, blood, remaining carcase and whole blood were calculated as concentration in fresh tissue and as a percentage of the dose."( Comparison of the retention in chicks and mice of 59Fe given orally as chloride, ethylene diamine tetra-acetate or nitrilotriacetate and in chicks given diets composed of conventional ingredients or semi-purified nutrients.
Bhabuta, A; Hill, R; Leighton, MJ, 1990
)
0.28
" Addition of GTP resulted in a rightward shift in the glutamate dose-response curve and a decrease in the maximum level of stimulation."( Guanine nucleotide modulation of [3H]TCP binding to the NMDA receptor complex.
Compton, RP; Hood, WF; Monahan, JB; Thomas, JW, 1990
)
0.28
" The ATPase log dose-response curve was linear between approximately 12."( Enzyme activation of human prolactin: a potential basis for a bioassay.
Bertrand, PV; Ryle, M, 1989
)
0.28
" Based on the pharmacokinetics of DTPA, chelation therapy immediately after an actinide accident involving inhalation or extensive skin damage will be more efficient and more effective if a fraction of the standard clinical ZnNa3-DTPA dosage is administered every few hours instead of as a single daily injection."( Predicting the kinetics of chelating agents in man from animal data.
Durbin, PW; Schmidt, CT, 1989
)
0.28
" Reirradiation tolerance was assessed from dose-response curves for renal damage in retreated mice compared with that in age matched controls which received only the second treatment."( The lack of long-term recovery and reirradiation tolerance in the mouse kidney.
Lebesque, JV; Luts, A; Stewart, FA, 1989
)
0.28
" It was concluded that CaEDTA is teratogenic in rats at concentrations which, except for decreased weight gain, produce no discernible toxicity to the dam, and which are comparable to the recommended therapeutic dosage in humans (1500 mg/m2/day corresponding to 4 mmol/m2/day)."( Teratogenic effect of calcium edetate (CaEDTA) in rats and the protective effect of zinc.
Aronson, AL; Brownie, C; Brownie, CF; Haluska, M; Krook, L; Noden, D, 1986
)
0.27
" However, food intake was also substantially reduced with gavage dosing of the test substance."( Evaluation of the teratogenicity of ethylenediamine dihydrochloride in Fischer 344 rats by conventional and pair-feeding studies.
DePass, LR; Woodside, MD; Yang, RS, 1987
)
0.27
" The NaF-PGI2 dose-response curve was moved to the left by the presence of adrenaline, phorbol 12,13-dibutyrate (PDBU) and the Ca2+ ionophore A23187 in the incubation media."( Fluoride stimulates in vitro vascular prostacyclin synthesis: interrelationship of G proteins and protein kinase C.
Dandona, P; Jeremy, JY, 1988
)
0.27
"Rate of passage from the rumen was estimated from samples from the rumen, duodenum, ileum, and rectum after four crossbred heifers were dosed with cobalt ethylenediaminetetraacetic acid and ytterbium-labeled alfalfa or corn grain as digesta markers."( Effects of sampling site on passage rate estimates in heifers fed alfalfa hay or a high concentrate diet.
Goetsch, AL; Owens, FN, 1985
)
0.27
" These responses allowed the construction of dose-response curves."( Effects of chlorpromazine and the antidepressant drugs amitriptyline, clomipramine and mianserin on the Ca-depleted rat uterus.
Anselmi, E; Sevilla, E; Villar, A, 1985
)
0.27
" Results are presented for several sets of experiments, including dose-response data for weakly chelated Mn2+ and time-response data for free and complexed Mn2+."( Magnetic field dependence of proton relaxation rates in tissue with added Mn2+: rabbit liver and kidney.
Brown, RD; Burnett, KR; Goldstein, EJ; Koenig, SH; Wolf, GL, 1985
)
0.27
" In somatic monkey-mouse hybrid cells, however, a significant decrease in the slope of the curve for primate interferon was observed, while the dose-response effect was unaltered for mouse interferon."( Mechanism of interferon uptake in parental and somatic monkey-mouse hybrid cells.
Besançon, F; Brown, P; Cassingena, R; Chany, C; Grégoire, A; Lemaitre-Moncuit, J; Suarez, H; Vignal, M, 1973
)
0.25
" The repair capacity of the kidney was assessed by comparing isoeffective doses from the dose-response curves."( Radiation induced renal damage in mice: influence of fraction size.
Denekamp, J; Williams, MV, 1984
)
0.27
" In the multiple-dose experiments, the sheep dosed with zinc sulphate showed progressively higher elevations of serum zinc (first dose, 5-10 micrograms Zn ml-1; day 13, 30-60 micrograms Zn ml-1) and six of the seven sheep so dosed died before the final dose."( The influence of chemical form of zinc on the effects of toxic intraruminal doses of zinc to sheep.
Embling, PP; Smith, BL, 1984
)
0.27
" (Leguminosae), was rapidly hydrolyzed to 3-nitropropanol (NPOH) in the rumen of cattle dosed with timber milkvetch (A."( Absorption of 3-nitropropanol (miserotoxin aglycone) from the compound stomach of cattle.
Majak, W; Muir, AD; Pass, MA; Rode, LM, 1984
)
0.27
" Thyrotrophin-releasing hormone stimulated prolactin secretion, but its dose-response slope and chromatographic mobility were quite different from those for bovine tissue extracts."( Heterogeneity of activity of the prolactin-releasing factor in the bovine hypothalamo-neurohypophysial complex.
Greer, SE; Yasuda, N; Yasuda, Y, 1984
)
0.27
" Two functional assays (urine output and 51Cr-EDTA excretion), and renal weight at sacrifice were used to obtain dose-response curves and estimate isoeffective doses."( Radiation induced renal damage in mice: influence of overall treatment time.
Denekamp, J; Williams, MV, 1984
)
0.27
" These signs were reversed with cessation of lead dosing and CaEDTA treatment."( Effect of chronic lead on the haematology, blood glutathione and bone marrow non-haeme iron of dogs.
Mitema, ES; Oehme, FW; Penumarthy, L, 1980
)
0.26
" After a 7-day stabilizaion period, lead dosing was conducted for 91 days (13 weeks), after which half of each group was treated with calcium ethylenediaminetetraacetic acid."( Effect of chronic lead exposure on the canine bone marrow.
Mitema, ES; Moore, WE; Oehme, FW; Penumarthy, L, 1980
)
0.26
" A single small dosage of calcium disodium edetate (150 mg dissolved in 75 ml 1:5 normal saline) was effective in normalizing the serum zinc level."( Acute zinc chloride ingestion in a young child.
Potter, JL, 1981
)
0.26
" CaNa2EDTA induced dose related recovery in ALA-D in 30 mg/kg group, and reduction of blood Pb levels in the group dosed with 150 mg/kg of lead acetate."( Acute lead poisoning of the pigeon induced by single, intraperitoneal administration of lead acetate.
Minowa, K; Mizoguchi, I; Ohi, G; Seki, H; Sugimori, F, 1980
)
0.26
" These findings suggest that the amount of protoporphyrin IX accumulation from ALA reflects the extent of deficiency of ferrochelatase and is proportional to the dosage of abnormal EPP gene in cultured fibroblasts."( Accumulation of protoporphyrin IX from delta-aminolevulinic acid in bovine skin fibroblasts with hereditary erythropoietic protoporphyria. A gene-dosage effect.
Ruth, G; Sassa, S; Schwartz, S, 1981
)
0.26
" The conventional low dosage nitrite/thiosulfate (6."( Cyanide intoxication in sheep; therapeutics.
Burrows, GE, 1981
)
0.26
" Radiation-induced loss of copper and zinc initially exhibits a linear dose-response relationship and is less severe than the drop in enzyme activity."( Concentration-dependent inactivation of superoxide dismutase.
Chelack, WS; Petkau, A, 1981
)
0.26
" Time- and dose-response relationships for neutrophil bipolar shape formation (BSF) agree with data reported for other neutrophil response measurements."( Neutrophil bipolar shape formation in whole blood. A simple and rapid method for the assessment of neutrophil leukocyte responsiveness.
Jadwin, DF; Meadows, TR; Smith, CW, 1981
)
0.26
" However, the diagnostic importance of its dosage on selective venous samples is still discussed."( PTH radioimmunoassay and loading tests in the diagnosis of patients with primary hyperparathyroidism.
Belgrano, E; Carmignani, G; Giordano, G; Giuliani, L; Giusti, M; Puppo, P; Repetto, U, 1982
)
0.26
" The sheep were then divided into three equal groups and duodenally dosed with a mixture containing MnSO4, ZnSO4, 54Mn, 65Zn, and water (control), thiosalicylic acid (TSA), or hydroxyethylethylenediaminetriacetic acid (HEDTA)."( The effects of thiosalicylic and hydroxyethylethylenediaminetriacetic acids on the absorption and excretion of 54Mn and 65Zn in the duodenally dosed sheep.
Hidiroglou, M; Ivan, M; Veira, DM, 1982
)
0.26
" NSAID dose-response curves produced using the two indices of damage showed that intestinal permeability is as sensitive and reproducible as ulceration, although changes could not be detected before visible ulceration occurred."( Assessment of intestinal permeability changes induced by nonsteroidal anti-inflammatory drugs in the rat.
Ford, J; Houston, JB; Martin, SW, 1995
)
0.29
" The dose-response curves for renal damage (using the [51Cr]EDTA end-point) were steep, and tended to shift towards lower doses with longer follow-up times."( Late renal damage after total body irradiation and bone marrow transplantation in a mouse model: effect of radiation fractionation.
el-Badawy, S; Nielsen, OS; Overgaard, J; Safwat, A, 1995
)
0.29
" An earlier dose of EDTA also modified the relation between ALAU and DMSA-chelatable lead in that workers who received EDTA before DMSA showed a much steeper dose-response relation between these two measures."( Provocative chelation with DMSA and EDTA: evidence for differential access to lead storage sites.
Ahn, KD; Lee, BK; Schwartz, BS; Stewart, W, 1995
)
0.29
" In Trial 1, 67% of the sheep treated with Cu EDTA at 2 mg Cu/kg live body mass died within 3 to 17 d after treatment, while no mortalities occurred in sheep where Cu heptonate was administered at the same dosage rate and even at 3 mg Cu/kg live body mass (P < or = 0,01)."( An assessment of the toxicity of parenteral treatment with copper EDTA and copper heptonate in sheep.
Cloete, SW; Coetzer, WA; Du Plessis, SS; Smith, WA; Van Niekerk, FE; Wellington, AC, 1994
)
0.29
" We dosed Sprague-Dawley rats with NSAIDs and corticosterone followed by 51Cr-EDTA under conditions reported for humans and measured urinary excretion of the marker."( Antiinflammatory drug-induced small intestinal permeability: the rat is a suitable model.
Davies, NM; Jamali, F; Wright, MR, 1994
)
0.29
"OH dosage and ventricular dysfunction, increase in coronary flow, structural damage, decrease in ATP and increase in lipid peroxidation."( Characterization of exogenous hydroxyl radical effects on myocardial function, metabolism and ultrastructure.
Ashraf, M; Onodera, T; Takemura, G, 1994
)
0.29
"GFR-based carboplatin dosing in children should be feasible and will be evaluated prospectively."( Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
Balmanno, K; Calvert, AH; Keir, M; Lewis, IJ; Newell, DR; Pearson, AD; Pinkerton, CR; Price, L; Stevens, MC; Wyllie, RA, 1993
)
0.29
" Estimates of reagent concentrations in brain interstitial fluid 30 min after dosing the animals indicated that both an extremely high dose of DyTTHA3- and severe disruption of the BBB would be required to shift the resonance frequency of extracellular Na+ appreciably."( Diffusion into rat brain of contrast and shift reagents for magnetic resonance imaging and spectroscopy.
Foster, DO; Preston, E,
)
0.13
" The method was also tested on milk from cows dosed with each of the tetracyclines."( Simultaneous determination of multiple tetracycline residues in milk using metal chelate affinity chromatography.
Carson, MC,
)
0.13
" Skeletal malformations, identical to those seen in the previous study, were increased in a dose-dependent manner with the highest incidence occurring in fetuses from females dosed from days 15-17 of gestation."( Developmental toxicity of mangafodipir trisodium and manganese chloride in Sprague-Dawley rats.
Blazak, WF; Gray, TJ; Treinen, KA, 1995
)
0.29
"5 mg/ml) and citrate mixture (100 microliters/ml), heparin dose-response, IL8 (human recombinant IL8) dose-response and protamine (80 micrograms/ml) neutralisation of heparin (4 U/ml) using donor blood (total of 38)."( Effect of heparin anticoagulation on neutrophil adhesion molecules and release of IL8: C3 is not essential.
El Habbal, MH; Elliott, MJ; Smith, L; Strobel, S, 1995
)
0.29
" Increasing heparin dosage reduces neutrophil activation and may reduce the morbidity of patients."( Effect of heparin anticoagulation on neutrophil adhesion molecules and release of IL8: C3 is not essential.
El Habbal, MH; Elliott, MJ; Smith, L; Strobel, S, 1995
)
0.29
"9 years) taking either amitriptyline or clomipramine in a daily dosage varying from 50 to 250 mg entered the study after giving informed consent."( Influence of heparin on the assay of amitriptyline, clomipramine, and their metabolites.
Levering, SC; Loonen, AJ; Oostelbos, MC; Toll, PJ, 1996
)
0.29
" Rats were dosed concomitantly with indomethacin (40 mg/kg, subcutaneously) and an amino or pyridinyl bisphosphonate (orally at."( Nonclinical model for assessing gastric effects of bisphosphonates.
Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN, 1997
)
0.3
" No sex differences in metabolic pattern were observed in any of the three dosage groups."( Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs.
Friisk, GA; Grant, D; Hustvedt, SO; Skotland, T; Toft, KG,
)
0.13
"In rat liver and pig organs both compounds produced a positive dose-response in R1 and tissue Mn concentration, and only small or no response in R2."( NMR relaxation studies with MnDPDP.
Bjørnerud, A; Grant, D; Martinsen, I; Moen, OM; Refsum, H; Southon, TE; Spilling, B, 1997
)
0.3
" Male Sprague-Dawley rats were dosed with two doses of metronidazole (50 mg/kg, 12 and 1 h pre-NSAID) or a single 100 mg/kg dose of tempo 1 h prior to NSAIDs."( Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers.
Davies, NM; Jamali, F, 1997
)
0.3
"65 mM EDTA, 30 mM H2O2), deduced from dose-response plots of FeCl2 on minimum surface tension (MST) of SUR, were used to assess the Fenton effect on biophysical properties of various surfactants."( Inhibitory effects of oxyradicals on surfactant function: utilizing in vitro Fenton reaction.
Amirkhanian, JD; Merritt, TA, 1998
)
0.3
" CGP 75254A was dosed to the apical side of Caco-2 cell monolayers, together with [14C]mannitol as an internal permeability standard."( Caco-2 cell permeability of a new (hydroxybenzyl)ethylenediamine oral iron chelator: correlation with physicochemical properties and oral activity.
Donnelly, H; Faller, B; Fox, R; Lowther, N; Sergejew, T; Tomlinson, B, 1998
)
0.3
" The purpose of this study was to determine the dose-response effects of G-D, N9, EDTA and G-D + EDTA on sperm motion parameters and acrosome status."( Dose-response effects of gramicidin-D, EDTA, and nonoxynol-9 on sperm motion parameters and acrosome status.
Centola, GM, 1998
)
0.3
" This study utilized computer-assisted methods to investigate the dose-response effects of incubation with G-D, N-9, EDTA, and G-D plus EDTA on sperm motion parameters and acrosome status."( Dose-response effects of gramicidin-D, EDTA, and nonoxynol-9 on sperm motion parameters and acrosome status.
Centola, GM, 1998
)
0.3
" The proposed method was applied for the determination of EDTA in certain pharmaceutical dosage forms, and the results obtained were in agreement with those obtained by a reference method."( Polarographic determination of EDTA in certain pharmaceutical dosage forms.
Aly, FA; Belal, F; Mesbah, AO; Walash, MI, 1998
)
0.3
" The protective effect of this dosage form for the incorporated model drug was evaluated in vitro."( Development and in vitro evaluation of a drug delivery system based on chitosan-EDTA BBI conjugate.
Bernkop-Schnürch, A; Krauland, A; Valenta, C, 1998
)
0.3
" The results have assisted in a targeted preformulation screen of potentially stabilising excipients and possible parenteral solution dosage forms have been identified."( Hybrid (BDBB) interferon-alpha: preformulation studies.
Allen, JD; Bentley, D; Lowther, N; Stringer, RA, 1999
)
0.3
"The frequent use of platinum (Pt) complexes in cancer chemotherapy and the application of new therapeutic options and dosing strategies have increased the need for rapid analytic procedures to determine Pt concentrations in the biologic fluids of patients."( Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay.
Appelius, H; Jaehde, U; Kloft, C; Schunack, W; Siegert, W, 1999
)
0.3
" The formulae developed here can be used to provide reliable estimates of GFR, particularly in regard to targeted dosing of carboplatin."( Estimation of glomerular filtration rate in cancer patients.
Boddy, AV; Calvert, AH; Fenwick, J; Highley, M; McGill, A; Wright, JG, 2001
)
0.31
"The depth of sedation, as measured by the Modified Ramsay Sedation Scale, was similar in the 2 groups, when adjusted for dosing differences."( Cation metabolism during propofol sedation with and without EDTA in patients with impaired renal function.
Bandi, V; Barr, J; Haupt, MT; Murray, MJ; Teres, D; Weinmann, M; Zaloga, GP, 2000
)
0.31
" At the same time, a number of nonmetallic ligands moderately accelerate the reaction of MT with Nbs2 and hyperbolic dose-response curves were obtained."( The effects of physiologically important nonmetallic ligands in the reactivity of metallothionein towards 5,5'-dithiobis(2-nitrobenzoic acid). A new method for the determination of ligand interactions with metallothionein.
Kangur, L; Palumaa, P, 2001
)
0.31
" Dose-response curves for glutamate show that zinc reduced the maximal current evoked by glutamate and increased EC(50) from 50 +/- 3 to 70 +/- 6 microM without changing the Hill coefficient."( Suppression by zinc of AMPA receptor-mediated synaptic transmission in the retina.
Mangel, SC; McMahon, DG; Ribelayga, C; Zhang, DQ, 2002
)
0.31
" Exposure to EDTA in most cosmetic formulations, therefore, would produce systemic exposure levels well below those seen to be toxic in oral dosing studies."( Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA.
Lanigan, RS; Yamarik, TA, 2002
)
0.31
"coli was induced at a low dosage of IPTG (0."( Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease.
Du, GX; Guan, RB; Hou, LH; Tong, YG; Wang, HT, 2002
)
0.31
" Calves in groups 2 to 5 were dosed daily with lead (5 mg/kg, PO) for 10 days."( Effects of calcium disodium EDTA and meso-2,3-dimercaptosuccinic acid on tissue concentrations of lead for use in treatment of calves with experimentally induced lead toxicosis.
Ko, KW; Meldrum, JB, 2003
)
0.32
" Moreover, for large-scale applications, agricultural measures as placement of agents, dosage splitting, the kind and amount of agents applied, and the soil properties are important factors governing plant growth, heavy metal concentrations, and leaching rates."( Enhancing phytoextraction: the effect of chemical soil manipulation on mobility, plant accumulation, and leaching of heavy metals.
Schmidt, U,
)
0.13
" There were only small differences in myocardial R1 responses between the three doses investigated, which was contrasted by a marked dose-response in liver tissue."( Relaxation enhancing properties of MnDPDP in human myocardium.
Haraldseth, O; Jynge, P; Kristoffersen, A; Larsson, HB; Skjold, A; Vangberg, TR, 2004
)
0.32
" The hypoglycemic effect the insulin-liposomes double-coated by CH and CEC was superior to that of other insulin-liposomes, and the dosage of 50 mu x kg(-1) decreased by 45."( [Studies on the insulin-liposomes double-coated by chitosan and chitosan-EDTA conjugates].
Cai, P; Lei, XM; Li, JY; Ping, QN; Song, YM; Wu, ZH, 2004
)
0.32
" Effect of dosage of hydrogen peroxide and acidity of reaction matrices on oxidation efficiencies were investigated."( Destruction of organic pollutants in reusable wastewater using advanced oxidation technology.
Chia, LS; Goh, NK; Teo, KC; Xie, RJ; Xu, YR; Yang, C, 2005
)
0.33
"To study the effect of the liposomes coated by chitosan and its derivatives as oral dosage form for peptide drugs on the gastrointestinal (GI) transit of drugs."( [Effects of the liposomes coated by chitosan and its derivatives on the gastrointestinal transit of insulin].
Cai, P; Lei, XM; Li, JY; Ping, QN; Wu, ZH, 2005
)
0.33
"The therapeutic success of L-3,4-dihydroxyphenylalanine (L-DOPA) treatment in Parkinson's disease (PD) patients remains controversial as many patients become tolerant requiring higher dosage regimens."( l-DOPA administration enhances 6-hydroxydopamine generation.
Daya, S; Maharaj, H; Mokokong, R; Scheepers, M; Sukhdev Maharaj, D, 2005
)
0.33
" The results demonstrated that the optimum dosage of EDTA for remediating heavy metals in rubbish compost by turfgrass was between 10 mmol/kg and 20 mmol/kg."( Heavy metal accumulation of urban domestic rubbish compost in turfgrass by EDTA chelating.
Duo, LA; Gao, YB; Zhao, SL, 2005
)
0.33
" The purified protein showed a strong insecticidal effect with a median lethal dosage of 12."( Purification and properties of a novel insecticidal protein from the locust pathogen Serratia marcescens HR-3.
Liu, K; Liu, S; Long, Z; Tao, K; Tao, Y, 2006
)
0.33
" Sulfide, either dosed externally or formed during the batch incubation out of endogenous sulfur sources or the supplied sulfate or sulfite, influences the production and consumption of the intermediate nitrous oxide (N2O) during Fe(II)EDTA2- bound NO reduction."( Effect of sulfur compounds on biological reduction of nitric oxide in aqueous Fe(II)EDTA2- solutions.
Lens, PN; Manconi, I; van der Maas, P, 2006
)
0.33
" Further studies regarding the mechanisms of EDTA and its interactions with ABLC are warranted, and further studies are needed to more fully examine the safety, tolerance, and optimal dosing of EDTA in the treatment of this and other fungal infections."( EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model.
Bahna, P; Hachem, R; Hanna, H; Raad, I; Stephens, LC, 2006
)
0.33
" The findings also suggest a gene dosing effect of CuZnSOD for increases in O2-, induction of cerebral vascular hypertrophy and impaired endothelium-dependent dilatation."( Hypertrophy of cerebral arterioles in mice deficient in expression of the gene for CuZn superoxide dismutase.
Baumbach, GL; Didion, SP; Faraci, FM, 2006
)
0.33
" N(2)O was dosed either directly as a gas to the headspace of the bottles or formed as intermediate during the denitrification of nitrite in Fe(II)EDTA(2-)-containing medium and nitrate in Fe(II)EDTA(2-)-free medium."( Effect of copper dosing on sulfide inhibited reduction of nitric and nitrous oxide.
Lens, P; Manconi, I; van der Maas, P, 2006
)
0.33
" The percentage of removed Zn did not exceed 75% regardless of the soil, EDTA dosage and leaching steps."( Multi-step leaching of Pb and Zn contaminated soils with EDTA.
Finzgar, N; Lestan, D, 2007
)
0.34
" In this work, the released titrant's activity was measured with a second ionophore-based ion-selective electrode and corresponded well with expected dosage levels on the basis of Faraday's law of electrolysis."( Selective coulometric release of ions from ion selective polymeric membranes for calibration-free titrations.
Bakker, E; Bhakthavatsalam, V; Shvarev, A, 2006
)
0.33
" In vivo studies in rats compared pharmacokinetic (PK) profiles of different formulations dosed intranasally."( In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.
Brandt, GC; Costantino, HR; Foerder, CA; Leonard, AK; Quay, SC; Sileno, AP, 2007
)
0.34
" Influence of varying the conditions for removal of chromium(VI), such as the pH of aqueous solution, the dosage of biosorbent, the contact time with the biosorbent, the temperature for the removal of chromium, the effect of light metal ions and the adsorption-desorption studies were investigated."( Sorption and desorption studies of chromium(VI) from nonviable cyanobacterium Nostoc muscorum biomass.
Gupta, VK; Rastogi, A, 2008
)
0.35
"CsA measurements are routinely used to allow adequate CsA dosage adjustments."( Heparinized blood provides equivalent results to EDTA in the CEDIA and FPIA cyclosporine immunoassays, thus facilitating routine cyclosporine determination.
Aldebert, E; Engler, H; Korte, WC; Riesen, WF, 2008
)
0.35
"Recent research has shown that chelant-assisted phytoextraction approaches often require a high dosage of chelant applied to soil."( Heating treatment schemes for enhancing chelant-assisted phytoextraction of heavy metals from contaminated soils.
Chen, Y; Li, X; Luo, C; Mao, Y; Shen, Z; Wang, C; Wang, G, 2008
)
0.35
" The analytical results demonstrate that the proper conditions for Fenton process were pH = 2, [Fe(2+)] = 10(-2) M, H(2)O(2) dosing rate = 5 x 10(-4) mol min(-1), reaction time = 12 min."( Assessing the performance of wastewater treatment with the combination of Fenton and ferrite process.
Huang, YJ; Lou, JC, 2009
)
0.35
" With the same total dosage of applied H2O2, the multiple steps addition did not show a much higher removal efficiency than that obtained by one step."( [Degradation of malachite green in aqueous solution by Fe3+/H2O2 catalyzed with EDTA].
Li, CJ; Ma, J; Yu, M; Zhang, YJ, 2008
)
0.35
"33 mg EDTA/g ZVI at pH 2, ZVI dosage of 424 g/L and HRT 10 min."( Removal of EDTA from low pH printed-circuit board wastewater in a fluidized zero valent iron reactor.
Chen, SS; Chin, PY; Hsu, HD; Lin, YJ, 2008
)
0.35
"Renal function-based carboplatin dosing is used routinely in paediatric oncology clinical practice."( Estimation of renal function and its potential impact on carboplatin dosing in children with cancer.
Boddy, AV; Chinnaswamy, G; Cole, M; English, M; Keir, M; Parry, A; Price, L; Veal, GJ, 2008
)
0.35
" Higher persulfate dosage under the EDTA/Fe(3+) molar ratio of 1/1 resulted in greater TCE degradation rates."( pH dependence of persulfate activation by EDTA/Fe(III) for degradation of trichloroethylene.
Chen, CC; Liang, C; Liang, CP, 2009
)
0.35
"In light-adapted rats, intraretinal enhancements responded in a dose-response manner."( Toward clinical application of manganese-enhanced MRI of retinal function.
Berkowitz, BA; Jin, Y; Porchia, A; Roberts, R; Tofts, PS, 2010
)
0.36
" The effect became less potent with time despite continuous dosing indicating adaptation for both topical and systemic effects."( Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety.
Campanella, C; Jamali, F, 2009
)
0.35
" The repeated dosing rather than the magnitude of t(1/2) may influence the gut safety profile of NSAIDs."( Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety.
Campanella, C; Jamali, F, 2009
)
0.35
"A highly sensitive and selective spectrofluorimetric method was developed for the determination of ciclopirox olamine in raw material and in dosage forms."( Spectrofluorimetric determination of ciclopirox olamine via ternary complex with Tb(III) and EDTA.
Eid, MI; Fathy, Mel S; Rizk, MS; Walash, MI, 2006
)
0.33
"Our data showed that BNP could not be dosed on different collection tubes without altering the results."( Measurement of Type B natriuretic peptide in heparin and K(2) EDTA plasma.
Cemin, R; Daves, M; Pusceddu, I, 2010
)
0.36
" Stratification shifted the dose-response curve to the right for benzalkonium chloride, thimerosal, chlorhexidine digluconate, potassium sorbate and EDTA."( Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells.
Evans, MG; Jessen, BA; Khoh-Reiter, S; Yanochko, GM, 2010
)
0.36
" Growth curves supported the dose-response observations."( Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
Burden, AD; Edward, M; Jardine, AG; Newton, BB; Quinn, JA, 2010
)
0.36
" Therefore monitoring plasma concentration of ribavirin is a useful tool for individualizing ribavirin dosing regimens."( Influence of pre-analytical conditions on plasma ribavirin concentrations.
Alric, L; Barange, K; Gandia, P; Houin, G; Izopet, J; Lavit, M; Nicot, F; Séraissol, P; Trancart, S, 2010
)
0.36
" These results provide a precise mechanism of the interaction TJ-34 and TC, suggesting a safe and effective dosage regimen to coadminister TJ-34 and TC in clinical use."( Mechanism of drug interaction between a Kampo medicine, byakkokaninjinto, and tetracycline in rats.
Hasegawa, T; Hitoshi, K; Hotta, K; Katoh, M; Kurono, S; Nadai, M; Saito, H; Tanaka, Y, 2012
)
0.38
" The objective is to calculate the dosage of NaFeEDTA for fortifying complementary foods assuming different population prevalences of underweight."( Fortifying complementary foods with NaFeEDTA--considerations for developing countries.
Schofield, D; Siekmann, J; Yang, Z, 2011
)
0.37
"In any context of iron supplementation in the prenatal prophylaxis or therapeutic dosage range, a large amount will remain unabsorbed and pass through the intestinal tract into the colonic digesta possibly causing increased oxidation."( Equivalent effects on fecal reactive oxygen species generation with oral supplementation of three iron compounds: ferrous sulfate, sodium iron EDTA and iron polymaltose.
Arriaga, C; Orozco, MN; Schümann, K; Solomons, NW, 2012
)
0.38
" This method is now applied for the determination of both compounds in specific patient populations to evaluate current dosing guidelines."( Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Beijnen, JH; Huitema, AD; Kromdijk, W; Rosing, H; van den Broek, MP, 2012
)
0.38
" This information will help to guide dosing regimens for in vivo topical cross-linking studies."( Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: corneal permeability considerations.
Kim, M; Paik, DC; Trokel, SL; Wen, Q, 2013
)
0.39
"Oral iron supplementation with ferrous sulfate (FeSO₄) at dosage levels suggested by the international guidelines poses a safety hazard to young children with malaria."( Oral administration of ferrous sulfate, but not of iron polymaltose or sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), results in a substantial increase of non-transferrin-bound iron in healthy iron-adequate men.
Marx, J; Orozco, M; Romero-Abal, ME; Schümann, K; Solomons, NW; Weiss, G, 2012
)
0.38
"To increase knowledge about lung tumor tissue levels of erlotinib and its primary active metabolite, and about erlotinib plasma levels in intercalated dosing schedules, a sensitive and accurate method for determination of erlotinib and O-desmethyl erlotinib (OSI-420) in human plasma and lung tumor tissue has been developed."( Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
Beijnen, JH; Burgers, JA; Huitema, AD; Lankheet, NA; Rosing, H; Schaake, EE; Schellens, JH, 2012
)
0.38
" Male and female rats dosed at 536."( Rat pancreatitis produced by 13-week administration of zinc oxide nanoparticles: biopersistence of nanoparticles and possible solutions.
Che, JH; Cho, WS; Cho, Y; Jang, A; Jeong, J; Kang, BC; Kim, H; Kim, T; Ko, S; Lee, JK; Na, Y; Park, JS; Seok, SH; You, JR, 2013
)
0.39
"Wheat flour and maize meal were sourced in Kenya, South Africa, and Tanzania, and the iron compound (sodium iron ethylenediaminetetraacetate [NaFeEDTA], ferrous fumarate, or ferrous sulfate) was varied and dosed at rates according to the WHO guidelines for consumption of 75 to 149 g/day of wheat flour and > 300 g/day of maize meal and tested again for 150 to 300 g/day for both."( Fortification of wheat flour and maize meal with different iron compounds: results of a series of baking trials.
Johnson, Q; Randall, P; Verster, A, 2012
)
0.38
"Single cycle carboplatin, dosed by glomerular filtration rate (GFR), is standard adjuvant therapy for stage 1 seminoma."( Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
Forte, C; Gillen, G; Macpherson, IR; Mark, PB; Morrison, P; Shepherd, ST; White, JD, 2014
)
0.4
"Our data support further evaluation of the CKD-EPI formula in this patient population but clinically significant variances in carboplatin dosing occur using non-isotopic methods of GFR estimation."( Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
Forte, C; Gillen, G; Macpherson, IR; Mark, PB; Morrison, P; Shepherd, ST; White, JD, 2014
)
0.4
" The maximum recommended dosage of this drug is 37 times higher than the maximum ADI of EDTA."( Reasons for raising the maximum acceptable daily intake of EDTA and the benefits for iron fortification of foods for children 6-24 months of age.
Wreesmann, CT, 2014
)
0.4
" Reactors were dosed with hydrogen peroxide (HP), and treatment was compared in reactors with SOM as the only chelate vs."( Modified Fenton oxidation of diesel fuel in arctic soils rich in organic matter and iron.
Cassidy, DP; Sherwood, MK, 2014
)
0.4
"Given that drug dosing schedules utilise eGFR values as the basis for modifying drug dosing, our results would suggest that a recommendation of a dose reduction according to eGFR alone should be treated with caution."( GFR may not accurately predict aspects of proximal tubule drug handling.
Duffull, SB; Putt, TL; Schollum, JB; Walker, RJ, 2014
)
0.4
" The results suggest that mats have the potential to be mucoadhesive dosage forms to maintain oral hygiene by reducing the bacterial growth that causes the dental caries."( Mucoadhesive electrospun chitosan-based nanofibre mats for dental caries prevention.
Kaomongkolgit, R; Ngawhirunpat, T; Opanasopit, P; Rojanarata, T; Samprasit, W; Sukma, M, 2015
)
0.42
"The radiolabeling of EDTA-MN with (99m)Tc was performed with direct labeling method, respectively, on the reaction dosage (10 mg, 5 mg, 2 mg), stannous chloride dosage (8 mg/mL, 4 mg/mL, 2 mg/mL), mark system pH (2, 4, 5, 6) one by one test, using orthogonal design analysis, to find the optimal labeling conditions."( [Preparation of (99m)Tc-EDTA-MN and Its Bioimaging in Mouse].
Chi, X; Du, L; Huang, B; Huang, K; Li, G; Qi, Y; Zhang, H, 2015
)
0.42
"As a part of the Japanese Center for the Validation of Alternative Methods (JaCVAM)-initiative international validation study of the in vivo alkaline comet assay (comet assay), we examined DNA damage in the liver, stomach, and bone marrow of rats dosed orally three times with up to 2000 mg/kg of benzene, di(2-ethylhexyl) phthalate, and trisodium ethylenediamine tetraacetic acid monohydrate."( Genotoxicity evaluation of benzene, di(2-ethylhexyl) phthalate, and trisodium ethylenediamine tetraacetic acid monohydrate using a combined rat comet/micronucleus assays.
Funabashi, H; Kimura, J; Kitamoto, S; Matsuyama, R; Miyata, K; Ogata, K; Ota, M; Saito, K; Uematsu, Y; Yamada, T, 2015
)
0.42
" Dose-response curves were plotted, and 50% inhibitory doses (IC50 ) were subjected to statistical analysis (anova and post hoc comparison test; P < 0."( Combined and independent cytotoxicity of sodium hypochlorite, ethylenediaminetetraacetic acid and chlorhexidine.
Economides, N; Koulaouzidou, E; Vouzara, T; Ziouti, F, 2016
)
0.43
"15mm) was applied on a kaolin with three different lead (Pb(2+)) contamination levels (50mg/kg, 300mg/kg and 1000mg/kg) at the dosage of 1% in w/w."( Salisbury biochar did not affect the mobility or speciation of lead in kaolin in a short-term laboratory study.
Al-Tabbaa, A; Jin, F; McMillan, O; Shen, Z, 2016
)
0.43
" With the optimized conditions of a pH range of 3-9, dosage ratio of BDE/Cu of 1:1, PAM dosage of 1 mg/L, and reaction time of 4 min, the removal efficiency of Cu(2+) was more than 98 % from simulated wastewater containing EDTA-Cu with initial concentrations of 5-100 mg/L."( Disodium N,N-bis-(dithiocarboxy)ethanediamine: synthesis, performance, and mechanism of action toward trace ethylenediaminetetraacetic acid copper (II).
Dai, Y; Han, D; Qiu, Y; Ren, J; Sun, S; Xiao, X; Yan, P; Ye, M, 2016
)
0.43
" Information regarding demographic, clinical and microbiological parameters, dosage and treatment duration, efficacy and adverse events (AEs) associated with the treatment were recorded."( Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Ayub, SG; Chaudhary, M; Mir, MA,
)
0.13
", 50% reduction in the dosage of EDTA was made possible."( Combined application of EDDS and EDTA for removal of potentially toxic elements under multiple soil washing schemes.
Baek, K; Beiyuan, J; Bolan, NS; Li, XD; Ok, YS; Rinklebe, J; Tsang, DCW; Valix, M; Zhang, W, 2018
)
0.48
" A total of 24 patients will be assigned into one of three dosing cohorts of eight patients (n = 6 for PP100-01 and NAC; n = 2 for NAC alone)."( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi
Dear, J, 2019
)
0.51
" The preliminary, dynamic, equilibrium activation experiments and speciation analysis of Pb, Cd and Tl in contaminated red soils were used to select six chelates with relatively good activation performance from nine chelates, and the effects of dosage and pH on the heavy metals activation were studied systematically."( Comparative Activation Process of Pb, Cd and Tl Using Chelating Agents from Contaminated Red Soils.
Huang, X; Liu, G; Liu, L; Liu, Y; Luo, D; Mai, X; Wei, L; Wu, Q; Xiao, T; Yao, G, 2020
)
0.56
" The CHA2DS2-VASc score-based decisions were more common among cardiologists, with substantial intra- and inter-specialty heterogeneity in the use and dosing of specific OAC drugs across CKD stages, heterogeneous strategies for OAC monitoring (especially among nephrologists) and a modest impact of CKD on rate and rhythm control treatment decisions."( Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based su
Dagres, N; Dan, GA; Ekart, R; Ferro, C; Lenarczyk, R; Lip, GYH; Mallamaci, F; Ortiz, A; Potpara, TS; Sarafidis, P, 2020
)
0.56
" Ruminal solid digesta samples from times 0, 12, and 24 h after bolus dosing were exposed to dialysis against Tris-EDTA."( Trace mineral source influences digestion, ruminal fermentation, and ruminal copper, zinc, and manganese distribution in steers fed a diet suitable for lactating dairy cows.
Brandao, VLN; Engle, TE; Guimaraes, O; Spears, JW; Wagner, JJ, 2022
)
0.72
" Leaching results showed that in general, MGDA exhibited higher Zn leaching efficiency and similar Cu, Ni and Cr leaching efficiencies with EDTA at same pH and dosage conditions."( Removal of heavy metals from sewage sludge by chemical leaching with biodegradable chelator methyl glycine diacetic acid.
Hu, J; Li, S; Liang, C; Lv, Q; Zhao, J; Zheng, X, 2022
)
0.72
" By introducing a low dosage of Fe(III), the DDTC could efficiently purify Cu(II) from the Cu(II)-EDTA acid wastewater and realize the near-zero discharge of metal pollutants in metal-organic complex wastewater."( Deep purification of copper from Cu(II)-EDTA acidic wastewater by Fe(III) replacement/diethyldithiocarbamate precipitation.
Han, M; He, J; Li, S; Sun, W; Wei, X; Yue, T; Zhang, C; Zhang, H, 2022
)
0.72
"After once-weekly pegademase dosage was adjusted to achieve therapeutic metabolic detoxification and trough ADA activity, patients transitioned to a bioequivalent dose of elapegademase."( PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID.
Dorsey, MJ; Fausnight, T; Haddad, E; Lehman, H; Rubinstein, A; Wiley, JM, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (110 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care92
Household Essentials10
Baby & Kids Products8

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Aloe Life Face and Body Lotion -- 16 ozAloe LifeBeauty & Personal Carecarbomer, panthenol, diazolidinyl urea, disodium EDTA, glyceryl stearate, phenoxyethanol, vitamin A, stearic acid2024-11-29 10:47:42
Australian Gold Botanical Sunscreen Mineral Lotion Non-Greasy - SPF 30 -- 5 fl ozAustralian GoldBeauty & Personal Carecaprylyl glycol, cyclopentasiloxane, panthenol, disodium edta, glycerin, phenoxyethanol, squalane, stearic acid2024-11-29 10:47:42
Australian Gold Botanical Sunscreen Mineral Lotion Non-Greasy - SPF 50 -- 5 fl ozAustralian GoldBeauty & Personal Carecaprylyl glycol, cyclopentasiloxane, panthenol, disodium edta, glycerin, phenoxyethanol, squalane, stearic acid2024-11-29 10:47:42
Australian Gold Botanical Tinted Face Sunscreen Lotion - Fair to Light SPF 50 -- 3 fl ozAustralian GoldBeauty & Personal Carecaprylyl glycol, panthenol, disodium EDTA, glycerin, triethoxycaprylylsilane, phenoxyethanol, squalane, stearic acid2024-11-29 10:47:42
Australian Gold Botanical Tinted Face Sunscreen Lotion - Medium to Tan SPF 50 -- 3 fl ozAustralian GoldBeauty & Personal Carecaprylyl glycol, panthenol, disodium EDTA, glycerin, triethoxycaprylylsilane, phenoxyethanol, squalane, stearic acid2024-11-29 10:47:42
Australian Gold Botanical Tinted Face Sunscreen Lotion - Rich to Deep SPF 50 -- 3 fl ozAustralian GoldBeauty & Personal Carecaprylyl glycol, panthenol, disodium EDTA, glycerin, triethoxycaprylylsilane, phenoxyethanol, squalane, stearic acid2024-11-29 10:47:42
Australian Gold Liquid Hand Soap Aloe Vera -- 11.5 fl ozAustralian GoldHousehold Essentialscitric acid, methylchloroisothiazolinone, benzyl alcohol, benzyl salicylate, citric acid, cocamidopropyl betaine, sodium laureth sulfate, disodium EDTA, glycerin, hexyl cinnamal, linalool, magnesium nitrate, propylene glycol, sodium bicarbonate, sodium sulfate, triethylene glycol2024-11-29 10:47:42
Australian Gold Liquid Hand Soap Cocoa Dreams -- 11.5 fl ozAustralian GoldHousehold Essentialscitric acid, methylchloroisothiazolinone, benzyl alcohol, citral, citric acid, cocamidopropyl betaine, coumarin, coumarin, sodium laureth sulfate, disodium EDTA, glycerin, limonene, linalool, magnesium nitrate, propylene glycol, sodium benzoate, sodium bicarbonate, sodium sulfate, triethylene glycol2024-11-29 10:47:42
Australian Gold Liquid Hand Soap Lavender Mint -- 11.5 fl ozAustralian GoldHousehold Essentialscitric acid, methylchloroisothiazolinone, benzyl alcohol, citric acid, cocamidopropyl betaine, sodium laureth sulfate, disodium EDTA, glycerin, limonene, linalool, magnesium nitrate, propylene glycol, sodium benzoate, sodium bicarbonate, sodium sulfate, triethylene glycol2024-11-29 10:47:42
Australian Gold Liquid Hand Soap Sugared Lemon -- 11.5 fl ozAustralian GoldHousehold Essentialscitric acid, methylchloroisothiazolinone, alpha-isomethyl ionone, benzyl alcohol, citral, citric acid, cocamidopropyl betaine, sodium laureth sulfate, disodium EDTA, glycerin, limonene, linalool, magnesium nitrate, propylene glycol, sodium benzoate, sodium bicarbonate, sodium sulfate, triethylene glycol2024-11-29 10:47:42
Australian Gold Liquid Hand Soap Sweet Apricot -- 11.5 fl ozAustralian GoldHousehold Essentialscitric acid, methylchloroisothiazolinone, benzyl alcohol, benzyl benzoate, citral, citric acid, citronellol, cocamidopropyl betaine, sodium laureth sulfate, disodium EDTA, geraniol, glycerin, hexyl cinnamal, limonene, linalool, magnesium nitrate, propylene glycol, sodium benzoate, sodium bicarbonate, sodium sulfate, triethylene glycol2024-11-29 10:47:42
Australian Gold Room Spray Aloe Vera -- 3.7 fl ozAustralian GoldHousehold Essentialsdisodium EDTA, ethylhexylglycerin, glycerin, phenoxyethanol2024-11-29 10:47:42
Australian Gold Room Spray Cocoa Dreams -- 3.7 fl ozAustralian GoldHousehold Essentialscitric acid, benzyl alcohol, citral, citric acid, coumarin, coumarin, disodium EDTA, ethylhexylglycerin, glycerin, limonene, linalool, phenoxyethanol2024-11-29 10:47:42
Australian Gold Room Spray Lavender Mint -- 3.7 fl ozAustralian GoldHousehold Essentialscitric acid, citric acid, tocopherol, disodium edta, ethylhexylglycerin, tocopherol, glycerin, limonene, linalool, phenoxyethanol2024-11-29 10:47:42
Australian Gold Room Spray Sugared Lemon -- 3.7 fl ozAustralian GoldHousehold Essentialscitric acid, benzyl alcohol, citral, citric acid, tocopherol, disodium EDTA, ethylhexylglycerin, tocopherol, glycerin, limonene, linalool, phenoxyethanol2024-11-29 10:47:42
Australian Gold Room Spray Sweet Apricot -- 3.7 fl ozAustralian GoldHousehold Essentialscitric acid, benzyl benzoate, citral, citric acid, tocopherol, disodium EDTA, ethylhexylglycerin, tocopherol, geraniol, glycerin, hexyl cinnamal, limonene, linalool, phenoxyethanol2024-11-29 10:47:42
Aveeno Apple Cider Vinegar Blend Conditioner -- 12 fl ozAveenoBeauty & Personal Careisopropyl alcohol, citric acid, vinegar, propylene glycol dicaprylate/dicaprate, cetearyl alcohol, cetyl alcohol, citric acid, disodium EDTA, glycerin, sodium benzoate, sodium hydroxide2024-11-29 10:47:42
Aveeno Calm + Restore Nourishing Oat Cleanser -- 7.8 fl ozAveenoBeauty & Personal Carecaprylyl glycol, butylene glycol, disodium EDTA, ethylhexylglycerin, glycerin, oat, phenoxyethanol, poloxamer 188, sodium hydroxide2024-11-29 10:47:42
Aveeno Clear Complexion Foaming Cleanser -- 6 fl ozAveenoBeauty & Personal CareButylene Glycol, Citric Acid, Butylparaben, Citric Acid, Cocamidopropyl Betaine, Disodium Edta, Ethylparaben, Glycerin, Isobutylparaben, Methylparaben, Phenoxyethanol, Propylparaben2024-11-29 10:47:42
Aveeno Fresh Greens Blend Conditioner -- 12 fl ozAveenoBeauty & Personal Careisopropyl alcohol, citric acid, propylene glycol dicaprylate/dicaprate, cetearyl alcohol, cetyl alcohol, citric acid, disodium EDTA, glycerin, sodium benzoate, sodium hydroxide2024-11-29 10:47:42
Aveeno Kids 2-in-1 Hydrating Shampoo & Conditioner Lightly Scented -- 12 fl ozAveenoBaby & Kids Productscitric acid, citric acid, cocamidopropyl betaine, decyl glucoside, disodium EDTA, glycerin, oat, sodium benzoate2024-11-29 10:47:42
Aveeno Kids Curly Hair Shampoo Lightly Scented -- 12 fl ozAveenoBaby & Kids Productscitric acid, citric acid, cocamidopropyl betaine, decyl glucoside, disodium EDTA, glycerin, oat, sodium benzoate2024-11-29 10:47:42
Aveeno Positively Radiant Daily Moisturizer -- 4 fl ozAveenoBeauty & Personal CareBHT, Cetearyl Alcohol, Behenyl Alcohol, Disodium EDTA, Glycerin, Dimethicone, Sodium Hydroxide2024-11-29 10:47:42
Aveeno Positively Radiant Intensive Night Cream with Vitamin B3 -- 1.7 ozAveenoBeauty & Personal CareCaprylyl Glycol, Cetearyl Alcohol, Chlorphenesin, Behenyl Alcohol, Disodium EDTA, Ethylhexylglycerin, Glyceryl Stearate, Glycerin, Hexylene Glycol, Microcrystalline Cellulose, Niacinamide, Phenoxyethanol, Trehalose, Triacetin, Urea2024-11-29 10:47:42
Babe Original Densifying Hair Serum -- 1.76 ozBabe OriginalBeauty & Personal Carecaprylyl glycol, butylene glycol, apigenin, arginine, benzoic acid, benzyl alcohol, gluconolactone, biotin, caffeine, tocopherol, dimethyl sulfone, disodium edta, tocopherol, glycerin, glycine, lactic acid, trisodium ethylenediamine disuccinate, oleanolic acid, phenoxyethanol, phenethyl alcohol, propanediol, sodium benzoate, sodium metabisulfite, sorbic acid, xylitol, zinc chloride2024-11-29 10:47:42
Babe Original Lash Enriching Liquid Eyeliner -- 1.5 mLBabe OriginalBeauty & Personal Carecaprylyl glycol, butylene glycol, benzoic acid, disodium EDTA, ethylhexylglycerin, glycerin, glyceryl caprylate, pvp, phenoxyethanol2024-11-29 10:47:42
Because No-Rinse Cleansing Spray -- 6 fl ozBecauseBeauty & Personal CareDMDM hydantoin, allantoin, betaine, vitamin E, D-panthenol, disodium EDTA, tocopherol, vitamin E, propylene glycol2024-11-29 10:47:42
Blue-Emu Arthritis Cream -- 3 FileBlue-EmuBeauty & Personal Careallantoin, tocopherol acetate, cetyl alcohol, vitamin E, D-panthenol, methylsulfonylmethane, disodium EDTA, ethylhexylglycerin, vitamin E, D-glucosamine, glycerin, dimethicone, phenoxyethanol, stearic acid, triethanolamine2024-11-29 10:47:42
Cantu Avocado Hydrating Conditioner -- 13.5 fl ozCantuBeauty & Personal Carecetyl alcohol, disodium EDTA, ethylhexylglycerin, glyceryl stearate, lactic acid, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Cantu Avocado Hydrating Shampoo -- 13.5 fl ozCantuBeauty & Personal Carecocamidopropyl betaine, panthenol, disodium EDTA, ethylhexylglycerin, phenoxyethanol, sodium hydroxide2024-11-29 10:47:42
Cantu Shea Butter Leave-in Conditioning Repair Cream -- 16 ozCantuBeauty & Personal Careorange, citric acid, benzyl salicylate, propylene glycol dicaprylate/dicaprate, cetearyl alcohol, citric acid, coumarin, coumarin, cyclopentasiloxane, panthenol, dicetyldimonium chloride, disodium EDTA, ethylhexylglycerin, glycerin, dimethicone, hexyl cinnamal, hydroxyethylcellulose, butylphenyl methylpropional, limonene, phenoxyethanol, propylene glycol2024-11-29 10:47:42
CeraVe Daily Moisturizing Lotion for Normal to Dry Skin -- 12 fl ozCeraVeBeauty & Personal Carecarbomer, ceramide 3, cetyl alcohol, disodium edta, glycerin, dimethicone, methylparaben, phytosphingosine, potassium phosphate, propylparaben2024-11-29 10:47:42
CeraVe Facial Moisturizing Lotion AM with Sunscreen Broad Spectrum SPF 30 -- 3 fl ozCeraVeBeauty & Personal Carebht, carbomer, ceramide NP, cetearyl alcohol, disodium EDTA, glycerin, dimethicone, hydroxyethylcellulose, methylparaben, niacinamide, triethoxycaprylylsilane, phytosphingosine, propylparaben2024-11-29 10:47:42
CeraVe Foaming Facial Cleanser For Normal to Oily Skin -- 12 fl ozCeraVeBeauty & Personal Carecitric acid, carbomer, ceramide NP, citric acid, disodium EDTA, glycerin, methylparaben, niacinamide, phytosphingosine, propylene glycol, propylparaben, sodium lauroyl sarcosinate2024-11-29 10:47:42
CeraVe Hydrating Facial Cleanser For Normal to Dry Skin -- 12 fl ozCeraVeBeauty & Personal Carecarbomer, ceramide NP, cetearyl alcohol, cetyl alcohol, tocopherol, disodium EDTA, tocopherol, glyceryl stearate, glycerin, phenoxyethanol, phytosphingosine, PEG-40 stearate, potassium phosphate, stearyl alcohol2024-11-29 10:47:42
CeraVe Itch Relief Moisturizing Lotion for Dry and Itchy Skin -- 8 fl ozCeraVeBeauty & Personal Careallantoin, carbomer, ceramide NP, cetearyl alcohol, cetyl alcohol, disodium EDTA, glyceryl stearate, glycerin, dimethicone, isopropyl myristate, myristic acid, niacinamide, palmitic acid, palmitic acid, phenoxyethanol, phytosphingosine, potassium phosphate, pramoxine hcl, sodium hydroxide, stearic acid2024-11-29 10:47:42
CeraVe Moisturizing Cream for Normal to Dry Skin -- 16 ozCeraVeBeauty & Personal Careceramide NP, cetearyl alcohol, cetyl alcohol, tocopherol, disodium EDTA, tocopherol, glycerin, dimethicone, phenoxyethanol, phytosphingosine, potassium phosphate2024-11-29 10:47:42
CeraVe PM Facial Moisturizing Lotion -- 3 fl ozCeraVeBeauty & Personal Carecaprylyl glycol, carbomer, ceramide NP, cetearyl alcohol, disodium EDTA, glycerin, dimethicone, niacinamide, phenoxyethanol, phytosphingosine, potassium phosphate2024-11-29 10:47:42
CeraVe Psoriasis Cleanser with Salicylic Acid Psoriasis Wash -- 8 fl ozCeraVeBeauty & Personal Carecitric acid, gluconolactone, ethoxydiglycol, carbomer, ceramide NP, citric acid, disodium EDTA, ethylhexylglycerin, glycerin, glycolic acid, hexylene glycol, lactic acid, niacinamide, phenoxyethanol, phytosphingosine, laureth-9, sodium benzoate, sodium citrate, sodium lactate, urea2024-11-29 10:47:42
CeraVe SA Body Lotion for Rough & Bumpy Skin with Salicylic Acid -- 8 fl ozCeraVeBeauty & Personal Careammonium lactate, carbomer, cetearyl alcohol, cetyl alcohol, cholecalciferol, disodium EDTA, glyceryl stearate, glycerin, dimethicone, methylparaben, phytosphingosine, propylparaben, salicylic acid, triethanolamine2024-11-29 10:47:42
CeraVe Skin Renewing Day Cream with Sunscreen SPF 30 -- 1.76 fl ozCeraVeBeauty & Personal Carebutylene glycol, hydroxyethyl acrylate, carbomer, ceramide 3, cetearyl alcohol, chlorphenesin, disodium EDTA, ethylhexylglycerin, glycerin, dimethicone, phenoxyethanol, phytosphingosine, retinol, sodium hydroxide, squalane, stearyl alcohol2024-11-29 10:47:42
Cococare Cocoa Butter Cream -- 15 ozCococareBeauty & Personal CareDMDM hydantoin, cetyl alcohol, EDTA, methylparaben, propylparaben, stearic acid, CI 191402024-11-29 10:47:42
Cococare Shea Butter Cream -- 15 ozCococareBeauty & Personal Carecetyl alcohol, EDTA, hydantoin, methylparaben, propylparaben, stearic acid2024-11-29 10:47:42
Comforts Baby Wipes Clean & Fresh -- 900 WipesComfortsBaby & Kids Productscitric acid, citric acid, disodium EDTA, glycerin, sodium benzoate, sodium bicarbonate, sodium citrate2024-11-29 10:47:42
Comforts Fragrance Free Baby Wipes -- 216 WipesComfortsBaby & Kids Productscitric acid, citric acid, disodium edta, glycerin, glycyrrhiza, sodium benzoate, sodium bicarbonate, sodium citrate2024-11-29 10:47:42
Comforts Fragrance Free Baby Wipes -- 600 WipesComfortsBaby & Kids Productscitric acid, citric acid, disodium edta, glycerin, glycyrrhiza, sodium benzoate, sodium bicarbonate, sodium citrate2024-11-29 10:47:42
Comforts Fragrance Free Baby Wipes -- 72 WipesComfortsBaby & Kids Productscitric acid, citric acid, disodium edta, glycerin, glycyrrhiza, sodium benzoate, sodium bicarbonate, sodium citrate2024-11-29 10:47:42
Comforts Fragrance Free Baby Wipes -- 900 WipesComfortsBaby & Kids Productscitric acid, citric acid, disodium EDTA, glycerin, sodium benzoate, sodium bicarbonate, sodium citrate2024-11-29 10:47:42
Common Ground NUE Aqua Micellar Water -- 8.4 fl ozCommon GroundBeauty & Personal Carecitric acid, citric acid, disodium edta, glycerin, phosphoric acid, propylene glycol, sodium benzoate, sodium sulfite2024-11-29 10:47:42
Daeng Gi Meo Ri Conditioner For All Hair Types -- 16.9 fl ozDaeng Gi Meo RiBeauty & Personal Carebutylene glycol, isopropyl alcohol, citric acid, alpha-isomethyl ionone, citric acid, citronellol, cocamidopropyl betaine, disodium EDTA, ethylhexylglycerin, glycerin, hexyl cinnamal, butylphenyl methylpropional, linalool, phenoxyethanol, sodium acetate, sodium benzoate2024-11-29 10:47:42
Daeng Gi Meo Ri Ginseng Blossom Shampoo -- 24 fl ozDaeng Gi Meo RiBeauty & Personal Carecaprylyl glycol, butylene glycol, citric acid, allantoin, ceramide NP, citric acid, cocamidopropyl betaine, panthenol, disodium edta, hexyl cinnamal, phenoxyethanol, phytosterols, propanediol, sodium benzoate, sodium citrate, squalane2024-11-29 10:47:42
Daeng Gi Meo Ri Hair Loss Shampoo For Thinning Hair -- 13.5 fl ozDaeng Gi Meo RiBeauty & Personal Carecitric acid, allantoin, citric acid, cocamidopropyl betaine, dexpanthenol, disodium EDTA, glycerin, butylphenyl methylpropional, linalool, niacinamide, phenoxyethanol, salicylic acid, sodium benzoate, sodium citrate2024-11-29 10:47:42
Daeng Gi Meo Ri Medicinal Herb Hair Color - Black -- 1 KitDaeng Gi Meo RiBeauty & Personal Carebutylene glycol, P-aminophenol, PCA, ceteth-20, cetyl alcohol, citronellol, dioleyl phosphate, behenyl alcohol, lauryl alcohol, disodium EDTA, ethanolamine, geraniol, hexyl cinnamal, hydroxycitronellal, butylphenyl methylpropional, limon- ene, linalool, myristic acid, myristyl alcohol, oleyl alcohol, palmitic acid, palmitic acid, phenacetin, resorcinol, sodium benzoate, stearic acid, stearyl alcohol, stearyl stearate, threonine2024-11-29 10:47:42
Daeng Gi Meo Ri Medicinal Herb Hair Color - Natural Brown -- 1 KitDaeng Gi Meo RiBeauty & Personal Carebutylene glycol, P-aminophenol, PCA, ceteth-20, cetyl alcohol, citronellol, dioleyl phosphate, behenyl alcohol, lauryl alcohol, disodium EDTA, ethanolamine, geraniol, hexyl cinnamal, hydroxycitronellal, butylphenyl methylpropional, limon- ene, linalool, myristic acid, myristyl alcohol, oleyl alcohol, palmitic acid, palmitic acid, phenacetin, resorcinol, sodium benzoate, stearic acid, stearyl alcohol, stearyl stearate, threonine2024-11-29 10:47:42
Daeng Gi Meo Ri Shampoo For All Hair Types -- 16 fl ozDaeng Gi Meo RiBeauty & Personal Carebutylene glycol, isopropyl alcohol, citric acid, alpha-isomethyl ionone, citric acid, citronellol, cocamidopropyl betaine, disodium EDTA, ethylhexylglycerin, glycerin, hexyl cinnamal, butylphenyl methylpropional, linalool, phenoxyethanol, sodium acetate, sodium benzoate2024-11-29 10:47:42
Daeng Gi Meo Ri Shampoo For Damaged Hair -- 16.9 fl ozDaeng Gi Meo RiBeauty & Personal Caremethylchloroisothiazolinone, allantoin, carbomer, cocamidopropyl betaine, panthenol, lauramine oxide, disodium EDTA, glycerin, dimethicone, menthol, methylparaben, sodium cocoyl glutamate, triethanolamine2024-11-29 10:47:42
Daeng Gi Meo Ri Shampoo For Oily Scalp -- 16.9 fl ozDaeng Gi Meo RiBeauty & Personal Carecarbomer, cocamidopropyl betaine, panthenol, lauramine oxide, disodium EDTA, dimethicone, limonene, linalool, menthol, phenoxyethanol, propylene glycol, sodium benzoate, triethanolamine2024-11-29 10:47:42
Earth Therapeutics Green Tea Hydrogel Under-Eye Patch -- 5 Under-Eye PatchesEarth TherapeuticsBeauty & Personal Carebutylene glycol, allantoin, disodium EDTA, glycerin, kaolin, octyldodecanol, phenoxyethanol, sorbitol, tartaric acid, titanium dioxide2024-11-29 10:47:42
Ecco Bella FlowerColor Liquid Foundation - Ivory Porcelain -- 1 fl ozEcco BellaBeauty & Personal Carecaprylyl glycol, cetyl alcohol, disodium edta, kaolin, titanium dioxide2024-11-29 10:47:42
Ecco Bella FlowerColor Liquid Foundation - Light Beige -- 1 fl ozEcco BellaBeauty & Personal Carecaprylyl glycol, cetyl alcohol, disodium edta, kaolin, titanium dioxide2024-11-29 10:47:42
Ecco Bella FlowerColor Liquid Foundation - Natural -- 1 fl ozEcco BellaBeauty & Personal Carecaprylyl glycol, cetyl alcohol, disodium edta, kaolin, titanium dioxide2024-11-29 10:47:42
EmBeba Soothing Bug Bite Relief Patch Senstive Skin for Infants 0+ Years -- 18 PatchesEmBebaBaby & Kids Productsbutylene glycol, citric acid, allantoin, carbomer, citric acid, tocopherol, panthenol, disodium edta, ethylhexylglycerin, tocopherol, glycerin2024-11-29 10:47:42
Emerita Intimate Moisturizer -- 4 fl ozEmeritaBeauty & Personal Carebutylene glycol, citric acid, allantoin, citric acid, disodium edta, glycerin, hydroxyethylcellulose, retinyl palmitate, sorbitol, squalane, xylitol2024-11-29 10:47:42
EOS Ultra Moisturizing Shave Cream Lavender -- 7 fl ozEOSBeauty & Personal Carecaprylyl glycol, citric acid, ascorbyl palmitate, carbomer, cetyl alcohol, citric acid, citronellol, coumarin, coumarin, disodium edta, geraniol, glycerin, dimethicone, hexylene glycol, limonene, phenoxyethanol, propylene glycol, sodium benzoate, sodium hydroxide, stearyl alcohol, titanium dioxide2024-11-29 10:47:42
EOS Ultra Moisturizing Shave Cream Pomegranate Raspberry -- 7 fl ozEOSBeauty & Personal Careascorbyl palmitate, red 40, carbomer, cetyl alcohol, disodium EDTA, glyceryl stearate, glycerin, dimethicone, hexyl cinnamal, butylphenyl methylpropional, linalool, oat, glycol stearate, propylene glycol, sodium benzoate, stearic acid, titanium dioxide, triethanolamine2024-11-29 10:47:42
EOS Ultra Moisturizing Shave Cream Vanilla Bliss -- 7 fl ozEOSBeauty & Personal Careascorbyl palmitate, red 40, gluconolactone, carbomer, cetyl alcohol, disodium EDTA, glyceryl stearate, glycerin, dimethicone, oat, glycol stearate, propylene glycol, sodium benzoate, stearic acid, yellow 5, titanium dioxide, triethanolamine2024-11-29 10:47:42
Eucerin Age Defense Lightweight Sunscreen Lotion for Face SPF 50 -- 2.5 fl ozEucerinBeauty & Personal Carecetearyl alcohol, cetyl alcohol, tocopherol, dibutyl adipate, behenyl alcohol, disodium edta, ethylcellulose, ethylhexylglycerin, tocopherol, glycerin, glyceryl behenate, glycyrrhetinic acid, dimethicone, l-carnitine, phenoxyethanol2024-11-29 10:47:42
Formula 10.0.6 Go Get Fresh Deodorizing Body Wash -- 10.1 fl ozFormula 10.0.6Beauty & Personal Caremethylchloroisothiazolinone, cocamidopropyl betaine, disodium EDTA, glycerin, propylene glycol, sorbic acid2024-11-29 10:47:42
Formula 10.0.6 Save My Sole Rescuing Foot Scrub Avocado and Peppermint -- 3.4 fl ozFormula 10.0.6Beauty & Personal Carecaprylyl glycol, betaine, cetearyl alcohol, disodium EDTA, glycerin, coco-betaine, stearyl alcohol2024-11-29 10:47:42
Formula 10.0.6 Soak Your Face Intensive Hydrating Sheet Mask -- 1 Single Use Sheet MaskFormula 10.0.6Beauty & Personal Carebutylene glycol, betaine, ceteth-20, carbomer, cyclopentasiloxane, disodium edta, glyceryl stearate, glycerin, maltodextrin, phenoxyethanol, sodium hydroxide2024-11-29 10:47:42
Formula 10.0.6 Step By Step Renewing Foot Balm Eucalyptus and Rosemary -- 3.4 fl ozFormula 10.0.6Beauty & Personal Carecaprylyl glycol, butylene glycol, cetyl alcohol, tocopherol, disodium EDTA, tocopherol, glycerin, dimethicone, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni 50:50 Balanced Conditioner Hydrating-Calming -- 2 fl ozGiovanniBeauty & Personal Carecitric acid, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, disodium edta, ethylhexylglycerin, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni 50:50 Balanced Conditioner Hydrating-Calming -- 8.5 fl ozGiovanniBeauty & Personal Carecitric acid, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, disodium EDTA, ethylhexylglycerin, glycerin, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Hempz Age Defying Body Moisturizer -- 17 fl ozHempzBeauty & Personal Carebutylene glycol, aminomethyl propanol, citric acid, alpha-isomethyl ionone, ascorbic acid, benzyl benzoate, caffeine, carbomer, cetyl alcohol, chlorphenesin, citric acid, coumarin, coumarin, tocopherol, disodium edta, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, dimethicone, hexyl cinnamal, isopropyl palmitate, nylon-12, phenoxyethanol, propanediol, retinyl palmitate, sodium benzoate, sodium lactate, stearic acid, yellow 52024-11-29 10:47:42
Hempz Beauty Smoothing Herbal Body Moisturizer Sweet Jasmine & Rose -- 17 fl ozHempzBeauty & Personal Carebutylene glycol, aminomethyl propanol, ascorbic acid, benzyl benzoate, carbomer, cetyl alcohol, chlorphenesin, tocopherol, disodium EDTA, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, dimethicone, hexyl cinnamal, isopropyl palmitate, nylon-12, butylphenyl methylpropional, phenoxyethanol, propanediol, retinyl palmitate, stearic acid2024-11-29 10:47:42
Hempz Herbal Body Moisturizer Exotic Green Tea & Asian Pear -- 17 fl ozHempzBeauty & Personal Carebutylene glycol, aminomethyl propanol, ascorbic acid, carbomer, cetyl alcohol, tocopherol, disodium EDTA, CI 42053, tocopherol, geraniol, glyceryl stearate, glycerin, dimethicone, hexyl cinnamal, nylon-12, limonene, linalool, phenoxyethanol, propanediol, retinyl palmitate, sodium benzoate, stearic acid2024-11-29 10:47:42
Hempz Herbal Body Moisturizer Original -- 17 fl ozHempzBeauty & Personal Carebutylene glycol, aminomethyl propanol, ascorbic acid, benzyl benzoate, benzyl cinnamate, carbomer, tocopherol, disodium EDTA, tocopherol, glyceryl stearate, glycerin, nylon-12, methyl 2-octynoate, phenoxyethanol, propanediol, sodium benzoate, yellow 52024-11-29 10:47:42
Hempz Herbal Body Moisturizer Pomegranate -- 17 fl ozHempzBeauty & Personal Carebutylene glycol, orange, citric acid, benzyl benzoate, benzyl salicylate, carbomer, cetyl alcohol, chlorphenesin, citric acid, tocopherol, red 33, disodium EDTA, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, dimethicone, hexyl cinnamal, isopropyl palmitate, nylon-12, phenoxyethanol, propanediol, retinyl palmitate2024-11-29 10:47:42
Hempz Herbal Body Moisturizer Sweet Pineapple & Honey Melon -- 17 fl ozHempzBeauty & Personal Carebutylene glycol, aminomethyl propanol, citric acid, red 40, ascorbic acid, benzyl benzoate, carbomer, cetyl alcohol, chlorphenesin, citric acid, tocopherol, disodium EDTA, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, dimethicone, isopropyl palmitate, nylon-12, limonene, linalool, phenoxyethanol, propanediol, retinyl palmitate, stearic acid, yellow 52024-11-29 10:47:42
Hempz Scalp Care Herbal Conditioner Tea Tree & Chamomile -- 17 fl ozHempzBeauty & Personal Careaminomethyl propanol, iodopropynyl butylcarbamate, citric acid, acetic acid, cetearyl alcohol, cetyl alcohol, chlorphenesin, citric acid, tocopherol, panthenol, disodium EDTA, etidronic acid, tocopherol, glycerin, PEG-4, dimethicone, hydroxyethylcellulose, menthol, octyldodecanol, phenoxyethanol, laureth-9, sodium acetate, stearyl alcohol2024-11-29 10:47:42
Hempz Scalp Care Herbal Shampoo Tea Tree & Chamomile -- 17 fl ozHempzBeauty & Personal Careaminomethyl propanol, citric acid, benzoic acid, citric acid, tocopherol, disodium EDTA, ethylhexylglycerin, tocopherol, glycerin, menthol, phenoxyethanol, propanediol, sodium benzoate, sodium hydroxide2024-11-29 10:47:42
Hempz Triple Moisture Herbal Conditioner Fresh Citrus -- 17 fl ozHempzBeauty & Personal Careiodopropynyl butylcarbamate, citric acid, acetic acid, benzyl benzoate, cetearyl alcohol, cetyl alcohol, chlorphenesin, citric acid, tocopherol, panthenol, disodium EDTA, etidronic acid, tocopherol, glycerin, PEG-4, dimethicone, hydroxyethylcellulose, limonene, linalool, octyldodecanol, phenoxyethanol, sodium acetate, sodium benzoate, stearyl alcohol2024-11-29 10:47:42
Hempz Triple Moisture Herbal Shampoo Fresh Citrus -- 17 fl ozHempzBeauty & Personal Careaminomethyl propanol, citric acid, benzoic acid, citric acid, cocamidopropyl betaine, tocopherol, disodium EDTA, ethylhexylglycerin, tocopherol, glycerin, limonene, linalool, phenoxyethanol, sodium benzoate, sodium hydroxide2024-11-29 10:47:42
Home Health Hyaluronic Acid Moisturizing Cream Fragrance Free -- 4 ozHome HealthBeauty & Personal Carecitric acid, vitamin C, bisabolol, citric acid, d-alpha tocopherol, and, panthenol, diazolidinyl urea, disodium EDTA, glycerin, dimethicone, vitamin B5, retinyl palmitate, Vitamin A2024-11-29 10:47:42
Love Beauty and Planet Coconut Water & Mimosa Flower Volumizing Conditioner -- 13.5 fl ozLove Beauty and PlanetBeauty & Personal Caremethylisothiazolinone, disodium EDTA, hexyl cinnamal, limonene2024-11-29 10:47:42
Love Beauty and Planet Silicone & Sulfate-Free Coconut Water & Mimosa Flower Vegan Shampoo -- 13.5 fl ozLove Beauty and PlanetBeauty & Personal Carecitric acid, citric acid, disodium EDTA, hexyl cinnamal, limonene, sodium benzoate2024-11-29 10:47:42
Love Beauty and Planet Silicone-Free Coconut Oil & Ylang Ylang Vegan Conditioner for Split Ends -- 13.5 fl ozLove Beauty and PlanetBeauty & Personal Caremethylisothiazolinone, disodium EDTA2024-11-29 10:47:42
Love Beauty and Planet Smooth & Serene Argan Oil & Lavender Conditioner -- 13.5 fl ozLove Beauty and PlanetBeauty & Personal Caremethylisothiazolinone, disodium EDTA2024-11-29 10:47:42
Love Beauty and Planet Soothe & Serene Argan Oil & Lavender Hand Lotion -- 1 fl ozLove Beauty and PlanetBeauty & Personal CareCaprylyl Glycol, BHT, Carbomer, Citronellol, Coumarin, Coumarin, Disodium EDTA, Hydroxycitronellal, Hydroxyethylcellulose, Limonene, Linalool, Phenoxyethanol, Triethanolamine2024-11-29 10:47:42
Love Beauty and Planet Sulfate-Free Coconut Milk & White Jasmine Shampoo for Curly Hair -- 13.5 fl ozLove Beauty and PlanetBeauty & Personal Carebenzyl alcohol, benzyl salicylate, disodium EDTA, hydroxycitronellal, sodium benzoate2024-11-29 10:47:42
Love Beauty and Planet Sulfate-Free Coconut Oil & Ylang Ylang Vegan Shampoo Split Ends & Damaged Hair -- 13.5 fl ozLove Beauty and PlanetBeauty & Personal Carecitric acid, benzyl alcohol, benzyl salicylate, citric acid, sodium laureth sulfate, disodium EDTA, limonene, sodium benzoate2024-11-29 10:47:42
Love Beauty and Planet Sulfate-Free Murumuru Butter & Rose Color-Treated Hair Vegan Conditioner -- 13.5 fl ozLove Beauty and PlanetBeauty & Personal Caremethylisothiazolinone, methylchloroisothiazolinone, benzyl salicylate, disodium EDTA2024-11-29 10:47:42
Love Beauty and Planet Sulfate-Free Smooth & Serene Argan Oil & Lavender Shampoo for Frizz Control -- 13.5 fl ozLove Beauty and PlanetBeauty & Personal Carecitric acid, citric acid, citronellol, coumarin, coumarin, sodium laureth sulfate, disodium EDTA, limonene, sodium benzoate2024-11-29 10:47:42
Maui Moisture Frizz-Free + Shea Butter Leave-In Conditioning Mist -- 8 fl ozMaui MoistureBeauty & Personal Careisopropyl alcohol, citric acid, cetearyl alcohol, citric acid, disodium EDTA, ethylhexylglycerin, glycerin, dodecane, tetradecane, phenoxyethanol, sodium hydroxide2024-11-29 10:47:42
Mill Creek Botanicals Dandruff Control Shampoo -- 16 fl ozMill CreekBeauty & Personal Carecitric acid, vitamin C, cholecalciferol, citric acid, cocamidopropyl betaine, tocopherol, panthenol, provitamin B5, disodium-EDTA, tocopherol, vitamin E, retinyl palmitate, vitamin A, sodium benzoate2024-11-29 10:47:42
Pacifica Aquarian Gaze Water Resistant Long Lash Mineral Mascara - Black -- 0.25 ozPacificaBeauty & Personal Carecaprylyl glycol, butylene glycol, kelp, panthenol, disodium EDTA, ethylhexylglycerin, hexylene glycol, hydroxyethylcellulose, vitamin B, sodium hydroxide2024-11-29 10:47:42
Penetrex Arthritis Pain Relief Cream -- 2 ozPenetrexBeauty & Personal Carecitric acid, camphor, ethoxydiglycol, cetearyl alcohol, citric acid, tocopherol, methylsulfonyl methane, disodium EDTA, ethylhexylglycerin, tocopherol, glyceryl stearates, glycerin, dimethicone, phenoxyethanol, pyridoxine HCI, beta-sitosterol, sodium benzoate2024-11-29 10:47:42
Sun Bum Original Face 50 Suncreen Lotion SPF 50 Fragrance Free -- 3 fl ozSun BumBeauty & Personal Caretocopherol acetate, BHT, behenyl alcohol, disodium EDTA, ethylhexylglycerin, glyceryl stearate, dimethicone2024-11-29 10:47:42
Sun Bum Original Lotion SPF 70 -- 6 fl ozSun BumBeauty & Personal Caremethylisothiazolinone, BHT, disodium edta, ethylhexylglycerin, glyceryl stearate, dimethicone2024-11-29 10:47:42
Sun Bum Original SPF 30 Sunscreen Lotion -- 3 fl ozSun BumBeauty & Personal Carebht, behenyl alcohol, disodium edta, ethylhexylglycerin, glyceryl stearate, dimethicone2024-11-29 10:47:42
Sun Bum Original SPF 50 Sunscreen Lotion -- 3 fl ozSun BumBeauty & Personal Carebht, behenyl alcohol, disodium edta, ethylhexylglycerin, glyceryl stearate, dimethicone2024-11-29 10:47:42
Sun Bum Original SPF 70 Sunscreen Lotion -- 3 fl ozSun BumBeauty & Personal Caremethylisothiazolinone, bht, disodium edta, ethylhexylglycerin, glyceryl stearate, dimethicone2024-11-29 10:47:42
Sun Bum Original Sunscreen Lotion SPF 30 -- 6 fl ozSun BumBeauty & Personal CareBHT, behenyl alcohol, disodium EDTA, ethylhexylglycerin, glyceryl stearate, dimethicone2024-11-29 10:47:42
Sun Bum Original Sunscreen Lotion SPF 50 -- 6 fl ozSun BumBeauty & Personal CareBHT, behenyl alcohol, disodium EDTA, ethylhexylglycerin, glyceryl stearate, dimethicone2024-11-29 10:47:42
Tecnu Rash Relief Spray -- 6 fl ozTecnuBeauty & Personal Carebenzethonium chloride, disodium EDTA, glycerin, menthol2024-11-29 10:47:42
Vanicream Gentle Body Wash for Sensitive Skin -- 12 fl ozVanicreamBeauty & Personal Carecaprylyl glycol, panthenol, disodium EDTA, glycerin, propanediol, sodium hydroxide, titanium dioxide2024-11-29 10:47:42
Vanicream Shampoo -- 12 fl ozVanicreamBeauty & Personal Carecaprylyl glycol, panthenol, disodium EDTA, glycerin, sodium cocoyl glutamate, sodium hydroxide2024-11-29 10:47:42
Vitabath Body Cream Cucumber & White Tea -- 8 ozVitabathBeauty & Personal Careascorbic acid, BHT, cetyl alcohol, tocopherol, panthenol, diazolidinyl urea, disodium EDTA, tocopherol, glycerin, dimethicone, niacinamide, PEG-150 stearate, retinyl palmitate, stearic acid, triethanolamine2024-11-29 10:47:42
Vitabath Body Cream Lavender Chamomile -- 8 fl ozVitabathBeauty & Personal Careascorbic acid, BHT, cetyl alcohol, tocopherol, panthenol, diazolidinyl urea, disodium EDTA, tocopherol, glycerin, dimethicone, niacinamide, PEG-150 stearate, retinyl palmitate, stearic acid, triethanolamine2024-11-29 10:47:42
Vitabath Men Gentle Face Wash Lime & Cedarleaf -- 8 fl ozVitabathBeauty & Personal Carecaprylyl glycol, ascorbic acid, chlorphenesin, cocamidopropyl betaine, panthenol, disodium EDTA, glycerin, menthol, niacinamide, phenoxyethanol, retinyl palmitate, sodium hydroxide2024-11-29 10:47:42

Roles (5)

RoleDescription
antidoteAny protective agent counteracting or neutralizing the action of poisons.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
chelatorA ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.
copper chelatorA chelator that is any compound containing a ligand (typically organic) which is able to form a bond to a central copper atom at two or more points.
anticoagulantAn agent that prevents blood clotting.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
tetracarboxylic acidAn oxoacid containing four carboxy groups.
ethylenediamine derivativeAny organic amino compound that is a derivative of ethylenediamine.
polyamino carboxylic acidAn amino acid containing one or more nitrogen atoms connected through carbon atoms to one or more carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency1.25890.004023.8416100.0000AID485290
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency3.10063.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.17610.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency0.93130.000221.22318,912.5098AID1259243; AID1259381
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency1.93940.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency0.00970.000417.946075.1148AID1346784
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency1.93940.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.19390.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.86970.000229.305416,493.5996AID1259244
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.28180.035520.977089.1251AID504332
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency2.76340.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency4.51520.039147.5451146.8240AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency24.33650.000627.21521,122.0200AID651741
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency3.54810.316212.765731.6228AID881
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency3.86970.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency1.93940.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency3.86970.001551.739315,848.9004AID1259244
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency3.54810.00638.235039.8107AID881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amyloid-beta precursor proteinHomo sapiens (human)IC50 (µMol)18.05000.00053.889510.0000AID769911; AID769915
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)14.00000.00010.533610.0000AID1350116
Beta-lactamase Pseudomonas aeruginosaIC50 (µMol)27.90005.00005.00005.0000AID682760
Beta-lactamase VIM-1 Pseudomonas aeruginosaIC50 (µMol)9.30009.30009.30009.3000AID530343
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (281)

Processvia Protein(s)Taxonomy
DNA repairEyes absent homolog 2Homo sapiens (human)
chromatin remodelingEyes absent homolog 2Homo sapiens (human)
mesodermal cell fate specificationEyes absent homolog 2Homo sapiens (human)
striated muscle tissue developmentEyes absent homolog 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandEyes absent homolog 2Homo sapiens (human)
mitochondrial outer membrane permeabilizationEyes absent homolog 2Homo sapiens (human)
anatomical structure developmentEyes absent homolog 2Homo sapiens (human)
positive regulation of DNA repairEyes absent homolog 2Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandEyes absent homolog 2Homo sapiens (human)
cell differentiationEyes absent homolog 2Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (67)

Processvia Protein(s)Taxonomy
magnesium ion bindingEyes absent homolog 2Homo sapiens (human)
protein bindingEyes absent homolog 2Homo sapiens (human)
histone H2AXY142 phosphatase activityEyes absent homolog 2Homo sapiens (human)
protein tyrosine phosphatase activityEyes absent homolog 2Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (65)

Processvia Protein(s)Taxonomy
nucleoplasmEyes absent homolog 2Homo sapiens (human)
mitochondrionEyes absent homolog 2Homo sapiens (human)
cytosolEyes absent homolog 2Homo sapiens (human)
nucleusEyes absent homolog 2Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (158)

Assay IDTitleYearJournalArticle
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1898412Bactericidal activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 planktonic cells assessed as planktonic eradication incubated for 24 hrs followed by incubation for overnight in fresh medium by Calgary biofilm device assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID144304Antimycobacterial activity was evaluated against Mycobacterium smegmatis; Inactive2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Ethambutol analogues as potential antimycobacterial agents.
AID1589222Inhibition of Stenotrophomonas maltophilia NDM1 expressed in Escherichia coli BL21 (DE3) expressing measured after 15 minutes at interval of 60 secs2019European journal of medicinal chemistry, Apr-01, Volume: 167H
AID1898418Hemolytic activity against human RBC at 200 uM measured after 1 hr2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID18221Biodistribution of [225Ac]-labeled compound in normal mice bone after 1 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1898416Bactericidal activity against methicillin-resistant Enterococcus faecalis OG1RF ATCC 47077 planktonic cells assessed as planktonic eradication incubated for 24 hrs followed by incubation for overnight in fresh medium by Calgary biofilm device assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID18216Biodistribution of [225Ac]-labeled compound in normal mice blood after 120 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1395979Bactericidal activity against methicillin-resistant Staphylococcus aureus BAA-1707 planktonic cells after 24 hrs by calgary biofilm device method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1304827Antibiofilm activity against methicillin-resistant Staphylococcus aureus isolate 2 assessed as biofilm eradication incubated for 24 hrs by CBD assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID769915Inhibition of amyloid beta aggregation (unknown origin) after 4 hrs by thioflavin S assay in presence of Zn2+2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID767774Inhibition of NDM-1 (unknown origin) expressed in Escherichia coli BL21 using meropenem as substrate compound preincubated for 15 min by spectrophotometry2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Polyketides with New Delhi metallo-β-lactamase 1 inhibitory activity from Penicillium sp.
AID1898409Antibiofilm activity against methicillin-resistant Staphylococcus aureus BAA-1707 biofilms assessed as biofilm eradication incubated for 24 hrs followed by incubation for 24 hrs in fresh medium by Calgary biofilm device assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID1060585Inhibition of Cu2+-induced amyloid beta (1 to 42) (unknown origin) aggregation assessed as reduction of H2O2 production at 800 nM after 30 mins by HRP/Amplex red assay2014European journal of medicinal chemistry, Jan, Volume: 71Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease.
AID18234Biodistribution of [225Ac]-labeled compound in normal mice liver after 24 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1317569Iron chelating activity assessed as Fe3+-compound complex-induced pro-oxidative activity by measuring ascorbate oxidation level at iron binding equivalent of 0.1 measured after 10 to 40 mins in presence of 500 uM citrate relative to control2016European journal of medicinal chemistry, Sep-14, Volume: 120Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.
AID1898397Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-44 assessed as bacterial growth inhibition incubated for 16 hrs by broth microdilution susceptibility test2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID1451134Binding affinity to bacterial NDM-1 expressed in Escherichia coli BL21(DE3) assessed as intrinsic tryptophan fluorescence quenching up to 32 uM after 30 mins by luminescence spectrometric method relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1600070Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 2 mM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectroph2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID492089Antioxidant activity assessed as ferrous ion chelating effect after 10 mins2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
(-)-N-Formylanonaine from Michelia alba as a human tyrosinase inhibitor and antioxidant.
AID18233Biodistribution of [225Ac]-labeled compound in normal mice liver after 1 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID18224Biodistribution of [225Ac]-labeled compound in normal mice heart after 120 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1173791Metal chelating activity of the compound assessed as formation of iron complex after 20 mins by spectrophotometry2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Antioxidant and antimicrobial studies on fused-ring pyrazolones and isoxazolones.
AID373169Induction of cell lysis in Pseudoalteromonas ER72M2 assessed as decrease in culture turbidity in presence of buffer containing Tris-HCL and NaCl2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Polymyxin B induces lysis of marine pseudoalteromonads.
AID210781Ability to remove iron from transferrin, at a concentration of 0.2 mM, expressed as % iron removal in 30 minutes1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Ferric ion sequestering agents. 11. Synthesis and kinetics of iron removal from transferrin of catechoyl derivatives of desferrioxamine B.
AID1770022Zinc chelation-dependent inhibition of IMP-4 (unknown origin) expressed in Escherichia coli BL21 (DE3) using imipenem as substrate preincubated with enzyme for 5 to 10 mins followed by substrate addition
AID377021Antispasmodic activity in guinea pig ileum assessed as inhibition of acetylcholine-induced contraction at 1000 uM2006Journal of natural products, Jun, Volume: 69, Issue:6
Spasmolytic effects of nonprenylated rotenoid constituents of Boerhaavia diffusa roots.
AID374027Inhibition of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID1169669Inhibition of full-length recombinant human MMP-13 assessed as prevention of bovine type-2 collagen degradation at 50 uM after 18 hrs by cartilage explant assay2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID18238Biodistribution of [225Ac]-labeled compound in normal mice spleen after 24 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1880752Induction of outer membrane permeabilization in Escherichia coli ATCC 10536 assessed as crystal violet uptake at 0.25 M incubated for 60 mins by crystal violet staining based UV-VIS spectrophotometer ( Rvb = 56%)2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
Antibacterial Nanoassembled Calix[4]arene Exposing Choline Units Inhibits Biofilm and Motility of Gram Negative Bacteria.
AID18220Biodistribution of [225Ac]-labeled compound in normal mice bone after 120 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID18227Biodistribution of [225Ac]-labeled compound in normal mice heart after 4 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID210778Ability to remove iron from human iron transport protein transferrin, at a concentration of 500 mM, expressed as % iron removal in 30 minutes1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Ferric ion sequestering agents. 11. Synthesis and kinetics of iron removal from transferrin of catechoyl derivatives of desferrioxamine B.
AID1395986Induction of biofilm eradication of methicillin-resistant Staphylococcus epidermidis ATCC 35984 after 24 hrs by calgary biofilm device method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1824261Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 10 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID769911Inhibition of amyloid beta aggregation (unknown origin) after 4 hrs by thioflavin S assay in absence of Zn2+2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.
AID340739Inhibition of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) using nitrocefin reporter substrate2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID278744Antimicrobial activity against Candida parapsilosis in silicone disk biofilm at 30 mg/ml after 60 mins2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID1405921Antioxidant activity assessed as DPPH radical scavenging activity relative to control2018European journal of medicinal chemistry, Aug-05, Volume: 156Current progress on antioxidants incorporating the pyrazole core.
AID1847343Inhibition of NDM-1 (unknown origin)2021European journal of medicinal chemistry, Nov-05, Volume: 223Recent research and development of NDM-1 inhibitors.
AID18219Biodistribution of [225Ac]-labeled compound in normal mice blood after 4 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID18232Biodistribution of [225Ac]-labeled compound in normal mice liver after 120 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID278733Antimicrobial activity against Candida parapsilosis embedded in MRD biofilm at 30 mg/ml after 15 mins in drug assessed as 24 hr regrowth2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID1322146Metal chelating activity assessed as Fe2+-compound complex fromation incubated for 5 mins in presence of ferrous chloride hexahydrate followed by ferrozine addition measured after 10 mins2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thioflavones as novel neuroprotective agents.
AID278726Antimicrobial activity against methicillin-resistant Staphylococcus aureus embedded in MRD biofilm model at 30 mg/ml after 15 mins2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID530343Inhibition of Pseudomonas aeruginosa VIM-1 beta-lactamase after 10 mins2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID18241Biodistribution of [225Ac]-labeled compound in normal mice kidney after 4 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1902192Inhibition of bacterial NDM-1 using CDC-1 as substrate incubated for 30 mins2022European journal of medicinal chemistry, Mar-15, Volume: 232Stereochemically altered cephalosporins as potent inhibitors of New Delhi metallo-β-lactamases.
AID427662Antioxidant activity assessed as ferrous ion chelating effect after 10 mins2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins.
AID1683482Inhibition of Collagenase (unknown origin) using FALGPA as substrate incubated for 20 mins followed by substrate addition and measured after 60 mins2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Xanthones for melanogenesis inhibition: Molecular docking and QSAR studies to understand their anti-tyrosinase activity.
AID574481Induction of outer membrane permeabilization of Klebsiella pneumoniae ATCC 13883 at 0.5 to 2 mg/mL by DiS-C2 dye based fluorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins.
AID18235Biodistribution of [225Ac]-labeled compound in normal mice liver after 4 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1770058Zinc chelation-dependent inhibition of NDM-1 (unknown origin) expressed in Escherichia coli DH5 alpha using meropenem as substrate preincubated with enzyme for 5 mins followed by substrate addition in the presence of zinc sulfate
AID1451136Fluorescence quenching activity assessed as reduction in tryptophan fluorescence up to 32 uM after 30 mins by luminescence spectrometric method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1684113Antibacterial activity against Escherichia coli DH5alpha assessed as MIC of meropenem at 32 mg/L by CLSI based broth microdilution method (Rvb < 0.25 mg/L)2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1898396Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-1707 assessed as bacterial growth inhibition incubated for 16 hrs by broth microdilution susceptibility test2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID1824260Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 30 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1458286Iron chelating activity in ammonium acetate buffer assessed as inhibition of [Fe(ferrozine)3]2+ formation at 100 uM at pH 6.7 measured after 10 mins by spectrophotometric analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Development of a Mitochondriotropic Antioxidant Based on Caffeic Acid: Proof of Concept on Cellular and Mitochondrial Oxidative Stress Models.
AID1784488Metal chelating activity assessed as compound-Fe2+ complex formation at 3 mM in presence of FeCl2 by UV-Vis spectra analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
AID1770020Zinc chelation-dependent inhibition of NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) using meropenem as substrate preincubated with enzyme for 5 to 10 mins followed by substrate addition
AID278727Antimicrobial activity against methicillin-resistant Staphylococcus aureus embedded in MRD biofilm model at 30 mg/ml after 15 mins in drug assessed as 24 h regrowth2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID1395973Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-1707 after 16 to 18 hrs by broth microdilution method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID682760Inhibition of recombinant Pseudomonas aeruginosa MBL IMP-1 using nitrocefin as substrate after 12 hrs by UV-spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-β-lactamases.
AID682761Inhibition of Bacillus anthracis MBL Bla2 using nitrocefin as substrate after 12 hrs by UV-spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-β-lactamases.
AID1684114Inhibition of Escherichia coli DH5alpha NDM-1 assessed as MIC of meropenem at 8 mg/L by CLSI based microdilution method (Rvb = 8 mg/L)2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors.
AID1684115Inhibition of Escherichia coli DH5alpha NDM-1 assessed as MIC of meropenem at 32 mg/L by CLSI based microdilution method (Rvb = 8 mg/L)2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors.
AID1330766Inhibition of Cu2+-amyloid beta (1 to 42 residues)-induced increase in H2O2 production at 800 nM after 30 mins by HRP/Amplex red assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
AID278745Antimicrobial activity against Candida parapsilosis in silicone disk biofilm at 30 mg/ml after 60 mins in drug assessed as 24 h regrowth2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1395985Bactericidal activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 planktonic cells after 24 hrs by calgary biofilm device method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID271702Increase in Fe(2+)-mediated hydroxyl radical production measured as hydroxylation of benzoate at IBE of 1 relative to control2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.
AID1451128Binding affinity to bacterial CoCoNDM-1 expressed in Escherichia coli BL21(DE3) assessed as metal stripping at 1 to 2 equiv after 30 mins by UV-Visible spectroscopic method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID18225Biodistribution of [225Ac]-labeled compound in normal mice heart after 1 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1898408Bactericidal activity against methicillin-resistant Staphylococcus aureus BAA-1707 planktonic cells assessed as planktonic eradication incubated for 24 hrs followed by incubation for overnight in fresh medium by Calgary biofilm device assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1898413Antibiofilm activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 biofilms assessed as biofilm eradication incubated for 24 hrs followed by incubation for 24 hrs in fresh medium by Calgary biofilm device assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID18230Biodistribution of [225Ac]-labeled compound in normal mice kidney after 24 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1543579Metal chelating activity assessed as inhibition of Cu(II)/ascorbate-induced ROS production at 100 uM measured at 20 secs interval for 1000 secs by fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease.
AID278738Antimicrobial activity against methicillin-resistant Staphylococcus aureus in silicone disk biofilm at 30 mg/ml after 60 mins2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID1784504Metal chelating activity assessed as compound-Cu2+ complex formation at ratio of 0.5:1 by pyrocatechol violet assay2021European journal of medicinal chemistry, Dec-05, Volume: 225From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
AID1504224Metal chelating activity assessed as compound-Fe2+ complex formation at 400 uM preincubated with ferrous ion FeCl2 followed by ferrozine addition measured after 10 mins by spectroscopic method2017European journal of medicinal chemistry, Dec-01, Volume: 141Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease.
AID18228Biodistribution of [225Ac]-labeled compound in normal mice kidney after 120 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID21034Partition coefficient(P) in octanol/water system1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
Partition coefficients (free ligands and their iron(III) complexes) and lipophilic behavior of new abiotic chelators. Correlation to biological activity.
AID1784502Metal chelating activity assessed as compound-Cu2+ complex formation at ratio of 2:1 by pyrocatechol violet assay2021European journal of medicinal chemistry, Dec-05, Volume: 225From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1317568Iron chelating activity assessed as Fe3+-compound complex-induced pro-oxidative activity by measuring ascorbate oxidation level at iron binding equivalent of 3 measured after 10 to 40 mins in presence of 500 uM citrate relative to control2016European journal of medicinal chemistry, Sep-14, Volume: 120Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.
AID1395980Induction of biofilm eradication of methicillin-resistant Staphylococcus aureus BAA-1707 after 24 hrs by calgary biofilm device method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1898417Antibiofilm activity against Enterococcus faecalis OG1RF ATCC 47077 biofilms assessed as biofilm eradication incubated for 24 hrs followed by incubation for 24 hrs in fresh medium by Calgary biofilm device assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID278732Antimicrobial activity against Candida parapsilosis embedded in MRD biofilm at 30 mg/ml after 15 mins2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID18226Biodistribution of [225Ac]-labeled compound in normal mice heart after 24 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1684112Antibacterial activity against Escherichia coli DH5alpha assessed as MIC of meropenem at 8 mg/L by CLSI based broth microdilution method (Rvb < 0.25 mg/L)2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1304831Antibacterial activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 assessed as biofilm eradication incubated for 24 hrs by CBD assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID18239Biodistribution of [225Ac]-labeled compound in normal mice spleen after 4 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID51033Concentration required for obtaining 50% of the fluorescence intensity of copper-free calcein 1, in bovine serum albumin2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
A green fluorescent chemosensor for amino acids provides a versatile high-throughput screening (HTS) assay for proteases.
AID751210Antioxidant activity assessed as inhibiton of Fe2+-induced Fenton reaction-mediated hydroxyl radical formation from H2O2 measured for 150 secs by ESR analysis in presence of DMPO2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists.
AID1395982Induction of biofilm eradication of methicillin-resistant Staphylococcus aureus 2 after 24 hrs by calgary biofilm device method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1574642Reversible inhibition of Plasmodium falciparum C-terminal His6-tagged M17 aminopeptidase (85 to 605 residues) expressed in Escherichia coli BL21(DE3) assessed as enzyme activity recovery at 2 mM preincubated followed by compound washout for 2 hrs and subs2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID18237Biodistribution of [225Ac]-labeled compound in normal mice spleen after 1 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID82763Inhibition of human DNA binding to HIV-EP1 (enhancer binding protein) at 4.0 mM concentration1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Novel zinc chelators which inhibit the binding of HIV-EP1 (HIV enhancer binding protein) to NF-kappa B recognition sequence.
AID374029Inhibition of Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID378146Inhibition of phosphodiesterase-12005Journal of natural products, Feb, Volume: 68, Issue:2
Bioactive constituents from Boswellia papyrifera.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1898400Antibacterial activity against Enterococcus faecalis OG1RF ATCC 47077 assessed as bacterial growth inhibition incubated for 16 hrs by broth microdilution susceptibility test2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
A Modular Synthetic Route Involving
AID1589200Inhibition of NDM4 in Escherichia coli ATCC 25922 assessed as potentiation of meropenem-induced antibacterial activity by measuring zone of inhibition by agar disk diffusion method (Rvb = 9.8 millimeter)2019European journal of medicinal chemistry, Apr-01, Volume: 167H
AID144354In vitro inhibition of N8-Acetylspermidine deacetylase from rat liver cytosol1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Inhibition of N8-acetylspermidine deacetylase by active-site-directed metal coordinating inhibitors.
AID1172496Inhibition of snake venom NPP1 using bis(p-nitrophenyl)phosphate preincubated for 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry, Nov-15, Volume: 22, Issue:22
Synthesis of triazole Schiff bases: novel inhibitors of nucleotide pyrophosphatase/phosphodiesterase-1.
AID1880753Induction of outer membrane permeabilization in Pseudomonas aeruginosa ATCC 9027 assessed as crystal violet uptake at 0.25 M incubated for 60 mins by crystal violet staining based UV-VIS spectrophotometer ( Rvb = 53%)2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
Antibacterial Nanoassembled Calix[4]arene Exposing Choline Units Inhibits Biofilm and Motility of Gram Negative Bacteria.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID530344Inhibition of Pseudomonas aeruginosa VIM-13 beta-lactamase after 10 mins2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID18222Biodistribution of [225Ac]-labeled compound in normal mice bone after 24 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1451123Binding affinity to bacterial CoCoNDM-1 expressed in Escherichia coli BL21(DE3) assessed as metal stripping at 1 to 2 equiv by 1H NMR spectroscopic method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1395989Hemolytic activity in human RBC at 200 uM after 1 hr relative to control2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID18236Biodistribution of [225Ac]-labeled compound in normal mice spleen after 120 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1300895Metal chelating activity of the compound assessed as ferrous ion complex formation after 10 mins2016European journal of medicinal chemistry, Jul-19, Volume: 117Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID1784501Metal chelating activity assessed as compound-Cu2+ complex formation at ratio of 5:1 by pyrocatechol violet assay2021European journal of medicinal chemistry, Dec-05, Volume: 225From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
AID1395981Bactericidal activity against methicillin-resistant Staphylococcus aureus 2 planktonic cells after 24 hrs by calgary biofilm device method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1543110Inhibition of Cobetia marina ALP using pNPP as substrate2019Journal of natural products, 06-28, Volume: 82, Issue:6
Guitarrins A-E and Aluminumguitarrin A: 5-Azaindoles from the Northwestern Pacific Marine Sponge Guitarra fimbriata.
AID1304844Induction of hemolysis in human RBC at 200 uM incubated for 1 hr2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID18217Biodistribution of [225Ac]-labeled compound in normal mice blood after 1 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID271695Increase in Fe(3+)-mediated ascorbate oxidation at IBE of 3 relative to control2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.
AID374028Inhibition of Enterobacter cloacae IMI1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID1451130Binding affinity to bacterial NDM-1 expressed in Escherichia coli BL21(DE3) assessed as Zn2+ stripping up to 128 uM after 30 mins by equilibrium dialysis method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID271700Increase in Fe(2+)-mediated hydroxyl radical production measured as hydroxylation of benzoate at IBE of 3 relative to control2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.
AID1350116Inhibition of ACE (unknown origin) using hippuryl-L-histidyl-L-leucine as substrate preincubated with substrate for 30 mins followed by enzyme addition measured after 30 mins by LC/MS analysis2018Journal of natural products, 02-23, Volume: 81, Issue:2
Metabolomics-Guided Discovery of Microginin Peptides from Cultures of the Cyanobacterium Microcystis aeruginosa.
AID18229Biodistribution of [225Ac]-labeled compound in normal mice kidney after 1 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1770059Zinc chelation-dependent inhibition of IMP-1 (unknown origin) expressed in Escherichia coli DH5 alpha using imipenem as substrate preincubated with enzyme for 5 mins followed by substrate addition in the presence of zinc sulfate
AID18223Biodistribution of [225Ac]-labeled compound in normal mice bone after 4 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID1589199Inhibition of IMP-4 in Escherichia coli ATCC 25922 assessed as potentiation of meropenem-induced antibacterial activity by measuring zone of inhibition by agar disk diffusion method (Rvb = 9.7 millimeter)2019European journal of medicinal chemistry, Apr-01, Volume: 167H
AID1784503Metal chelating activity assessed as compound-Cu2+ complex formation at ratio of 1:1 by pyrocatechol violet assay2021European journal of medicinal chemistry, Dec-05, Volume: 225From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
AID1245381Metal chelating activity of the compound assessed as reduction of Cu2+-amyloid beta (1 to 42)-complex induced H2O2 production from ascorbate at 800 nM after 30 mins by HRP/Amplex Red assay relative to control2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Multifunctional novel Diallyl disulfide (DADS) derivatives with β-amyloid-reducing, cholinergic, antioxidant and metal chelating properties for the treatment of Alzheimer's disease.
AID644237Inhibition of Bothrops atrox venom phosphodiesterase-1 assessed as conversion of p-nitrophenyl phosphate to p-nitrophenol using bis(p-nitropheny1) phosphate as substrate preincubated for 30 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
6-Nitrobenzimidazole derivatives: potential phosphodiesterase inhibitors: synthesis and structure-activity relationship.
AID278739Antimicrobial activity against methicillin-resistant Staphylococcus aureus in silicone disk biofilm at 30 mg/ml after 60 mins in drug assessed as 24 h regrowth2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1824262Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 3 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1256112Antioxidant activity assessed as inhibition of Fe2+-induced DMPO-OH adduct formation from H2O2 preincubated for 30 secs followed by DMPO/H2O2 addition measured after 150 secs by ESR analysis2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Identification of Highly Promising Antioxidants/Neuroprotectants Based on Nucleoside 5'-Phosphorothioate Scaffold. Synthesis, Activity, and Mechanisms of Action.
AID1322147Metal chelating activity assessed as Fe2+-compound complex fromation at 3 uM incubated for 5 mins in presence of ferrous chloride hexahydrate followed by ferrozine addition measured after 10 mins2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thioflavones as novel neuroprotective agents.
AID271694Increase in Fe(3+)-mediated ascorbate oxidation at IBE of 1 relative to control2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.
AID1770021Zinc chelation-dependent inhibition of VIM-2 (unknown origin) expressed in Escherichia coli BL21 (DE3) using nitrocefin as substrate preincubated with enzyme for 5 to 10 mins followed by substrate addition
AID18218Biodistribution of [225Ac]-labeled compound in normal mice blood after 24 hr1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Improved in vivo stability of actinium-225 macrocyclic complexes.
AID82760Inhibition of human DNA binding to HIV-EP1 (enhancer binding protein) at 1.0 mM concentration1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Novel zinc chelators which inhibit the binding of HIV-EP1 (HIV enhancer binding protein) to NF-kappa B recognition sequence.
AID82757Inhibition of human DNA binding to HIV-EP1 (enhancer binding protein) at 0.7 mM concentration1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Novel zinc chelators which inhibit the binding of HIV-EP1 (HIV enhancer binding protein) to NF-kappa B recognition sequence.
AID1770060Zinc chelation-dependent inhibition of VIM-2 (unknown origin) expressed in Escherichia coli DH5 alpha using nitrocefin as substrate preincubated with enzyme for 5 mins followed by substrate addition in presence of zinc sulfate
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1369006Inhibition of NDM1 in Escherichia coli assessed as potentiation of meropenem-induced antibacterial activity by measuring meropenem inhibition zone at 0.1mol/L incubated for 16 to 18 hrs by CLSI protocol based disc diffusion method (Rvb = 10.76 mm)2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26,351)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014335 (54.40)18.7374
1990's3914 (14.85)18.2507
2000's3769 (14.30)29.6817
2010's3266 (12.39)24.3611
2020's1067 (4.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.12 (24.57)
Research Supply Index10.25 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index107.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.79%)5.53%
Trials629 (2.28%)5.53%
Reviews7 (6.25%)6.00%
Reviews539 (1.96%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies803 (2.91%)4.05%
Observational0 (0.00%)0.25%
Observational7 (0.03%)0.25%
Other103 (91.96%)84.16%
Other25,575 (92.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (86)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single Arm Phase II Study of Bone-Targeted Sn-117m-DTPA in Symptomatic Castration Resistant Prostate Cancer With Skeletal Metastases [NCT04616547]Phase 21 participants (Actual)Interventional2021-12-18Active, not recruiting
In-vivo Comparison of Antibacterial Efficacy of Three Different Solutions as Final Irrigant During Endodontic Therapy: A Randomized Controlled Trial [NCT03853200]Phase 2/Phase 390 participants (Actual)Interventional2017-04-03Completed
Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma [NCT04176016]Phase 120 participants (Anticipated)Interventional2020-01-10Recruiting
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients [NCT03803475]Phase 3485 participants (Actual)Interventional2018-10-11Completed
Investigator Initiated Investigational New Drug Application to Study the Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease [NCT02947022]Phase 1/Phase 21 participants (Actual)Interventional2016-10-31Terminated(stopped due to PI left institution.)
Double-blind, Randomized, Phase III Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of Three Consecutive Doses of dTpa, or of dTpa-IPV Followed by Two Doses of Td Vaccine , and Compared to Three Consecutive Doses of Td Vaccine Administere [NCT01294605]Phase 4460 participants (Actual)Interventional2003-04-30Completed
68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA [NCT02673151]Phase 2/Phase 361 participants (Actual)Interventional2017-05-20Completed
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer [NCT05034562]Phase 20 participants (Actual)Interventional2022-09-26Withdrawn(stopped due to Per PI no participants enrolled)
Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence [NCT03353740]Phase 3346 participants (Actual)Interventional2017-09-20Completed
Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy [NCT03515577]Phase 250 participants (Actual)Interventional2019-04-12Completed
Impact of 68GA-PSMA-11 PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer [NCT04050215]Phase 2937 participants (Actual)Interventional2018-04-02Completed
A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients With First-line mCRC [NCT03654729]Phase 3291 participants (Actual)Interventional2018-11-07Terminated(stopped due to On 23 January 2020, the Sponsor announced that the United States (US) Food and Drug Administration (FDA) had issued a clinical hold in the US of the POLAR program.)
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence [NCT03389451]Phase 2/Phase 340 participants (Anticipated)Interventional2018-02-16Active, not recruiting
Iron Absorption From Wheat Flour in Haiti [NCT02096250]44 participants (Actual)Interventional2014-06-30Completed
Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients [NCT02611882]Phase 2225 participants (Actual)Interventional2015-12-18Completed
Radiologic Detection and Characterization of Benign and Malignant Liver Lesions in Contrast-Enhanced MRI [NCT02156739]100 participants (Actual)Interventional2014-10-13Active, not recruiting
The Efficacy of 2780 nm Er,Cr;YSGG and 940 nm Diode Laser in Root Canal Disinfection: A Randomized Clinical Trial [NCT05964686]Phase 230 participants (Actual)Interventional2022-01-01Completed
MultiGFR: Equivalency Study of Different Methods of Measuring Glomerular Filtration Rate [NCT02286258]Phase 1/Phase 2166 participants (Actual)Interventional2014-10-31Terminated(stopped due to The study was suspended after a suspected unexpected serious adverse event.)
68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients [NCT03388346]Phase 2/Phase 340 participants (Anticipated)Interventional2018-02-16Active, not recruiting
Designing a Bayesian Model of the Plasma Clearance of Calcium Edetate de Sodium, With a Limited Sampling Strategy for the Calculation of Glomerular Filtration Rate (GFR) and Validity Assessment Compared to the Renal Clearance of Inulin : DFGBay [NCT02300376]Phase 330 participants (Actual)Interventional2014-12-31Completed
Trial to Assess Chelation Therapy (TACT) [NCT00044213]Phase 31,708 participants (Actual)Interventional2003-09-30Completed
New Imaging Modalities in the Evaluation of Patients With Ectopic Cushing's Syndrome [NCT00001849]Phase 295 participants (Actual)Interventional1999-05-20Completed
68Ga-PSMA-11 PET in Patients With Prostate Cancer [NCT04777071]Phase 2213 participants (Anticipated)Interventional2021-05-17Recruiting
Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer [NCT05415228]0 participants Expanded AccessNo longer available
Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging [NCT04750473]Phase 122 participants (Actual)Interventional2021-07-16Active, not recruiting
Immunogenicity and Safety of GSK Biological's DTPa-HBV-IPV/Hib Vaccine or DTPa-IPV/Hib Co-administered With HBV Vaccine as Primary and Booster Vaccination in Healthy Infants Born to Hepatitis B Surface Antigen Negative Mothers [NCT00880477]Phase 3140 participants (Actual)Interventional2001-01-31Completed
Early Detection, Accurate Staging, and Biologic Characterization of HCC With Hybrid 68Ga-PSMA-Dual -Contrast PET/MRI and PET/CT Using Cyclotron-Produced 68Ga [NCT04762888]Phase 260 participants (Anticipated)Interventional2021-02-24Recruiting
[NCT02429817]6 participants (Actual)Interventional2015-04-30Completed
Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT With 99mTc-MDP Bone Scan and CT for Detection of M1b Disease in Prostate Cancer Patients With Biochemical Progression During ADT [NCT04928820]Phase 222 participants (Actual)Interventional2021-06-16Terminated(stopped due to slow recruitment)
Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (C [NCT01101412]Phase 1/Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to Study was not opened.)
High Precision Stereotactic Radiotherapy to the Whole Prostate With Focal Boost and Varying Hormonal Therapy (HEATWAVE) [NCT06067269]Phase 295 participants (Anticipated)Interventional2023-12-01Not yet recruiting
PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in Patients With Non-Prostate Cancers: An Exploratory Biodistribution Study With Histopathology Validation [NCT04147494]Early Phase 130 participants (Anticipated)Interventional2019-11-05Recruiting
Optimizing Outcomes of Patients With Advanced HCC Undergoing Immunotherapy Through Novel 68Ga PSMA PET Imaging [NCT05176223]Phase 230 participants (Anticipated)Interventional2022-01-25Recruiting
MR Techniques in the Evaluation of Hepatocellular Carcinoma: Gadoxetate [NCT02578602]Phase 126 participants (Actual)Interventional2010-10-31Completed
DTPA Chelation for Symptoms After Gadolinium-assisted MRI [NCT05359835]Early Phase 16 participants (Anticipated)Interventional2023-04-11Recruiting
Post-operative Pain After Laser Root Canal Treatment of Necrotic Teeth With Apical Periodontitis: A Randomized Clinical Trial [NCT06129643]Phase 230 participants (Actual)Interventional2022-01-01Completed
Evaluation of Bacterial and Fungal Contamination During Propofol Continuous Infusion in Patients Undergoing General Anesthesia [NCT00757458]652 participants (Anticipated)Interventional2008-12-31Not yet recruiting
Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence [NCT03822845]Phase 2/Phase 3240 participants (Anticipated)Interventional2019-03-01Active, not recruiting
A Pilot Prospective Comparison of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients [NCT05034783]Early Phase 120 participants (Actual)Interventional2021-10-01Active, not recruiting
A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer [NCT04216134]Phase 119 participants (Actual)Interventional2019-12-12Completed
68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy [NCT02940262]Phase 31,138 participants (Actual)Interventional2016-09-15Completed
Assess Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Admnd at 3 & 4 Mths & DTPa-HBV-IPV/Hib Vaccine Admnd at 5 Mths, Followed by DTPa-IPV/Hib Vaccine at 18 Mths in Infants Who Received hepatitisB Vaccine at Birth & at One Month of Age [NCT00325143]Phase 3702 participants (Actual)Interventional2003-12-01Completed
A Multicentric Study to Compare the Immunogenicity, Safety & Reactogenicity of GSK Biologicals' DTPa-IPV Vaccine vs. Co-administration of GSK's DTPa Vaccine & Sanofi-Pasteurs' IPV Vaccine at Different Injection Sites, to Healthy Children [NCT00290342]Phase 3458 participants (Actual)Interventional2006-01-01Completed
[NCT01879488]19 participants (Actual)Interventional2013-07-31Completed
Long-Term Repeated Lead Chelation Therapy in Non-Diabetic Patients With Chronic Renal Insufficiency and High-Normal Body Lead Burden [NCT00227409]0 participants Interventional2001-11-30Completed
Evaluation of 68Ga-PSMA-11 PET Guided Prostate Biopsy in Men With Suspicion of Clinically Significant Prostate Cancer and Prior Negative/Inconclusive Biopsy: A Prospective Exploratory Study [NCT05160597]Early Phase 130 participants (Anticipated)Interventional2022-01-13Recruiting
Evaluate the Immunogenicity, Reactogenicity, Safety of 4 Different Formulations of GSK Biologicals' Conjugate Vaccine (MenACWY) vs 1 Dose of MenC-CRM197 or Mencevax™ ACWY in Children Aged 12-14 Months & 3-5 Years [NCT00196976]Phase 2461 participants (Actual)Interventional2005-03-24Completed
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy [NCT03630991]Phase 158 participants (Anticipated)Interventional2018-10-11Recruiting
The Clinical Comparative Evaluation of Different Final Irrigation Protocols on Postoperative Endodontic Pain In Devital Teeth: A Prospective Randomized Clinical Trial [NCT04310254]90 participants (Actual)Interventional2019-09-01Completed
68Ga-PSMA-11 PET/CT for Staging of Intermediate and High Risk Prostate Cancer Prior to Radical Prostatectomy [NCT03368547]400 participants (Actual)Interventional2016-12-12Completed
Vorinostat to Augment Response to Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer [NCT06145633]Phase 215 participants (Anticipated)Interventional2024-04-01Not yet recruiting
PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease [NCT00714064]Phase 3227 participants (Actual)Interventional2006-06-30Completed
A Multi-center, Double-blind, Randomized, Controlled Study to Determine the Efficacy and Safety of a New Formulation of Acetylcysteine Injection [NCT01118663]Phase 317 participants (Actual)Interventional2010-09-30Terminated
Evaluation by 68Ga-PSMA-11 PET Imaging of Monosodium Glutamate as a Potential Agent for Salivary Gland Protection Under PSMA-targeted Alpha-therapy: a Randomized Pilot Imaging Research Study [NCT04282824]Early Phase 114 participants (Actual)Interventional2019-06-05Completed
68Ga-PSMA-11 PET/CT for Screening Prior to 177Lu-PSMA-617 Therapy [NCT05547386]Phase 3250 participants (Anticipated)Interventional2022-05-09Enrolling by invitation
Development and Validation of Innovative Hybrid Molecular Imaging, 68Ga-PSMA-Dual Contrast PET/MRI and 68Ga-PSMA PET/CT, to Transform the Care of Patients With Hepatocellular Carcinoma [NCT04310540]Early Phase 160 participants (Anticipated)Interventional2020-06-05Recruiting
Pre-Surgical Treatment or Radio Frequency Ablation (RFA) Evaluation of Future Remnant Liver Function Using Gd-EOB-DTPA Enhanced MRI in Patients Undergoing Hepatic Resection /RFA for Hepatocellular Carcinoma [NCT01490203]71 participants (Actual)Observational2011-12-31Completed
Abbreviated MRI (AMRI) vs. Ultrasound for HCC Surveillance in Cirrhosis [NCT04288323]Phase 4150 participants (Anticipated)Interventional2018-04-27Recruiting
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas [NCT01469975]Phase 120 participants (Actual)Interventional2011-12-31Terminated(stopped due to Too slow accrual.)
Phase III Randomized Multicenter Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT] [NCT03582774]Phase 3193 participants (Anticipated)Interventional2018-07-12Active, not recruiting
A Phase 2 Comparison Study of 68Ga-PSMA-HBED-CC Positron Emission Tomography (PET)/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer [NCT03439033]Phase 2273 participants (Actual)Interventional2018-04-03Terminated(stopped due to Study Drug was FDA approved Summer 2021)
[NCT00001575]Phase 1/Phase 287 participants (Actual)Interventional1997-04-30Completed
Pilot Trial of Limb Preservation Using Chelation Therapy in Diabetic Patients With Critical Limb Ischemia [NCT03424746]Early Phase 111 participants (Actual)Interventional2015-08-31Completed
Gallium-68 Prostate Specific Membrane Antigen for Ovarian Cancer: A Pilot Feasibility Study [NCT03857087]7 participants (Actual)Observational2018-04-02Completed
Trial to Assess Chelation Therapy in Critical Limb Ischemia [NCT03982693]Phase 350 participants (Anticipated)Interventional2019-03-19Recruiting
A Phase II Study Evaluating Panitumumab-IRDye800 vs. Sentinel Node Biopsy and (Selective) Neck Dissection for Metastatic Lymph Node Identification in Patients With Head and Neck Cancer [NCT03405142]Phase 23 participants (Actual)Interventional2019-08-01Completed
Role of the BMP Pathway in Myelodysplastic Syndromes Progression and in the Transition to Acute Myeloid Leukemia [NCT06175923]60 participants (Anticipated)Observational2023-12-13Not yet recruiting
Early Screening and Diagnosis of Chronic Kidney Disease [NCT02841371]1,000 participants (Anticipated)Observational2009-08-01Recruiting
Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients [NCT02919111]Phase 2/Phase 3299 participants (Actual)Interventional2016-09-23Completed
Pulmonary Functional Imaging for Radiation Treatment Planning [NCT01982123]12 participants (Actual)Interventional2014-01-17Completed
Intraindividual Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMAPET/CT in Patients With HCC: Pilot Study [NCT05111314]Early Phase 10 participants (Actual)Interventional2022-02-11Withdrawn(stopped due to PI requested)
Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Vaccine Mixed With Hib Vaccine to Healthy Infants at 3, 5 and 11 Months of Age, Compared to Each Vaccine Administered Separately [NCT01457508]Phase 3440 participants (Actual)Interventional1999-01-31Completed
Study to Assess Immunogenicity and Reactogenicity of SB Biologicals' DTPa-HBV-IPV/Hib Vaccine Given as Three-dose Primary Vaccination Course Compared to DTPa-IPV/Hib and HBV Administered Concomitantly at Separate Sites [NCT01457495]Phase 2312 participants (Actual)Interventional1998-09-30Completed
Intrabony Defects Management Using Growth Factor Enhanced Matrix Versus Platelet Rich Fibrin Utilizing Minimally Invasive Surgical Technique. A Randomized Clinical and Radiographic Trial. [NCT04786327]Phase 221 participants (Actual)Interventional2018-01-01Completed
Effects of Novel Androgen Receptor Signaling Inhibitors on PSMA PET Signal Intensity in Patients With Castrate-Resistant Prostate Cancer: A Prospective Exploratory Study [NCT04279561]Phase 19 participants (Actual)Interventional2020-04-16Terminated(stopped due to slow accrual)
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence [NCT02918357]Phase 2/Phase 3385 participants (Actual)Interventional2016-09-15Completed
Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age [NCT01457547]Phase 4494 participants (Actual)Interventional2003-10-31Completed
Trial to Assess Chelation Therapy 2 [NCT02733185]Phase 31,000 participants (Actual)Interventional2016-10-31Completed
68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study [NCT02488070]Phase 1/Phase 210 participants (Actual)Interventional2015-06-30Completed
Renal Perfusion, Filtration and Oxygenation After Liver Transplantation -Effects of av Postoperative Blood Pressure [NCT02455115]12 participants (Actual)Interventional2015-01-31Completed
[NCT02450279]20 participants (Anticipated)Interventional2016-03-31Terminated(stopped due to Never started)
Prolonged Gadolinium Retention After MRI Imaging in Patients With Normal Renal Function [NCT02421029]Phase 40 participants (Actual)Interventional2017-07-31Withdrawn(stopped due to it was logistically difficult to obtain the drug needed to conduct the study)
Phenotypic Spectrum of Circulating Tumor Cell Populations as Markers of Liquid Biopsy in Tumors of the Female Reproductive System [NCT04817501]150 participants (Actual)Observational2014-02-14Completed
A Double Blinded Randomised Three Armed Phase II Trial of PledOx in Two Different Doses in Combination With FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Advanced Metastatic Colorectal (Stage IV) Cancer [NCT01619423]Phase 1/Phase 2186 participants (Actual)Interventional2012-09-30Completed
Role Of Wound Lavage in Direct Pulp Capping Of Permanent Teeth With Carious Exposure: A Randomized Controlled Trial [NCT05878249]140 participants (Anticipated)Interventional2022-11-01Active, not recruiting
[NCT02298101]6 participants (Actual)Interventional2014-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00001575 (3) [back to overview]Clinical Response
NCT00001575 (3) [back to overview]Number of Participants With Adverse Events
NCT00001575 (3) [back to overview]Maximum Tolerated Dose (MTD) of 90Y-HAT
NCT00001849 (2) [back to overview]Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Specific Lesions
NCT00001849 (2) [back to overview]Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients
NCT00044213 (2) [back to overview]A Composite of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke.
NCT00044213 (2) [back to overview]A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina.
NCT00196976 (30) [back to overview]Number of Seroprotected Subjects Against Different Meningococcal Serogroups
NCT00196976 (30) [back to overview]Number of Toddlers With Any Solicited Local Symptoms
NCT00196976 (30) [back to overview]Number of Toddlers With Any Solicited General Symptoms
NCT00196976 (30) [back to overview]Number of Subjects With Any Solicited Local Symptoms
NCT00196976 (30) [back to overview]Number of Subjects With Any Solicited General Symptoms
NCT00196976 (30) [back to overview]Number of Subjects With SAEs
NCT00196976 (30) [back to overview]Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination
NCT00196976 (30) [back to overview]Number of Subjects With Any Unsolicited AEs
NCT00196976 (30) [back to overview]Number of Subjects With an Immune Response to Different Meningococcal Serogroups
NCT00196976 (30) [back to overview]Number of Seropositive Subjects for Anti-tetanus (Anti-T)
NCT00196976 (30) [back to overview]Number of Seroprotected Subjects Against Different Meningococcal Serogroups
NCT00196976 (30) [back to overview]Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides
NCT00196976 (30) [back to overview]Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides
NCT00196976 (30) [back to overview]Number of Seropositive Subjects for Different Anti-meningococcal Serogroups
NCT00196976 (30) [back to overview]Number of Seropositive Subjects for Different Anti-meningococcal Serogroups
NCT00196976 (30) [back to overview]Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides
NCT00196976 (30) [back to overview]Number of Subjects With Any Unsolicited AEs During the Primary Vaccination
NCT00196976 (30) [back to overview]Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides
NCT00196976 (30) [back to overview]Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups
NCT00196976 (30) [back to overview]Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides
NCT00196976 (30) [back to overview]Number of Children With Any Solicited Local Symptoms
NCT00196976 (30) [back to overview]Number of Children With Any Solicited General Symptoms
NCT00196976 (30) [back to overview]Antibody Titers Against Different Meningococcal Serogroups
NCT00196976 (30) [back to overview]Antibody Titers Against Different Meningococcal Serogroups
NCT00196976 (30) [back to overview]Antibody Titers Against Different Meningococcal Serogroups
NCT00196976 (30) [back to overview]Antibody Concentrations Against Tetanus (Anti-T)
NCT00196976 (30) [back to overview]Antibody Concentrations Against Different Meningococcal Polysaccharides
NCT00196976 (30) [back to overview]Antibody Concentrations Against Different Meningococcal Polysaccharides
NCT00196976 (30) [back to overview]Number of Subjects With Serious Adverse Events (SAEs)
NCT00196976 (30) [back to overview]Antibody Concentrations Against Different Meningococcal Polysaccharides
NCT00290342 (12) [back to overview]Number of Subjects With Vaccine Response to Pertussis Toxoid (PT), Pertactin (PRN) and Filamentous Haemagglutinin (FHA) Antigens
NCT00290342 (12) [back to overview]Number of Subjects Reporting Any Serious Adverse Events (SAEs)
NCT00290342 (12) [back to overview]Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)
NCT00290342 (12) [back to overview]Concentration of Antibodies Against Diphteria (Anti-D) and Tetanus (Anti-T)
NCT00290342 (12) [back to overview]Concentrations of Antibodies Against Pertussis Toxoid (Anti-PT), Pertactin (Anti-PRN) and Filamentous Haemagglutinin (Anti-FHA)
NCT00290342 (12) [back to overview]Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T)
NCT00290342 (12) [back to overview]Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T)
NCT00290342 (12) [back to overview]Number of Seroprotected Subjects Against Poliovirus (Anti-polio) Types 1, 2 and 3
NCT00290342 (12) [back to overview]Number of Subjects Reporting Solicited General Symptoms
NCT00290342 (12) [back to overview]Number of Subjects Reporting Solicited Local Symptoms
NCT00290342 (12) [back to overview]Titers for Poliovirus Type 1, 2 and 3 Antibodies
NCT00290342 (12) [back to overview]Number of Subjects With a Vaccine Response for Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Haemagglutinin (Anti-FHA)
NCT00325143 (5) [back to overview]Number of Subjects Reporting Any Serious Adverse Events (SAEs)
NCT00325143 (5) [back to overview]Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)
NCT00325143 (5) [back to overview]Number of Subjects Reporting Any Solicited General Symptoms
NCT00325143 (5) [back to overview]Number of Subjects Reporting Any Solicited Local Symptoms
NCT00325143 (5) [back to overview]Number of Subjects Reporting Any Large Swelling Reactions
NCT01118663 (2) [back to overview]To Evaluate the Incidence of Treatment Emergent Adverse Events
NCT01118663 (2) [back to overview]To Evaluate the Incidence of Anaphylactoid Reaction.
NCT01619423 (1) [back to overview]Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia)
NCT01982123 (2) [back to overview]Radiation Dose With 50% Decrease in Lung Perfusion, Assessed Using 99mTc-MAA and 99mTc-DTPA SPECT/CT
NCT01982123 (2) [back to overview]Spatial Stability of Lung Perfusion and Ventilation Over Time, as Assessed Using 99mTc-MAA SPECT/CT
NCT02488070 (5) [back to overview]Feasibility of Ga-68 PSMA PET/CT or PET/MRI Scan
NCT02488070 (5) [back to overview]Average SUVmax Focal Uptake of Ga68 PSMA (F/N Ratio)
NCT02488070 (5) [back to overview]Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution
NCT02488070 (5) [back to overview]Average SUVmean Focal Uptake of Ga68 PSMA (F/N Ratio)
NCT02488070 (5) [back to overview]Average SUVmean of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution
NCT02611882 (6) [back to overview]Positive Predictive Value (PPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis
NCT02611882 (6) [back to overview]Negative Predictive Value (NPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis
NCT02611882 (6) [back to overview]Specificity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis
NCT02611882 (6) [back to overview]Overall Detection Rates of Ga68-PSMA-11 by PSA Levels for the BCR Group
NCT02611882 (6) [back to overview]Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases
NCT02611882 (6) [back to overview]Number of Patients in Biochemical Recurrence (BCR) Group Who Had a Reported Change in Medical Management
NCT02673151 (3) [back to overview]Overall 68Ga-PSMA-11 PET/CT Scan Quality Stratified by PSA Level
NCT02673151 (3) [back to overview]68Ga-PSMA-11 PET/CT Sensitivity and Specificity
NCT02673151 (3) [back to overview]68Ga-PSMA-11 PET/CT Predictive Value by Region
NCT02918357 (11) [back to overview]PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up
NCT02918357 (11) [back to overview]PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up
NCT02918357 (11) [back to overview]Safety Assessment - Heart Rate
NCT02918357 (11) [back to overview]Sensitivity on a Per-patient Basis
NCT02918357 (11) [back to overview]Sensitivity on a Per-region Basis
NCT02918357 (11) [back to overview]Safety Assessment - Blood Pressure
NCT02918357 (11) [back to overview]Inter-reader Agreement Per-region
NCT02918357 (11) [back to overview]Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value
NCT02918357 (11) [back to overview]Percentage of Participants With Change in Clinical Management
NCT02918357 (11) [back to overview]Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation
NCT02918357 (11) [back to overview]Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation
NCT02919111 (5) [back to overview]Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy
NCT02919111 (5) [back to overview]Number of Participants With Grade 3 Treatment-related Adverse Events
NCT02919111 (5) [back to overview]Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy
NCT02919111 (5) [back to overview]Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy
NCT02919111 (5) [back to overview]Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy
NCT03353740 (12) [back to overview]Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)
NCT03353740 (12) [back to overview]Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value
NCT03353740 (12) [back to overview]True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only
NCT03353740 (12) [back to overview]Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment
NCT03353740 (12) [back to overview]True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only
NCT03353740 (12) [back to overview]True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only
NCT03353740 (12) [back to overview]True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only
NCT03353740 (12) [back to overview]PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only
NCT03353740 (12) [back to overview]PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only
NCT03353740 (12) [back to overview]PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only
NCT03353740 (12) [back to overview]PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only
NCT03353740 (12) [back to overview]Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events
NCT03405142 (1) [back to overview]Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800
NCT03439033 (3) [back to overview]Number of Subjects With Pathologic Lesions Detected by PSMA PET and PET/CT Compared to MP MRI
NCT03439033 (3) [back to overview]Number of Pathological Lesions Detected by PSMA PET/MRI and PET/CT Compared to MP MRI in Prostate Cancer Patients With Biochemical Recurrence by Anatomical Region
NCT03439033 (3) [back to overview]Number of Pathological Lesions Detected by PSMA PET/MRI and PET/CT Compared to MP MRI in Prostate Cancer Patients With Biochemical Recurrence by Anatomical Region Stratified by PSA Level
NCT03654729 (10) [back to overview]Cumulative Dose of Oxaliplatin During Chemotherapy
NCT03654729 (10) [back to overview]Overall Response Rate (ORR)
NCT03654729 (10) [back to overview]Worst Pain in Hands or Feet
NCT03654729 (10) [back to overview]Vibration Sensitivity on the Lateral Malleolus
NCT03654729 (10) [back to overview]Sensitivity to Touching Cold Items
NCT03654729 (10) [back to overview]Progression-free Survival (PFS)
NCT03654729 (10) [back to overview]Overall Survival (OS)
NCT03654729 (10) [back to overview]Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT03654729 (10) [back to overview]Mild, Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT03654729 (10) [back to overview]Functional Impairment (in the Non-dominant Hand)
NCT03803475 (5) [back to overview]Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group
NCT03803475 (5) [back to overview]Detection Rate of PSMA-11 PET for Positive Disease in Bones (Osseous Lesions) by PSA Group
NCT03803475 (5) [back to overview]Detection Rate of PSMA-11 PET for Positive Disease in Distant Soft Tissues by PSA Group
NCT03803475 (5) [back to overview]Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group
NCT03803475 (5) [back to overview]Detection Rate of PSMA-11 PET for Positive Disease in Pelvic Nodes by PSA Group

Clinical Response

Clinical Response of patient is measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Tumor responses were evaluated by In-HAT imaging (i.e., simultaneous with administration of therapeutic 90Y-daclizumab), Fludeoxyglucose (18F) positron-emission tomography (FDG PET) scans and computed tomography (CT) scans. Complete response is a disappearance of all measurable and evaluable disease lasting more than I month. Partial response is a reduction by ≥ 50% of leukemic cell count or ≥ 50% reduction in the size of all measurable lesions, and no increase in size of any measurable or evaluable lesion or appearance of new lesions for 1 month. Stable disease is less than partial response with no more than a 25% increase in leukemic cell count, no new lesions, or less than a 25% increase in any measurable lesion. Progressive disease is at least a 25% increase in leukemic cell count, appearance of new lesions, or an increase of 25% or greater in any measurable lesion after 2 weeks. (NCT00001575)
Timeframe: Patient would be measured with computed tomography (CT) scan, Fludeoxyglucose (18F) positron-emission tomography (FDG PET) scan in 28 days before treatment. Patient would be evaluated with In-HAT imaging at Day 1,4,5,6 and Day 7 in week 1 of each cycle.

Interventionparticipants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressive Disease
Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)149149

[back to top]

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00001575)
Timeframe: 16 yrs 18 days

Interventionparticipants (Number)
Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)57

[back to top]

Maximum Tolerated Dose (MTD) of 90Y-HAT

Phase I portion maximum tolerated dose (MTD) is defined as the dose level below the dose at which 2 out of 2-6 patients develop DLT (if any patient develops grade IV toxicity of any type (excluding grade IV neutropenia) or grade III non-hematologic toxicity that patient may not continue on the study at the same dose level and therefore has had a dose limiting toxicity). There can be no more than 1 out of 6 patients with DLT at the MTD. The MTD will be assessed using only the results from the first cycle of therapy. (NCT00001575)
Timeframe: Patients could receive 90Y-HAT 15mCi per cycle and complete up to a maximum of 7 doses or 2 doses by the average of every 6 weeks.

Interventionmci (Number)
Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)15

[back to top]

Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Specific Lesions

The percentage of lesions for which imaging correctly identified an ACTH-secreting non-pituitary tumor within six months of resection or for which imaging identified a recurrence at a site of previous resection. (NCT00001849)
Timeframe: six months or less

Interventionpercentage of lesions (Number)
CT Scan Results75.4
MRI Results67.3
FDG-PET Results46.2
F-DOPA PET Results95.8
Standard Dose Pentetreotide Results40.4
High Dose (18 mCi) Octreotide Results40.9

[back to top]

Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients

The percentage of patients in whom imaging correctly identified an ACTH-secreting non-pituitary tumor within six months of resection or in which imaging identified a recurrence at a site of previous resection. (NCT00001849)
Timeframe: six months or less

Interventionpercentage of patients (Number)
CT Scan Results96.3
Magnetic Resonance Imaging (MRI) Results77.1
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Results66.7
[18F]-L-3,4-dihydroxyphenylalanine (18F-DOPA) PET Results100
Standard Dose Pentetreotide Results45.1
High Dose (18 mCi) Pentetreotide Results42.9

[back to top]

A Composite of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke.

Number of patients with events (composite of cardiovascular death, non-fatal MI, non-fatal stroke) Events were centrally adjudicated where available; otherwise site reported events were used. (NCT00044213)
Timeframe: Measured over a maximum 5-year follow-up period- 55 month median

Interventionparticipants (Number)
EDTA + High Dose Vitamin39
EDTA + High Dose Vitamin Placebo57
EDTA Placebo + High Dose Vitamin55
EDTA Placebo + High Dose Vitamin Placebo58

[back to top]

A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina.

Number of patients with events (composite of death from any cause, MI, stroke, coronary revascularization or hospitalization for angina) Events were centrally adjudicated where available; otherwise site reported events were used. (NCT00044213)
Timeframe: Measured over a maximum 5-year follow-up period- 55 month median

Interventionparticipants (Number)
EDTA + High Dose Vitamin108
EDTA + High Dose Vitamin Placebo114
EDTA Placebo + High Dose Vitamin122
EDTA Placebo + High Dose Vitamin Placebo139

[back to top]

Number of Seroprotected Subjects Against Different Meningococcal Serogroups

A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8. (NCT00196976)
Timeframe: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

,,,,,,,,,
InterventionParticipants (Count of Participants)
rSBA-MenA, Month 0rSBA-MenA, Month 1rSBA-MenC, Month 0rSBA-MenC, Month 1rSBA-MenW-135, Month 0rSBA-MenW-135, Month 1rSBA-MenY, Month 0rSBA-MenY, Month 1
Control (C), Primary Group3943144327443644
Control (T), Primary Group202333415152225
GSK134612A Form1 (C), Primary Group4150165034503751
GSK134612A Form1 (T), Primary Group233653617352335
GSK134612A Form2 (C), Primary Group424784724484248
GSK134612A Form2 (T), Primary Group223823819381738
GSK134612A Form3 (C), Primary Group4048174725483948
GSK134612A Form3 (T), Primary Group193022812301629
GSK134612A Form4 (C), Primary Group4750124936504250
GSK134612A Form4 (T), Primary Group213453513351935

[back to top]

Number of Toddlers With Any Solicited Local Symptoms

The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. (NCT00196976)
Timeframe: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose

,,,,
InterventionParticipants (Count of Participants)
Pain, Dose 1Redness, Dose 1Swelling, Dose 1Pain, Dose 2Redness, Dose 2Swelling, Dose 2
Control (T), Primary Group4114673
GSK134612A Form1 (T), Primary Group491373
GSK134612A Form2 (T), Primary Group812610137
GSK134612A Form3 (T), Primary Group3107699
GSK134612A Form4 (T), Primary Group696787

[back to top]

Number of Toddlers With Any Solicited General Symptoms

The toddlers subgroup received 2 primary vaccine doses, as follows: first dose of a meningococcal vaccine and second dose of a diphtheria, tetanus and acellular pertusis-containing vaccine. Assessed solicited general symptoms included drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination. (NCT00196976)
Timeframe: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose

,,,,
InterventionParticipants (Count of Participants)
Drowsiness, Dose 1Fever (Axillary), Dose 1Irritability, Dose 1Loss of appetite, Dose 1Drowsiness, Dose 2Fever (Axillary), Dose 2Irritability, Dose 2Loss of appetite, Dose 2
Control (T), Primary Group55563852
GSK134612A Form1 (T), Primary Group15412464
GSK134612A Form2 (T), Primary Group58962573
GSK134612A Form3 (T), Primary Group48653532
GSK134612A Form4 (T), Primary Group43537596

[back to top]

Number of Subjects With Any Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. (NCT00196976)
Timeframe: During the 8-day (Days 0-7) post-vaccination period following booster dose

,
InterventionParticipants (Count of Participants)
Any PainAny RednessAny Swelling
Control (T), Booster Group031
GSK134612A Form1 (T), Booster Group131

[back to top]

Number of Subjects With Any Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, fever [defined as rectal temperature equal to or above 38.0 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination. (NCT00196976)
Timeframe: During the 8-day (Days 0-7) post-vaccination period following booster dose

,
InterventionParticipants (Count of Participants)
Any DrowsinessAny Fever (Rectally)Any IrritabilityAny Loss of appetite
Control (T), Booster Group5352
GSK134612A Form1 (T), Booster Group3542

[back to top]

Number of Subjects With SAEs

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00196976)
Timeframe: Since the last study contact in the primary study up to the end of the booster study (from Month 2 up to Month 13)

InterventionParticipants (Count of Participants)
GSK134612A Form1 (T), Booster Group0
Control (T), Booster Group0
GSK134612A Form1 (C), Booster Group0
Control (C), Booster Group0

[back to top]

Number of Subjects With Any Unsolicited Adverse Events (AEs) After the Primary Vaccination

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. (NCT00196976)
Timeframe: Within 31 days (Days 0-30) after the primary meningococcal vaccination

InterventionParticipants (Count of Participants)
GSK134612A Form1 (T), Primary Group11
GSK134612A Form2 (T), Primary Group16
GSK134612A Form3 (T), Primary Group5
GSK134612A Form4 (T), Primary Group8
Control (T), Primary Group14
GSK134612A Form1 (C), Primary Group6
GSK134612A Form2 (C), Primary Group12
GSK134612A Form3 (C), Primary Group7
GSK134612A Form4 (C), Primary Group5
Control (C), Primary Group6

[back to top]

Number of Subjects With Any Unsolicited AEs

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. (NCT00196976)
Timeframe: Within 31 days (Days 0-30) after the booster vaccination

InterventionParticipants (Count of Participants)
GSK134612A Form1 (T), Booster Group3
Control (T), Booster Group5

[back to top]

Number of Subjects With an Immune Response to Different Meningococcal Serogroups

A responder to serum bactericidal assay meningococcal serogroups A, C, W and Y, using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) was defined as follows: -for initially seronegative subjects (antibody titers < 1:8 for rSBA-Men), a subject achieving a post-vaccination rSBA-Men antibody titer of ≥ 1:32; - for initially seropositive subjects (antibody titers ≥ 1:8 for rSBA-Men), a subject having a ≥ 4-fold increase in rSBA-Men antibody titer from pre to post vaccination. (NCT00196976)
Timeframe: One month after the first vaccine dose (Month 1)

,,,,,,,,,
InterventionParticipants (Count of Participants)
rSBA-MenArSBA-MenCrSBA-MenW-135rSBA-MenY
Control (C), Primary Group36343634
Control (T), Primary Group63033
GSK134612A Form1 (C), Primary Group41454646
GSK134612A Form1 (T), Primary Group30303433
GSK134612A Form2 (C), Primary Group38444447
GSK134612A Form2 (T), Primary Group32323634
GSK134612A Form3 (C), Primary Group41444645
GSK134612A Form3 (T), Primary Group26262726
GSK134612A Form4 (C), Primary Group42464847
GSK134612A Form4 (T), Primary Group27333534

[back to top]

Number of Seropositive Subjects for Anti-tetanus (Anti-T)

A seropositive subject for anti-tetanus was defined as having antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units per milliliter (IU/mL). Antibody titers were determined by enzyme-linked immunosorbent assay (ELISA). (NCT00196976)
Timeframe: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

,,,,,,,,,
InterventionParticipants (Count of Participants)
Anti-T, Month 0Anti-T, Month 1
Control (C), Primary Group4343
Control (T), Primary Group3334
GSK134612A Form1 (C), Primary Group4948
GSK134612A Form1 (T), Primary Group3436
GSK134612A Form2 (C), Primary Group4747
GSK134612A Form2 (T), Primary Group3637
GSK134612A Form3 (C), Primary Group4648
GSK134612A Form3 (T), Primary Group3030
GSK134612A Form4 (C), Primary Group4850
GSK134612A Form4 (T), Primary Group3235

[back to top]

Number of Seroprotected Subjects Against Different Meningococcal Serogroups

A seroprotected subject against meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY assessed, was defined as having antibody titers greater than or equal to (≥) 1:8. (NCT00196976)
Timeframe: At one month (M1) and 12 months (M12) post-primary vaccination

,,,
InterventionParticipants (Count of Participants)
rSBA-MenA, Month 1rSBA-MenC, Month 1rSBA-MenW-135, Month 1rSBA-MenY, Month 1rSBA-MenA, Month 12rSBA-MenC, Month 12rSBA-MenW-135, Month 12rSBA-MenY, Month 12
Control (C), Booster Group3636373733223136
Control (T), Booster Group1829112020251123
GSK134612A Form1 (C), Booster Group4343434439404141
GSK134612A Form1 (T), Booster Group3131303023293031

[back to top]

Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides

A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA). (NCT00196976)
Timeframe: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

,,,,,,,,,
InterventionParticipants (Count of Participants)
Anti-PSA, Month 0Anti-PSA, Month 1Anti-PSC, Month 0Anti-PSC, Month 1Anti-PSW-135, Month 0Anti-PSW-135, Month 1Anti-PSY, Month 0Anti-PSY, Month 1
Control (C), Primary Group540244039042
Control (T), Primary Group000330000
GSK134612A Form1 (C), Primary Group148244041146
GSK134612A Form1 (T), Primary Group035033033034
GSK134612A Form2 (C), Primary Group144245131240
GSK134612A Form2 (T), Primary Group035037027034
GSK134612A Form3 (C), Primary Group047045041039
GSK134612A Form3 (T), Primary Group030029023027
GSK134612A Form4 (C), Primary Group234047039047
GSK134612A Form4 (T), Primary Group025034032133

[back to top]

Number of Seroprotected Subjects Against Different Meningococcal Polysaccharides

A seroprotected subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the value of 2.0 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA). (NCT00196976)
Timeframe: At one month (M1) and 12 months (M12) post primary vaccination

,,,
InterventionParticipants (Count of Participants)
Anti-PSA, Month 1Anti-PSC, Month 1Anti-PSW-135, Month 1Anti-PSY, Month 1Anti-PSA, Month 12Anti-PSC, Month 12Anti-PSW-135, Month 12Anti-PSY, Month 12
Control (C), Booster Group3337323522242330
Control (T), Booster Group029000421
GSK134612A Form1 (C), Booster Group413734391201019
GSK134612A Form1 (T), Booster Group30282829102615

[back to top]

Number of Seropositive Subjects for Different Anti-meningococcal Serogroups

A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128. (NCT00196976)
Timeframe: Prior to (Month 0) and one month after (Month 1) after the first vaccine dose

,,,,,,,,,
InterventionParticipants (Count of Participants)
rSBA-MenA, Month 0rSBA-MenA, Month 1rSBA-MenC, Month 0rSBA-MenC, Month 1rSBA-MenW-135, Month 0rSBA-MenW-135, Month 1rSBA-MenY, Month 0rSBA-MenY, Month 1
Control (C), Primary Group374353912423043
Control (T), Primary Group1720127891718
GSK134612A Form1 (C), Primary Group414994919502951
GSK134612A Form1 (T), Primary Group19363358351735
GSK134612A Form2 (C), Primary Group394744611483748
GSK134612A Form2 (T), Primary Group19380349381137
GSK134612A Form3 (C), Primary Group40485459483248
GSK134612A Form3 (T), Primary Group1329026429929
GSK134612A Form4 (C), Primary Group465074815493350
GSK134612A Form4 (T), Primary Group19343314351234

[back to top]

Number of Seropositive Subjects for Different Anti-meningococcal Serogroups

A seropositive subject for meningococcal serogroups rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Y assessed, was defined as having antibody titers greater than or equal to (≥) 1:128. (NCT00196976)
Timeframe: At one month (M1) and 12 months (M12) post-primary vaccination

,,,
InterventionParticipants (Count of Participants)
rSBA-MenA, Month 1rSBA-MenC, Month 1rSBA-MenW-135, Month 1rSBA-MenY, Month 1rSBA-MenA, Month 12rSBA-MenC, Month 12rSBA-MenW-135, Month 12rSBA-MenY, Month 12
Control (C), Booster Group3634353632102732
Control (T), Booster Group14236131915617
GSK134612A Form1 (C), Booster Group4242434439274140
GSK134612A Form1 (T), Booster Group3131303023132730

[back to top]

Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides

A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA). (NCT00196976)
Timeframe: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

,,,,,,,,,
InterventionParticipants (Count of Participants)
Anti-PSA, Month 0Anti-PSA, Month 1Anti-PSC, Month 0Anti-PSC, Month 1Anti-PSW-135, Month 0Anti-PSW-135, Month 1Anti-PSY, Month 0Anti-PSY, Month 1
Control (C), Primary Group1044244144144
Control (T), Primary Group021340012
GSK134612A Form1 (C), Primary Group1048349148249
GSK134612A Form1 (T), Primary Group135133134234
GSK134612A Form2 (C), Primary Group445445445445
GSK134612A Form2 (T), Primary Group236138036037
GSK134612A Form3 (C), Primary Group648148248246
GSK134612A Form3 (T), Primary Group030030130230
GSK134612A Form4 (C), Primary Group948148048148
GSK134612A Form4 (T), Primary Group134135135134

[back to top]

Number of Subjects With Any Unsolicited AEs During the Primary Vaccination

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. (NCT00196976)
Timeframe: Within 31 days (Days 0-30) post-vaccination with diphteria, tetanus and acellular pertusis-containing vaccine, during the primary vaccination

InterventionParticipants (Count of Participants)
GSK134612A Form1 (T), Primary Group5
GSK134612A Form2 (T), Primary Group8
GSK134612A Form3 (T), Primary Group5
GSK134612A Form4 (T), Primary Group5
Control (T), Primary Group7

[back to top]

Number of Seropositive Subjects for Different Anti-meningococcal Polysaccharides

A seropositive subject for meningococcal polysaccharide A (PSA), C (PSC), W-135 (PSW-135) and Y (PSY) assessed, was defined as having antibody (anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY) concentrations greater than or equal to (≥) the cut-off value of 0.3 micrograms per milliliter (μg/mL). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA). (NCT00196976)
Timeframe: At one month (M1) and 12 months (M12) post-primary vaccination

,,,
InterventionParticipants (Count of Participants)
Anti-PSA, Month 1Anti-PSC, Month 1Anti-PSW-135, Month 1Anti-PSY, Month 1Anti-PSA, Month 12Anti-PSC, Month 12Anti-PSW-135, Month 12Anti-PSY, Month 12
Control (C), Booster Group3737373734363235
Control (T), Booster Group1300221833
GSK134612A Form1 (C), Booster Group4142414234183434
GSK134612A Form1 (T), Booster Group3028292922132526

[back to top]

Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Serogroups

A seropositive subject for rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY was defined as a vaccinated subject with antibody titers greater than or equal to (≥) 1:128, while for a seroprotected subject, titers were ≥1:8. (NCT00196976)
Timeframe: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination

,
InterventionParticipants (Count of Participants)
rSBA-MenA ≥ 1:8, PRErSBA-MenC ≥ 1:8, PRErSBA-MenW-135 ≥ 1:8, PRErSBA-MenY ≥ 1:8, PRErSBA-MenA ≥ 1:128, PRErSBA-MenC ≥ 1:128, PRErSBA-MenW-135 ≥ 1:128, PRErSBA-MenY ≥ 1:128, PRErSBA-MenA ≥ 1:8, Month 13rSBA-MenC ≥ 1:8, Month 13rSBA-MenW-135 ≥ 1:8, Month 13rSBA-MenY ≥ 1:8, Month 13rSBA-MenA ≥ 1:128, Month 13rSBA-MenC ≥ 1:128, Month 13rSBA-MenW-135 ≥ 1:128, Month 13rSBA-MenY ≥ 1:128, Month 13
Control (T), Booster Group172091816124141924212219241820
GSK134612A Form1 (T), Booster Group202526272010232662525256242525

[back to top]

Number of Seropositive and Seroprotected Subjects Against Different Meningococcal Polysaccharides

A seropositive subject for anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY was defined as a vaccinated subject with antibody concentrations greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL), while for a seroprotected subject, antibody concentrations were ≥ 2.0 μg/mL. (NCT00196976)
Timeframe: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination

,
InterventionParticipants (Count of Participants)
Anti-PSA ≥ 0.3 μg/mL, PREAnti-PSC ≥ 0.3 μg/mL, PREAnti-PSW-135 ≥ 0.3 μg/mL, PREAnti-PSY ≥ 0.3 μg/mL, PREAnti-PSA ≥ 2.0 μg/mL, PREAnti-PSC ≥ 2.0 μg/mL, PREAnti-PSW-135 ≥ 2.0 μg/mL, PREAnti-PSY ≥ 2.0 μg/mL, PREAnti-PSA ≥ 0.3 μg/mL, Month 13Anti-PSC ≥ 0.3 μg/mL, Month 13Anti-PSW-135 ≥ 0.3 μg/mL, Month 13Anti-PSY ≥ 0.3 μg/mL, Month 13Anti-PSA ≥ 2.0 μg/mL, Month 13Anti-PSC ≥ 2.0 μg/mL, Month 13Anti-PSW-135 ≥ 2.0 μg/mL, Month 13Anti-PSY ≥ 2.0 μg/mL, Month 13
Control (T), Booster Group115220310192218201322912
GSK134612A Form1 (T), Booster Group19112324715142625252525252424

[back to top]

Number of Children With Any Solicited Local Symptoms

The children subgroup received one dose of the meningococcal vaccine. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. (NCT00196976)
Timeframe: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose

,,,,
InterventionParticipants (Count of Participants)
PainRednessSwelling
Control (C), Primary Group1374
GSK134612A Form1 (C), Primary Group1097
GSK134612A Form2 (C), Primary Group11119
GSK134612A Form3 (C), Primary Group9108
GSK134612A Form4 (C), Primary Group11910

[back to top]

Number of Children With Any Solicited General Symptoms

The children subgroup received one primary meningococcal vaccine dose. Assessed solicited general symptoms included drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = incidence of a particular symptom regardless of intensity or relationship to vaccination. (NCT00196976)
Timeframe: During the 8-day (Days 0-7) post-vaccination period after each primary vaccine dose

,,,,
InterventionParticipants (Count of Participants)
DrowsinessFever (Axillary)IrritabilityLoss of appetite
Control (C), Primary Group4373
GSK134612A Form1 (C), Primary Group4422
GSK134612A Form2 (C), Primary Group2443
GSK134612A Form3 (C), Primary Group0322
GSK134612A Form4 (C), Primary Group5346

[back to top]

Antibody Titers Against Different Meningococcal Serogroups

Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs). (NCT00196976)
Timeframe: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

,,,,,,,,,
InterventionTiters (Geometric Mean)
rSBA-MenA, Month 0rSBA-MenA, Month 1rSBA-MenC, Month 0rSBA-MenC, Month 1rSBA-MenW-135, Month 0rSBA-MenW-135, Month 1rSBA-MenY, Month 0rSBA-MenY, Month 1
Control (C), Primary Group427.44556.811.9378.331.5912.7123.61527.3
Control (T), Primary Group69.1125.95.3404.51821.752.875.6
GSK134612A Form1 (C), Primary Group359.77469.512.5967.645.84317.498.75249.1
GSK134612A Form1 (T), Primary Group84.266486.9656.419.82781.457.72599.9
GSK134612A Form2 (C), Primary Group367.27569.77.4111522.33856.5181.95150.5
GSK134612A Form2 (T), Primary Group77.35406.84.5495.721.13447.524.42150.9
GSK134612A Form3 (C), Primary Group375.913668.311.81738.823.75262.1146.85896.3
GSK134612A Form3 (T), Primary Group68.46225.24.6477.214.5254532.41920.9
GSK134612A Form4 (C), Primary Group465.248788.91197.644.64556.1140.67548.4
GSK134612A Form4 (T), Primary Group763928.66.6464.312.13260.832.93544.7

[back to top]

Antibody Titers Against Different Meningococcal Serogroups

Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs). (NCT00196976)
Timeframe: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination

,
InterventionTiters (Geometric Mean)
rSBA-MenA, PRErSBA-MenC, PRErSBA-MenW-135, PRErSBA-MenY, PRErSBA-MenA, Month 13rSBA-MenC, Month 13rSBA-MenW-135, Month 13rSBA-MenY, Month 13
Control (T), Booster Group175.7102.515.593.6984.69209.3255.6323.8
GSK134612A Form1 (T), Booster Group2163.482.5436634.53695.27067.45642.43337.7

[back to top]

Antibody Titers Against Different Meningococcal Serogroups

Antibody titers against meningococcal serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and MenY) have been assessed, using rabbit complement and expressed as geometric mean titers (GMTs). (NCT00196976)
Timeframe: At one month (M1) and 12 months (M12) post-primary vaccination

,,,
InterventionTiters (Geometric Mean)
rSBA-MenA, Month 1rSBA-MenC, Month 1rSBA-MenW-135, Month 1rSBA-MenY, Month 1rSBA-MenA, Month 12rSBA-MenC, Month 12rSBA-MenW-135, Month 12rSBA-MenY, Month 12
Control (C), Booster Group4649.5416.21004.41641.11134.341.7181.7347.2
Control (T), Booster Group84.9440.217.257.7179.312218.9110.6
GSK134612A Form1 (C), Booster Group6565.3893.63893.64808.52356.7172.51322.21400.8
GSK134612A Form1 (T), Booster Group6577.8660.42523.52483.92369.1110.2541.8740.3

[back to top]

Antibody Concentrations Against Tetanus (Anti-T)

Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) method, presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). (NCT00196976)
Timeframe: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

,,,,,,,,,
InterventionIU/mL (Geometric Mean)
Anti-T, Month 0Anti-T, Month 1
Control (C), Primary Group1.0831.231
Control (T), Primary Group0.7920.696
GSK134612A Form1 (C), Primary Group1.42617.284
GSK134612A Form1 (T), Primary Group1.0077.559
GSK134612A Form2 (C), Primary Group1.31215.823
GSK134612A Form2 (T), Primary Group1.1595.353
GSK134612A Form3 (C), Primary Group1.23219.369
GSK134612A Form3 (T), Primary Group1.2038.094
GSK134612A Form4 (C), Primary Group1.1815.957
GSK134612A Form4 (T), Primary Group1.2937.675

[back to top]

Antibody Concentrations Against Different Meningococcal Polysaccharides

The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). (NCT00196976)
Timeframe: Before (PRE= at Month 12) and one month after (at Month 13) booster vaccination

,
Interventionμg/mL (Geometric Mean)
Anti-PSA, PREAnti-PSC, PREAnti-PSW-135, PREAnti-PSY, PREAnti-PSA, Month 13Anti-PSC, Month 13Anti-PSW-135, Month 13Anti-PSY, Month 13
Control (T), Booster Group0.160.193.11.340.50.1915.234.19
GSK134612A Form1 (T), Booster Group0.981.3325.6756.940.322.3411.6379.03

[back to top]

Antibody Concentrations Against Different Meningococcal Polysaccharides

The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). (NCT00196976)
Timeframe: At one month (M1) and 12 months (M12) post-primary vaccination

,,,
Interventionµg/mL (Geometric Mean)
Anti-PSA, Month 1Anti-PSC, Month 1Anti-PSW-135, Month 1Anti-PSY, Month 1Anti-PSA, Month 12Anti-PSC, Month 12Anti-PSW-135, Month 12Anti-PSY, Month 12
Control (C), Booster Group1314.58.1718.124.432.93.166.9
Control (T), Booster Group0.1712.430.150.160.170.540.210.21
GSK134612A Form1 (C), Booster Group18.295.644.238.071.320.281.111.84
GSK134612A Form1 (T), Booster Group32.7211.256.6510.371.250.391.362.36

[back to top]

Number of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00196976)
Timeframe: During the primary vaccination study (from Month 0 up to Month 2)

InterventionParticipants (Count of Participants)
GSK134612A Form1 (T), Primary Group1
GSK134612A Form2 (T), Primary Group1
GSK134612A Form3 (T), Primary Group1
GSK134612A Form4 (T), Primary Group1
Control (T), Primary Group1
GSK134612A Form1 (C), Primary Group0
GSK134612A Form2 (C), Primary Group0
GSK134612A Form3 (C), Primary Group0
GSK134612A Form4 (C), Primary Group0
Control (C), Primary Group0

[back to top]

Antibody Concentrations Against Different Meningococcal Polysaccharides

The meningococcal polysaccharides assessed included polysaccharide A (anti-PSA), polysaccharide B (anti-PSB), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY). Antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). (NCT00196976)
Timeframe: Prior to (Month 0) and one month after (Month 1) the first vaccine dose

,,,,,,,,,
Interventionμg/mL (Geometric Mean)
Anti-PSA, Month 0Anti-PSA, Month 1Anti-PSC, Month 0Anti-PSC, Month 1Anti-PSW-135, Month 0Anti-PSW-135, Month 1Anti-PSY, Month 0Anti-PSY, Month 1
Control (C), Primary Group0.2513.790.1814.440.167.930.1518.96
Control (T), Primary Group0.150.170.1611.990.150.150.150.16
GSK134612A Form1 (C), Primary Group0.220.010.186.330.154.760.169.41
GSK134612A Form1 (T), Primary Group0.1630.650.1610.670.157.520.1610.86
GSK134612A Form2 (C), Primary Group0.1712.620.187.760.173.20.196.59
GSK134612A Form2 (T), Primary Group0.1622.090.1611.230.153.120.156.71
GSK134612A Form3 (C), Primary Group0.1724.690.167.710.163.850.165.75
GSK134612A Form3 (T), Primary Group0.1534.680.1512.910.163.620.166.01
GSK134612A Form4 (C), Primary Group0.213.630.157.780.154.990.1511.7
GSK134612A Form4 (T), Primary Group0.164.030.1510.740.157.090.1613.38

[back to top]

Number of Subjects With Vaccine Response to Pertussis Toxoid (PT), Pertactin (PRN) and Filamentous Haemagglutinin (FHA) Antigens

Vaccine response to pertussis toxoid (PT), pertactin (PRN) and filamentous haemagglutinin (FHA) was defined as the appearance of antibodies in subjects who were initially (i.e. before vaccination) seronegative (i.e. with concentrations < 5 EL.U/mL), or at least as the maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e. with concentrations ≥ 5 EL.U/mL value). (NCT00290342)
Timeframe: One month (Month 5) post-primary vaccination course

,
InterventionSubjects (Number)
Anti-PT (N=200; 209)Anti-FHA (N=202; 211)Anti-PRN (N=202; 211)
Infanrix + IMOVAX Polio Group206209210
Infanrix-IPV Group200201202

[back to top]

Number of Subjects Reporting Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00290342)
Timeframe: During the entire study period (from Month 0 up to Month 5)

InterventionSubjects (Number)
Infanrix-IPV Group15
Infanrix + IMOVAX Polio Group17

[back to top]

Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. (NCT00290342)
Timeframe: During the 31-day (Days 0-30) post-vaccination period

InterventionSubjects (Number)
Infanrix-IPV Group135
Infanrix + IMOVAX Polio Group138

[back to top]

Concentration of Antibodies Against Diphteria (Anti-D) and Tetanus (Anti-T)

Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per millilitre (mIU/mL). (NCT00290342)
Timeframe: Before (Pre) and one month after (Post) the primary vaccination course

,
InterventionIU/mL (Geometric Mean)
Anti-D, PRE (N=202; 212)Anti-D, POST (N=204; 211)Anti-T, PRE (N=202; 212)Anti-T, POST (N=204; 211)
Infanrix + IMOVAX Polio Group0.0532.630.067.139
Infanrix-IPV Group0.0524.3330.05910.306

[back to top]

Concentrations of Antibodies Against Pertussis Toxoid (Anti-PT), Pertactin (Anti-PRN) and Filamentous Haemagglutinin (Anti-FHA)

Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL). (NCT00290342)
Timeframe: Before (Pre) and one month after (Post) the primary vaccination course

,
InterventionEL.U/mL (Geometric Mean)
Anti-PT, PRE (N=200; 210)Anti-PT, POST (N=204; 211)Anti-FHA, PRE (N=202; 212)Anti-FHA, POST (N=204; 211)Anti-PRN, PRE (N=202; 212)Anti-PRN, POST (N=204; 211)
Infanrix + IMOVAX Polio Group3.255.68.5259.62.7155.6
Infanrix-IPV Group363.37.4294.32.7205

[back to top]

Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T)

A seroprotected subject was defined as a vaccinated subject with anti-diphteria (anti-D) and anti-tetanus (anti-T) antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units/milliliter (IU//mL). (NCT00290342)
Timeframe: One month (Month 5) post-primary vaccination course

,
InterventionSubjects (Number)
Anti-DAnti-T
Infanrix + IMOVAX Polio Group211211
Infanrix-IPV Group204204

[back to top]

Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T)

A seroprotected subject was defined as a vaccinated subject with anti-diphteria (anti-D) and anti-tetanus (anti-T) antibody concentrations greater than or equal to (≥) the cut-off value of 1 international units/milliliter (IU//mL). (NCT00290342)
Timeframe: Before (Pre) and one month after (Post) the primary vaccination course

,
InterventionSubjects (Number)
Anti-D, PRE (N=202; 212)Anti-D, POST (N=204; 211)Anti-T, PRE (N=202; 212)Anti-T, POST (N=204; 211)
Infanrix + IMOVAX Polio Group01871208
Infanrix-IPV Group01941204

[back to top]

Number of Seroprotected Subjects Against Poliovirus (Anti-polio) Types 1, 2 and 3

A seroprotected subject was defined as a vaccinated subject with anti-poliovirus types 1, 2 and 3 (Anti-Polio 1, 2 and 3) antibody titers greater than or equal to (≥) the cut-off value of 8. (NCT00290342)
Timeframe: One month (Month 5) post-primary vaccination course

,
InterventionSubjects (Number)
Anti-polio 1 (N=204; 207)Anti-polio 2 (N=204; 205)Anti-polio 3 (N=204; 207)
Infanrix + IMOVAX Polio Group207204206
Infanrix-IPV Group204204203

[back to top]

Number of Subjects Reporting Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 Loss of appetite = not eating at all. Related = symptom symptoms considered by the investigator to have a causal relationship to vaccination. (NCT00290342)
Timeframe: During the 4-day (Days 0-3) post-vaccination period, across doses

,
InterventionSubjects (Number)
Any DrowsinessGrade 3 DrowsinessRelated DrowsinessAny Fever (axillary)Grade 3 Fever (axillary)Related Fever (axillary)Any IrritabilityGrade IrritabilityRelated IrritabilityAny Loss of appetiteGrade 3 Loss of appetiteRelated Loss of appetite
Infanrix + IMOVAX Polio Group9925338122139109178046
Infanrix-IPV Group9545463445140148584150

[back to top]

Number of Subjects Reporting Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = crying when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site. (NCT00290342)
Timeframe: During the 4-day (Days 0-3) post-vaccination period, across doses

,
InterventionSubjects (Number)
Any PainGrade 3 PainAny RednessGrade 3 RednessAny SwellingGrade 3 Swelling
Infanrix + IMOVAX Polio Group968116267920
Infanrix-IPV Group925115227417

[back to top]

Titers for Poliovirus Type 1, 2 and 3 Antibodies

Titers for anti-polio 1, 2 and 3 are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was greater than or equal to (≥) 8. (NCT00290342)
Timeframe: Before (Pre) and one month after (Post) the primary vaccination course

,
InterventionTiters (Geometric Mean)
Anti-polio 1, PRE (N=199; 212)Anti-polio 1, POST (N=204; 207)Anti-polio 2, PRE (N=202; 211)Anti-polio 2, POST (N=204; 205)Anti-polio 3, PRE (N=202; 212)Anti-polio 3, POST (N=204; 207)
Infanrix + IMOVAX Polio Group6.12636.5267.64.9438.3
Infanrix-IPV Group6.3755.75.8704.751209.5

[back to top]

Number of Subjects With a Vaccine Response for Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Haemagglutinin (Anti-FHA)

Vaccine response was defined as: - for initially seronegative subjects, antibody concentrations ≥ 5 EL.U/mL one month after third vaccine dose; - for initially seropositive subjects, at least maintenance of pre-vaccination antibody concentrations one month after third vaccine dose. (NCT00290342)
Timeframe: One month (Month 5) post-primary vaccination course

,
InterventionSubjects (Number)
Anti-PTAnti-FHAAnti-PRN
Infanrix + IMOVAX Polio Group206209210
Infanrix-IPV Group200201202

[back to top]

Number of Subjects Reporting Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00325143)
Timeframe: During the entire study period (from Month 0 up to Month 21)

InterventionParticipants (Count of Participants)
Infanrix Hexa Group108

[back to top]

Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. (NCT00325143)
Timeframe: During the 31-day (Days 0-30) post-vaccination period

InterventionParticipants (Count of Participants)
Infanrix Hexa Group321

[back to top]

Number of Subjects Reporting Any Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade. (NCT00325143)
Timeframe: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

InterventionParticipants (Count of Participants)
Any Drowsiness, Dose 1Any Temperature (Axillary) (°C), Dose 1Any Irritability, Dose 1Any Loss of appetite, Dose 1Any Drowsiness, Dose 2Any Temperature (Axillary) (°C), Dose 2Any Irritability, Dose 2Any Loss of appetite, Dose 2Any Drowsiness, Dose 3Any Temperature (Axillary) (°C), Dose 3Any Irritability, Dose 3Any Loss of appetite, Dose 3Any Drowsiness, Booster doseAny Temperature (Axillary) (°C), Booster doseAny Irritability, Booster doseAny Loss of appetite, Booster doseAny Drowsiness, Across dosesAny Temperature (Axillary) (°C), Across dosesAny Irritability, Across dosesAny Loss of appetite, Across doses
Infanrix Hexa Group16513922917314012419215510610016110689152163118290330381324

[back to top]

Number of Subjects Reporting Any Solicited Local Symptoms

Assessed solicited local and general symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. (NCT00325143)
Timeframe: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

InterventionParticipants (Count of Participants)
Any Pain, Dose 1Any Redness, Dose 1Any Swelling, Dose 1Any Pain, Dose 2Any Redness, Dose 2Any Swelling, Dose 2Any Pain, Dose 3Any Redness, Dose 3Any Swelling, Dose 3Any Pain, Booster doseAny Redness, Booster doseAny Swelling, Booster doseAny Pain, Across dosesAny Redness, Across dosesAny Swelling, Across doses
Infanrix Hexa Group1301208913413710097126100166148115301273215

[back to top]

Number of Subjects Reporting Any Large Swelling Reactions

A large swelling reaction was defined as swelling with a diameter greater than (>) 50 millimeters (mm), noticeable diffuse swelling or noticeable increase of limb circumference. (NCT00325143)
Timeframe: At Month 15, post-booster dose

InterventionParticipants (Count of Participants)
Infanrix Hexa Group0

[back to top]

To Evaluate the Incidence of Treatment Emergent Adverse Events

(NCT01118663)
Timeframe: 21-42 hours

InterventionNumber of Events (Number)
Acetadote Without EDTA13
Acetadote14

[back to top]

To Evaluate the Incidence of Anaphylactoid Reaction.

Data analysis was conducted on the subjects enrolled in the study prior to study termination. Because the study was terminated prematurely due to lack of enrollment, there was an insufficient sample size to conduct an efficacy analysis. (NCT01118663)
Timeframe: 1 hour

Interventionparticipants (Number)
Acetadote Without EDTA0
Acetadote1

[back to top] [back to top]

Radiation Dose With 50% Decrease in Lung Perfusion, Assessed Using 99mTc-MAA and 99mTc-DTPA SPECT/CT

For lung tissue inside the radiation field, changes in tracer uptake at the global lung, regional lung, and lung image voxel scales (compared to baseline) will be plotted against the radiation dose at the same scales to generate multiscale radiation dose response curves. These curves will be fit to linear and sigmoid dose-response functions. Lung regions in the upper quartile and lower quartile of ventilation and perfusion will also be separated out, and separate radiation dose response curves per region will be generated. We report here the dose at which there is a 50% decrease in lung perfusion based on the above analysis. (NCT01982123)
Timeframe: Baseline to up to 3 months post-treatment

InterventionGy (Median)
SPECT/CT Mid-& Post-RT21

[back to top]

Spatial Stability of Lung Perfusion and Ventilation Over Time, as Assessed Using 99mTc-MAA SPECT/CT

Perfusion and ventilation on SPECT/CT pre-radiation, mid-radiation, and post-radiation were compared to assess stability over time. Coefficient of determination (R²) was generated based on voxel-based comparisons between scans (R²=1 means perfect reproducibility in perfusion and ventilation between scans), based on regions outside the radiation field. (NCT01982123)
Timeframe: Baseline to up to 3 months post-treatment

Interventioncorrelation coefficient (Number)
SPECT/CT Mid-& Post-RT0.95

[back to top]

Feasibility of Ga-68 PSMA PET/CT or PET/MRI Scan

Feasibility of Ga68 PSMA PET/CT or PET/MRI is expressed as the number of subjects for whom the scan was successfully completed. (NCT02488070)
Timeframe: an estimated average of 2 hours

Interventionparticipants (Number)
Diagnostic (68Ga-PSMA PET/CT or PET/MRI)10

[back to top]

Average SUVmax Focal Uptake of Ga68 PSMA (F/N Ratio)

Focal uptake will be measured by drawing regions-of-interest (ROI) around areas with visually appreciable increased focal uptake over background (mediastinal blood pool) and calculating a SUVmax (a semi-quantitative measurement of the maximum value of radiopharmaceutical uptake within the ROI). The result will be expressed as the F/N ratio, ie, SUVmax of focal uptake divided by SUVmax of background. (NCT02488070)
Timeframe: an estimated average of 1 hour

InterventionF/N ratio (Mean)
Diagnostic (68Ga-PSMA PET/CT or PET/MRI)10.4

[back to top]

Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution

The biodistribution (ie, the location(s) of physiologic radiopharmaceutical uptake within the body) of Ga68 PSMA will be evaluated using PET/CT or PET/MRI. Biodistribution will be measured by drawing regions of interest (ROI) around areas with visually appreciable increased focal uptake over background (mediastinal blood pool) and calculating a standardized uptake value maximum (SUVmax), which is a semi-quantitative measurement of the maximum value of radiopharmaceutical uptake within the ROI. (NCT02488070)
Timeframe: an estimated average of 1 hour

InterventionSUVmax (Mean)
Diagnostic (68Ga-PSMA PET/CT or PET/MRI)12.4

[back to top]

Average SUVmean Focal Uptake of Ga68 PSMA (F/N Ratio)

Focal uptake will be measured by drawing regions-of-interest (ROI) around areas with visually appreciable increased focal uptake over background (mediastinal blood pool) and calculating a SUVmean (a semi-quantitative measurement of the average value of radiopharmaceutical uptake within the ROI). The result will be expressed as the F/N ratio, ie, SUVmax of focal uptake divided by SUVmax of background. (NCT02488070)
Timeframe: an estimated average of 1 hour

InterventionF/N ratio (Mean)
Diagnostic (68Ga-PSMA PET/CT or PET/MRI)9.2

[back to top]

Average SUVmean of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution

The biodistribution (ie, the location(s) of physiologic radiopharmaceutical uptake within the body) of Ga68 PSMA will be evaluated using PET/CT or PET/MRI. Biodistribution will be measured by drawing regions of interest (ROI) around areas with visually appreciable increased focal uptake over background (mediastinal blood pool) and calculating a SUVmean which is a semi-quantitative measurement of the average value of radiopharmaceutical uptake within the ROI. (NCT02488070)
Timeframe: an estimated average of 1 hour

InterventionSUVmean (Mean)
Diagnostic (68Ga-PSMA PET/CT or PET/MRI)7.1

[back to top]

Positive Predictive Value (PPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis

Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval. (NCT02611882)
Timeframe: 1 day

Interventionproportion of true positives (Number)
High-risk Prostate Cancer Pre-prostatectomy (preRP) Population.67
Biochemical Recurrence (BCR) Population.906

[back to top]

Negative Predictive Value (NPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis

Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval. (NCT02611882)
Timeframe: one month

Interventionproportion of true negatives (Number)
High-risk Prostate Cancer Pre-prostatectomy (preRP) Population.74
Biochemical Recurrence (BCR) Population.24

[back to top]

Specificity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis

Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval. (NCT02611882)
Timeframe: 1 day

Interventionproportion of participants (Number)
High-risk Prostate Cancer Pre-prostatectomy (preRP) Population.80
Biochemical Recurrence (BCR) Population.31

[back to top]

Overall Detection Rates of Ga68-PSMA-11 by PSA Levels for the BCR Group

68Ga-labeled prostate-specific membrane antigen 11 (Ga68-PSMA-11) PET positivity rate by prostate-specific antigen (PSA) level is calculated by the number of positive reads divided by the total number of patients in the BCR Group per PSA value quintile (Detection rate (d) = total number of positive reads (t)/ total number of participants (N)). (NCT02611882)
Timeframe: Up to 1 year

Interventionproportion of participants (Number)
<0.5 ng/dl0.5 to < 1.0 ng/dl1.0 to < 2.0 ng/dl2.0 to < 5.0 ng/dl>=5.0 ng/dl
Biochemical Recurrence (BCR) Population.55.62.80.88.96

[back to top]

Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases

Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true positive rate will be calculated with the corresponding 95% confidence interval. (NCT02611882)
Timeframe: 1 day

Interventionproportion of participants (Number)
High-risk Prostate Cancer Pre-prostatectomy (preRP) Population.59
Biochemical Recurrence (BCR) Population.89

[back to top]

Number of Patients in Biochemical Recurrence (BCR) Group Who Had a Reported Change in Medical Management

Change in participant medical management was determined based on the results of surveys given to each participant's treating physician. Results of the survey were categorized as a major change in participant's medical management, a minor change in participant's medical management, no change to participant's medical management, or change to participant's medical management is unknown. These categories were developed based on a predetermined categorization schema. (NCT02611882)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
Major ChangeMinor Change
Biochemical Recurrence (BCR) Population678

[back to top]

Overall 68Ga-PSMA-11 PET/CT Scan Quality Stratified by PSA Level

"Scan quality was assessed by sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) determinations for the 68Ga-PSMA-11 PET/CT scans in participants stratified by prostate-specific antigen (PSA) level in ng/mL. Stratification levels were as follows.~0.2 to < 0.5~0.5 to < 1.0~1.0 to < 2.0~2.0 to < 5.0~≥ 5.0, The outcome is expressed as the Sensitivity, Specificity, PPV, and NPV values observed for the PSA level strata, with 95% confidence interval." (NCT02673151)
Timeframe: up to 12 months

,,,,
Interventionpercentage point estimate (Number)
Positive predictive value (PPV)Negative predictive value (NPV)SensitivitySpecificity
Diagnostic (68Ga-PSMA-11 PET/CT) for PSA ≥ 5.0 ng/mL84.7100.0100.074.3
Diagnostic (68Ga-PSMA-11 PET/CT) for PSA 0.2 to < 0.5 ng/m?31.3100.0100.091.4
Diagnostic (68Ga-PSMA-11 PET/CT) for PSA 0.5 to < 1.0 ng/mL75100.0100.088.9
Diagnostic (68Ga-PSMA-11 PET/CT) for PSA 1.0 to < 2.0 ng/mL100.0NA100.0NA
Diagnostic (68Ga-PSMA-11 PET/CT) for PSA 2.0 to < 5.0 ng/mL82.1100.0100.075.0

[back to top]

68Ga-PSMA-11 PET/CT Sensitivity and Specificity

68Ga-PSMA-11 PET/CT sensitivity and specificity were assessed by comparing 68Ga-PSMA-11 PET/CT scan results with conventional imaging follow-up and/or histopathology/biopsy within the following 1 year. Sensitivity is a percentage that estimates, within a group of participants, the proportion within that group that truly has a disease or condition. Specificity is a percentage that estimates, within a group of participants, the proportion within that group that truly does not have the disease or condition. The outcome is reported as the point estimates for sensitivity and specificity, given as percentages representing agreement between the 68Ga-PSMA-11 PET/CT scan result and the conventional assessment, and the 95% CI. A higher point estimate represents better agreement between the methodologies. (NCT02673151)
Timeframe: up to 12 months

Interventionpercentage point estimate (Number)
SensitivitySpecificity
Diagnostic (68Ga-PSMA-11 PET/CT)100.086.8

[back to top]

68Ga-PSMA-11 PET/CT Predictive Value by Region

Positive predictive value (PPV) is the probability that participants with a positive screening test truly have the disease, and negative predictive value (NPV) is the probability that participants with a negative screening test truly do not have the disease. Predictive Value for 68Ga-PSMA-11 PET/CT was assessed by evaluating scans of the prostate, pelvic lymph nodes, paraaortic lymph nodes, mediastinal lymph nodes, bone, and lung. The outcome is reported as the probability as a percentage and the 95% CI. (NCT02673151)
Timeframe: up to 12 months

Interventionpercentage point estimate (Number)
Positive predictive value (PPV)Negative predictive value (NPV)
Diagnostic (68Ga-PSMA-11 PET/CT)76.4100.0

[back to top]

PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up

PPVs on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI. (NCT02918357)
Timeframe: 1 month

Interventionpercentage of times value is true (Number)
Pet Positive (Per Patient)0.81

[back to top]

PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up

PPVs on a per-region-basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI. (NCT02918357)
Timeframe: 1 month

Interventionpercentage of times value is true (Number)
Pet Positive (Per Patient)0.92

[back to top]

Safety Assessment - Heart Rate

Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated. (NCT02918357)
Timeframe: 1 day

Interventionbeats per minute (Mean)
Pre-Infusion Heart Rate67.8
Post-Infusion Heart Rate66.9
Absolute Change in Heart Rate0.9

[back to top]

Sensitivity on a Per-patient Basis

Sensitivity, on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method. (NCT02918357)
Timeframe: 1 month

Interventionpercentage of sensitivity (Number)
Ga-68 Labeled PSMA-11 PET0.92

[back to top]

Sensitivity on a Per-region Basis

Sensitivity, on a per-region basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method. (NCT02918357)
Timeframe: 1 month

Interventionpercentage of sensitivity (Number)
Ga-68 Labeled PSMA-11 PET0.90

[back to top]

Safety Assessment - Blood Pressure

Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated. (NCT02918357)
Timeframe: 1 day

,,
InterventionmmHg (Mean)
Systolic blood pressureDiastolic blood pressure
Absolute Mean Change1.00.6
Post-Injection137.081.1
Pre-Injection137.880.3

[back to top]

Inter-reader Agreement Per-region

Inter-reader reproducibility for positivity at region level was reported using the Fleiss' Kappa test for multiple readers. Kappa value varies from 0 (no agreement) to 1 (perfect agreement). (NCT02918357)
Timeframe: 1 month

Interventionkappa (Number)
Prostate Bed0.65
Pelvic Nodes0.73
Extrapelvic Soft Tissue0.70
Bone0.78

[back to top]

Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value

Detection rate was defined as proportion of 68Ga-PSMA-11 PET positive patients, independent of the reference standard stratified by PSA value (0.2-<0.5; 0.5-<1.0; 1.0-<2.0; 2.0-<5.0, and ≥5.0). (NCT02918357)
Timeframe: 1 month

Interventionpercentage detected (Number)
PSA <0.540
PSA 0.5 - <1.051
PSA 1.0 - <2.087
PSA 2.0 - <5.083
PSA ≥5.096

[back to top]

Percentage of Participants With Change in Clinical Management

Clinical management changes were assessed using surveys of Intended Management to determine the percent change in clinical management after 68Ga-PSMA-11 PET. (NCT02918357)
Timeframe: Up to 1 year

InterventionPercentage of participants (Number)
Ga-68 Labeled PSMA-11 PET72

[back to top]

Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation

PPVs were calculated across the group on a per-patient basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% confidence intervals (CI). The CIs were constructed using the Wilson score method. (NCT02918357)
Timeframe: 1 month

Interventionpercentage of times value is true (Number)
Pet Positive (Per Patient)0.90

[back to top]

Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation

PPVs were calculated across the group on a per-region-basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% CIs. The CIs were constructed using the Wilson score method. (NCT02918357)
Timeframe: 1 month

Interventionpercentage of times value is true (Number)
Pet Positive (Per Region)0.91

[back to top]

Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy

NPV is the ratio of participants truly diagnosed as negative to all those who had negative test results. Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Follow-up scans for obtained up to one year after study scan be used in analysis. (NCT02919111)
Timeframe: Up to 1 year

Interventionproportion of true negatives (Number)
Ga-68 Labeled PSMA-11 PET.87

[back to top] [back to top]

Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy

PPV is the proportion of patients with positive test who actually have the disease. Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true-negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Follow-up scans for up to one year can be used in analysis (NCT02919111)
Timeframe: Up to 1 year

Interventionproportion of true positives (Number)
Ga-68 Labeled PSMA-11 PET.64

[back to top]

Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy

Sensitivity is defined as the ratio of the proportion of the patients who have the condition of interest and whose test results are positive over the number who have the disease. Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true-negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Follow-up scans for up to one year can be used in analysis (NCT02919111)
Timeframe: Up to 1 year

Interventionproportion of participants (Number)
Ga-68 Labeled PSMA-11 PET.43

[back to top]

Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy

Specificity is defined as the number of non-diseased participants correctly classified divided by all non-diseased individuals. Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true-negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Follow-up scans for up to one year can be used in analysis (NCT02919111)
Timeframe: Up to 1 year

Interventionproportion of participants (Number)
Ga-68 Labeled PSMA-11 PET.94

[back to top]

Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)

Detection rate (sensitivity) on a per-patient basis of 68Ga-PSMA-11 PET stratified by prior use of ADT as a cancer treatment (Prior treatment with ADT, No prior treatment with ADT) will be summarized in tabular format. (NCT03353740)
Timeframe: 1 Day

Interventionproportion of participants (Number)
Prior treatment with ADTNo prior treatment with ADT
Ga-68 Labeled PSMA-11 PET0.80.8

[back to top]

Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value

Detection rate (sensitivity) on a per-patient basis of 68Ga-PSMA-11 PET stratified by PSA value (0.2- <0.5, 0.5 - <1.0, 1.0 - <2.0, 2.0 - <5.0, >=5.0) will be summarized in tabular format for participants with PSMA positive disease, independent of pathology, imaging or clinical follow-up. (NCT03353740)
Timeframe: 1 Day

Interventionproportion of participants (Number)
PSA = < 0.5PSA = 0.5 - <1.0PSA = 1.0 - <2.0PSA = 2.0 - <5.0PSA >= 5.0
Ga-68 Labeled PSMA-11 PET0.530.680.680.930.94

[back to top]

True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only

The true positive rate or detection rate is defined as the proportion of all participants who have prostate cancer detected in the prostate bed using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy only. (NCT03353740)
Timeframe: 1 Day

Interventionproportion of participants (Number)
Ga-68 Labeled PSMA-11 PET0.88

[back to top]

Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment

Detection rates (sensitivity) on a per-patient basis of 68Ga-PSMA-11 PET stratified by prior cancer treatment (Prostatectomy, Radiation, or Prostatectomy plus Radiation) will be summarized in tabular format. (NCT03353740)
Timeframe: 1 Day

Interventionproportion of participants (Number)
Prostatectomy onlyRadiation therapy onlyProstatectomy and salvage radiation therapy
Ga-68 Labeled PSMA-11 PET0.930.650.84

[back to top]

True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only

The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the visceral tissue using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy only. (NCT03353740)
Timeframe: 1 Day

Interventionproportion of participants (Number)
Ga-68 Labeled PSMA-11 PET0.86

[back to top]

True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only

The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the lymph nodes using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy only. (NCT03353740)
Timeframe: 1 Day

Interventionproportion of participants (Number)
Ga-68 Labeled PSMA-11 PET0.40

[back to top]

True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only

The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the bone tissue using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy only. (NCT03353740)
Timeframe: 1 Day

Interventionproportion of participants (Number)
Ga-68 Labeled PSMA-11 PET1.00

[back to top]

PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only

Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the visceral tissue as confirmed by by histopathology/biopsy (NCT03353740)
Timeframe: 1 Day

Interventionproportion (Number)
Ga-68 Labeled PSMA-11 PET0.86

[back to top]

PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only

Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the prostate bed as confirmed by by histopathology/biopsy (NCT03353740)
Timeframe: 1 Day

Interventionproportion (Number)
Ga-68 Labeled PSMA-11 PET0.92

[back to top]

PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only

Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the lymph nodes as confirmed by by histopathology/biopsy (NCT03353740)
Timeframe: 1 Day

Interventionproportion (Number)
Ga-68 Labeled PSMA-11 PET0.5

[back to top]

PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only

Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the bone tissue as confirmed by by histopathology/biopsy (NCT03353740)
Timeframe: 1 Day

Interventionproportion (Number)
Ga-68 Labeled PSMA-11 PET1.00

[back to top] [back to top]

Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800

After administration of panitumumab-IRDye800 alone or with Lymphoseek, lymph nodes potentially containing malignant tumor cells were surgically removed, and the lymph node tissue was evaluated for panitumumab-IRDye800 fluorescence intensity. For each subject, the 5 lymph nodes with the strongest fluorescence signal were tabulated against the Lymphoseek and histopathologic findings for those specific lymph nodes. For each of the 3 modalities, a positive finding is considered indicative of malignancy. The outcome is reported as the number of positive findings by modality for each cohort. The outcome is a number without dispersion. (NCT03405142)
Timeframe: Up to 30 days

,
InterventionLymph nodes (Number)
Panitumumab-IRDye800LymphoseekHistopathology
Any T Stage and Node-positive5NA0
T1 or T2 Stage and Node-negative1032

[back to top]

Number of Subjects With Pathologic Lesions Detected by PSMA PET and PET/CT Compared to MP MRI

A scan was considered positive if the clinical interpretation was suspicious based on the clinical judgement of the reader. (NCT03439033)
Timeframe: At each visit, immediately after administration of the study drug, approximately 2-3 hours; with up to two visits within 2 years or less

InterventionParticipants (Count of Participants)
PSMA PET/MRI and PET/CT Scan63
MRI Scan37

[back to top]

Number of Pathological Lesions Detected by PSMA PET/MRI and PET/CT Compared to MP MRI in Prostate Cancer Patients With Biochemical Recurrence by Anatomical Region

True positive rates for detecting lesions between PSMA PET/MRI and MP MRI in various anatomical locations were compared, including prostate/prostatic bed, N1 lymph nodes, N2 lymph nodes, and osseous lesions. Other anatomical sites are other than bone, node, and prostate. (NCT03439033)
Timeframe: At each visit, immediately after administration of the study drug, approximately 2-3 hours; with up to two visits within 2 years or less

,
Interventionlesions (Number)
Total Number of LesionsN1 lymph nodesN2 lymph nodesOsseousProstateProstatic BedOther Anatomical Sites
MRI Scan4711714771
PSMA PET/MRI and PET/CT Scan92342024383

[back to top]

Number of Pathological Lesions Detected by PSMA PET/MRI and PET/CT Compared to MP MRI in Prostate Cancer Patients With Biochemical Recurrence by Anatomical Region Stratified by PSA Level

Patients were divided into subgroups based on their PSA levels and primary treatment modality. The primary treatment modality subgroups were post radical prostatectomy, post radiation therapy, and post radical prostatectomy and radiation therapy. 109 subjects out of 273 enrolled have data reported. Multiple patients sought care elsewhere and a small number of subjects had 2-year follow-up. This lead to a smaller analysis. (NCT03439033)
Timeframe: At each visit, immediately after administration of the study drug, approximately 2-3 hours; with up to two visits within 2 years or less

,
Interventionlesions (Number)
Total Number of LesionsPSA Levels 0 to < 0.2 ng/mLPSA Levels 0.2 to < 0.5 ng/mLPSA Levels 0.5 to 2.0 ng/mLPET/MRI: PSA Levels > 2.0 ng/mL
MRI Scan470191018
PSMA PET/MRI and PET/CT Scan9210222535

[back to top]

Cumulative Dose of Oxaliplatin During Chemotherapy

Mean cumulative dose of oxaliplatin administered per patient during mFOLFOX6 chemotherapy, 9 months after the first dose of IMP. (NCT03654729)
Timeframe: 9 months

Interventionmg/m^2 (Least Squares Mean)
PledOx (2 µmol/kg)780.69
PledOx (5 µmol/kg)803.54
Placebo764.52

[back to top]

Overall Response Rate (ORR)

Percentage of patients with an overall response (complete response or partial response) according to RECIST v1.1 for target lesions and assessed by CT (preferred) or MRI. Complete response=disappearance of all target lesions; partial response >=30% decrease in the sum of the longest diameter of target lesions. (NCT03654729)
Timeframe: 12, 15 and 18 months

InterventionParticipants (Count of Participants)
Month 1272581391Month 1272581392Month 1272581390Month 1572581390Month 1572581391Month 1572581392Month 1872581390Month 1872581391Month 1872581392
MissingNoYes
PledOx (2 µmol/kg)22
PledOx (5 µmol/kg)19
Placebo19
PledOx (2 µmol/kg)6
PledOx (5 µmol/kg)13
Placebo12
PledOx (2 µmol/kg)13
PledOx (5 µmol/kg)12
Placebo8
PledOx (2 µmol/kg)9
PledOx (5 µmol/kg)14
Placebo7
PledOx (2 µmol/kg)7
PledOx (5 µmol/kg)7
Placebo3
PledOx (5 µmol/kg)2
Placebo2
PledOx (2 µmol/kg)2
PledOx (5 µmol/kg)3
Placebo0
PledOx (2 µmol/kg)1
PledOx (5 µmol/kg)0
Placebo1

[back to top]

Worst Pain in Hands or Feet

Mean change from baseline in worst pain in hands or feet in the past week, using the Pain Assessment (Numerical Rating Scale (NRS)), at 9 months after the first dose of IMP. The NRS is a 10 point scale with 0 as no pain at all and 10 as pain as bad as you can imagine and evaluates the intensity of pain in hands and feet during the past week. A higher value means worse outcome. (NCT03654729)
Timeframe: Baseline and 9 months

InterventionScores on a scale (Least Squares Mean)
PledOx (2 µmol/kg)2.19
PledOx (5 µmol/kg)1.58
Placebo1.92

[back to top]

Vibration Sensitivity on the Lateral Malleolus

Mean change from baseline in vibration sense, on the lateral malleolus (left and right), using a graduated tuning fork, at 9 months after the first dose of IMP. When the tuning fork was struck against the ball of the thumb, the base of the tuning fork was placed over the appropriate bony surface (i.e., lateral malleolus left and right) and the patient was asked to indicate the moment when the vibration was no longer detected. The intensity at which the patient no longer detected the vibration is reported on a scale of 0 (minimum score, representing the maximum vibration amplitude) to 8 (maximum score, representing the minimum vibration amplitude) (NCT03654729)
Timeframe: Baseline and 9 months

InterventionScores on a scale (Mean)
PledOx (2 µmol/kg)-1.53
PledOx (5 µmol/kg)-1.61
Placebo-1.36

[back to top]

Sensitivity to Touching Cold Items

Mean change from baseline in sensitivity to touching cold items on day 2, Cycle 4 of mFOLFOX6 chemotherapy, as assessed by the Cold Sensitivity Questionnaire (measuring sensitivity when touching or swallowing cold objects/fluid). 10 point scale from 0 meaning no sensitivity/discomfort at all to 10 meaning sensitivity/discomfort as bad as it can be. (NCT03654729)
Timeframe: Baseline and 8 weeks

InterventionScores on a scale (Least Squares Mean)
PledOx (2 µmol/kg)3.88
PledOx (5 µmol/kg)4.13
Placebo3.41

[back to top]

Progression-free Survival (PFS)

Patients with progression-free survival (NCT03654729)
Timeframe: Analyses at 12 and 24 months were planned; the analysis was performed once based on available data at cut-off 31 August 2020 as the study was terminated early by the Sponsor

Interventionparticipants (Number)
PledOx (2 µmol/kg)40
PledOx (5 µmol/kg)36
Placebo36

[back to top]

Overall Survival (OS)

Patients with overall survival (NCT03654729)
Timeframe: An analysis at 36 months was planned. The analysis was performed based on available data at cut-off 31 August 2020 as the study was terminated early by the Sponsor

Interventionparticipants (Number)
PledOx (2 µmol/kg)9
PledOx (5 µmol/kg)9
Placebo16

[back to top]

Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)

"Percentage of patients (with moderate or severe chronic CIPN) scoring 3 or 4 in at least 1 of the first 4 items of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity-13-item subscale (FACT/GOG-NTX-13; i.e., FACT/GOG-NTX-4) 9 months after the first dose of IMP (i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy). The FACT/GOG-13 questionnaire includes 13 items that measure the severity and impact of symptoms of neurotoxicity over the past 7 days. Patients rate each item as 0 (not at all), 1 ( a little bit), 2 (somewhat), 3 (quite a bit) or 4 (very much). These 13 items are summed to create a total score, ranging from 0 to 52, with a higher score representing a worse outcome. The FACT/GOG-NTX-4 is a 4 item subscale targeting numbness, tingling or discomfort in hands and/or feet." (NCT03654729)
Timeframe: 9 months

InterventionParticipants (Count of Participants)
PledOx (2 µmol/kg)31
PledOx (5 µmol/kg)27
Placebo25

[back to top]

Mild, Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)

"Percentage of patients (with mild, moderate or severe chronic CIPN) scoring 2, 3 or 4 in at least 1 of the first 4 items of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity-13-item subscale (FACT/GOG-NTX-13; i.e., FACT/GOG-NTX-4) 9 months after the first dose of IMP (i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy). The FACT/GOG-13 questionnaire includes 13 items that measure the severity and impact of symptoms of neurotoxicity over the past 7 days. Patients rate each item as 0 (not at all), 1 ( a little bit), 2 (somewhat), 3 (quite a bit) or 4 (very much). These 13 items are summed to create a total score, ranging from 0 to 52, with a higher score representing a worse outcome. The FACT/GOG-NTX-4 is a 4 item subscale targeting numbness, tingling or discomfort in hands and/or feet." (NCT03654729)
Timeframe: 9 months

InterventionParticipants (Count of Participants)
PledOx (2 µmol/kg)43
PledOx (5 µmol/kg)40
Placebo42

[back to top]

Functional Impairment (in the Non-dominant Hand)

Mean change from baseline in the time to complete the grooved Pegboard with the non-dominant hand, at 9 months after the first dose of IMP. (NCT03654729)
Timeframe: Baseline and 9 months

Interventionseconds (Least Squares Mean)
PledOx (2 µmol/kg)9.68
PledOx (5 µmol/kg)14.24
Placebo12.01

[back to top]

Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group

Detection rate is defined as the proportion of all patients who have prostate cancer and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging. (NCT03803475)
Timeframe: 1 day

Interventionproportion (Number)
PSA Level of 0 to 0.19PSA Level of 0.2 to 0.49PSA Level of 0.5 to 0.99PSA Level of 1 to 1.99PSA Level of 2 to 4.99PSA Level of 5 to maximum
Ga-68 Labeled PSMA-11 PET PSMA0.380.450.760.730.820.62

[back to top]

Detection Rate of PSMA-11 PET for Positive Disease in Bones (Osseous Lesions) by PSA Group

Detection rate is defined as the proportion of all patients who have prostate cancer located in the bone (osseous lesions) and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging. (NCT03803475)
Timeframe: 1 day

Interventionproportion (Number)
PSA Level of 0 to 0.19PSA Level of 0.2 to 0.49PSA Level of 0.5 to 0.99PSA Level of 1 to 1.99PSA Level of 2 to 4.99PSA Level of 5 to maximum
Ga-68 Labeled PSMA-11 PET PSMA0.030.090.180.220.250.26

[back to top]

Detection Rate of PSMA-11 PET for Positive Disease in Distant Soft Tissues by PSA Group

Detection rate is defined as the proportion of all patients who have prostate cancer located in the distant soft tissues and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging. (NCT03803475)
Timeframe: 1 day

Interventionproportion (Number)
PSA Level of 0 to 0.19PSA Level of 0.2 to 0.49PSA Level of 0.5 to 0.99PSA Level of 1 to 1.99PSA Level of 2 to 4.99PSA Level of 5 to maximum
Ga-68 Labeled PSMA-11 PET PSMA0.100.090.100.180.300.21

[back to top]

Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group

Detection rate is defined as the proportion of all patients who have prostate cancer located in the prostate bed and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging. (NCT03803475)
Timeframe: 1 day

Interventionproportion (Number)
PSA Level of 0 to 0.19PSA Level of 0.2 to 0.49PSA Level of 0.5 to 0.99PSA Level of 1 to 1.99PSA Level of 2 to 4.99PSA Level of 5 to maximum
Ga-68 Labeled PSMA-11 PET PSMA0.140.090.180.370.500.76

[back to top]

Detection Rate of PSMA-11 PET for Positive Disease in Pelvic Nodes by PSA Group

Detection rate is defined as the proportion of all patients who have prostate cancer located in the pelvic nodes and are true-positives confirmed by the imaging based on local reads for the detection of metastatic disease. Detection rates will be stratified based upon the PSA group at time of imaging. (NCT03803475)
Timeframe: 1 day

Interventionproportion (Number)
PSA Level of 0 to 0.19PSA Level of 0.2 to 0.49PSA Level of 0.5 to 0.99PSA Level of 1 to 1.99PSA Level of 2 to 4.99PSA Level of 5 to maximum
Ga-68 Labeled PSMA-11 PET PSMA0.100.270.510.240.340.37

[back to top]